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ABSTRACT 
Background: OAB is defined by subjective symptoms, rather than objective measure, 
the patient’s perspective is important in managing OAB (Hung et al., 2013). As such 
providers need to capture the patient’s perspective of their OAB symptoms and their 
impact on the quality of life. A patient work up helps providers determine the cause of 
the symptoms as well as the degree of bother to the patient (Barkin, 2016). The diagnosis 
of OAB is essentially clinical and can be performed through structured questionnaires 
(Juliato et al., 2016). When conducting a patient history, it is important to determine the 
onset and severity of the nocturia, and also determine if the nocturia is consistent or 
intermittent (Barkin, 2016). Healthcare providers should acertain any medical conditions 
or drugs that may cause nocturia.  
Method: A quality improvement study was designed and implemented in a retail health 
clinic to determine an effective standard OAB screening tool; to determine the knowledge 
level of providers regarding OAB; and measure provider’s perception of the ABSST 
effectiveness in assessing for OAB in patients. An appraisal of literature published from 
2006 through 2016 was conducted to determine if the use of a simple symptom screener 
in primary care settings, may facilitate discussions between the patient and healthcare 
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provider regarding OAB, and thereby help to identify women who could benefit from 
treatment. Over 1000 potential providers were targeted to participate and of those, 153 
providers agreed to participate but only 52 providers completed the study including the 
pre- and post-surveys, the educational module and utilized the ABSST tool with their 
patients that met the criteria. 
Results: The two questions that sought to measure the provider knowledge pre-and post-
educational module were not statistically significant. The questions that sought to 
measure the provider perception of the ABSST effectiveness in assessing for OAB in 
patients were statistically significant (N= 148; N=145 pre-survey and N=51 and N=52 
post-survey). The validated overactive bladder screening tool (ABSST) was found to be 
statistically significant in highlighting the presence of bladder symptoms consistent with 
OAB at a 95% confidence interval (-0.8163 - -0.3366) with p< 0.0001 (N=148 pre-survey 
and N=51 post survey). The ABSST was effective in facilitating critical communication 
between patient and provider, was significant at 95% confidence interval (-0.8787 - -
0.3995, p<0.0001) (N=145 pre-survey and N=52 post survey). Provider knowledge level 
for assessing OAB post intervention was statistically significant (p=0.0004) (N=153 pre-
survey and N=52 post-survey). 
Conclusion: Findings indicated that providers’ knowledge and awareness of OAB 
symptoms and screening in adult women were increased following an educational online 
module. This results suggest that the ABSST is likely to improve patient outcomes for 
patients who are screened and if criteria met, to initiate treatment early.  
Implications: This study created an awareness in the providers who did not routinely 
screen their patients for OAB symptoms.  Further recommendations would include 
vii 
 
replicating this project with a larger sample, as well as expanding the content to assess all 
adults, both male and female.   
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CHAPTER 1 
BACKGROUND AND SIGNIFICANCE OF THE PROBLEM 
Overactive bladder (OAB) is defined by the International Continence Society 
(ICS) (2005) as “urgency with or without urgency incontinence, usually with frequency 
and nocturia” (Levkowicz, Whitmore, & Muller, 2011).  About 25 percent of young 
women, 44 to 57 percent of middle-aged and postmenopausal women, and about 75 
percent of older women experience some involuntary urine loss (Agency for Healthcare 
Research and Quality (AHRQ), 2013). The cost of incontinence care in the United States 
averaged 19.5 billion in 2004 (AHRQ, 2013). The NOBLE study showed the prevalence 
of OAB in the United States was 16.9 percent in women (Eapen & Radomski, 2016). The 
NOBLE study found that OAB symptoms were more common in women than in men, 
younger than 60 years of age (Eapen & Radomski, 2016). The EPIC study, which was 
one of the largest population based surveys that studied the prevalence of lower urinary 
tract symptoms and OAB, showed an overall prevalence of lower urinary tract symptoms 
(LUTS) suggestive of OAB was 12.8 percent in women. 
The EpiLUTS survey done in the United States, United Kingdom and Sweden, 
showed that 43.1 percent of women of 40 years and older reported urgency or urge 
incontinence ‘at least sometimes’, and of these women, 67.6 percent and 38.9 percent 
reported ‘somewhat’ or ‘quite a bit’ bother (De Ridder, Roumeguere, & Kaufman, 2013). 
LUTS severity has been associated with decreased sexual activity and sexual satisfaction 
(Coyne et al., 2008). According to Levkowicz et al. (2011), nocturia disrupts a woman’s 
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physical health and sense of normalcy and can also affect ones emotional and social 
circumstances. The rising prevalence of OAB creates a burden for individuals and society 
and increases the potential for impaired functional status and lower health-related quality 
of life (Barile et al., 2015). 
 In terms of screening for OAB, many women believe that some amount of 
urinary incontinence is inevitable with aging (Hartmann, McPheeters, & Biller, 2009). 
The majority of women with these symptoms do not talk with their healthcare providers 
concerning their bladder dysfunction and providers may not systematically inquire 
(Hartmann, McPheeters, & Biller, 2009). Consequently, very few women obtain adequate 
treatment for their symptoms.  
The purposes of this project were to (1) determine an effective standard OAB 
screening tool to be used in a retail clinic environment and to (2) determine the 
knowledge level of providers regarding OAB, and (3) measure the provider’s perception 
of the Actionable Bladder Screening Tool (ABSST) effectiveness in assessing for OAB 
in patients. 
1.1 BACKGROUND 
Typical symptoms include urinating more than eight times per day (urinary 
frequency) and a strong, sudden desire to urinate (urinary urgency) (Van Kerrebroek et 
al., 2002; Levkowicz et al., 2011). Nocturia is described by the ICS (2005) as “sleep-
disturbing voiding” (Levkowicz et al., 2011). The fundamental symptom is urgency, and 
is considered to be the driver of the urological symptoms (De Ridder, Roumeguere, & 
Kaufman, 2013). Daytime urinary frequency is hallmark symptom of OAB increasing 
with age (Levkowicz et al., 2011). OAB is a subset of storage lower urinary tract 
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symptoms characterized by urinary urgency but commonly occurring with other storage 
symptoms, including frequency, nocturia, and urgency urinary incontinence (Coyne et al., 
2008). OAB is defined as bothersome urgency, usually associated with daytime voiding 
frequency (more than every 2 hours) and nocturia (more than one episode per night for 
adults under 65 years of age and three or more episodes for adults aged 65 years or older) 
with or without urge urinary incontinence and occurring in the absence of pathologic or 
metabolic conditions that might explain these symptoms (Gray & Moore, 2009, p. 122).   
Risk factors for OAB and urge urinary incontinence (UI) include functional 
deficits such as impaired mobility or dexterity, cognitive difficulties, and female gender 
(Gray & Moore, 2009). Other risk factors to OAB are Caucasian, insulin-dependent 
diabetes mellitus, increased body mass index, arthritis, depression, and age greater than 
75 (Gomella, 2010).  According to Gray and Moore (2009), before age of 60, OAB is 
more common in women than in men, with women more likely to experience mixed UI 
with OAB (Gray & Moore, 2009).   
Conditions associated with OAB are neurologic disorders such as stroke, 
hydrocephalus, brain tumors, dementia or parkinsonism; stress urinary incontinence; 
inflammatory disorders such as urinary tract infection, bladder stones, or tumors; 
idiopathic factors; and obstruction as a cause of detrusor over activity (Gray & Moore, 
2009).  Over activity of detrusor muscle may also be due to transient causes such as 
delirium, infection, atrophic urethritis/ vaginitis, pharmaceutical, psychological, 
excessive urine output, restricted mobility and stool impaction (Gomella, 2010).   
Because OAB is defined by subjective symptoms, rather than objective measures, 
the patient’s perspective is important in managing OAB (Hung et al., 2013). As such 
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clinicians need to capture the patient’s perspective of their OAB symptoms and their 
impact on the quality of life. A patient work up helps clinicians determine the cause of 
the symptoms as well as the degree of bother to the patient (Barkin, 2016). The diagnosis 
of OAB is essentially clinical and can be performed through structured questionnaires 
(Juliato et al., 2016).  When conducting a patient history, it is important to determine the 
onset and severity of the nocturia, and also determine if the nocturia is consistent or 
intermittent (Barkin, 2016). Healthcare providers should ascertain any medical conditions 
or drugs that may cause nocturia. Medications such as diuretics, sedatives, narcotics, 
antidepressants, antihistamine, calcium channel-blockers and alpha blocker can possibly 
cause or worsen OAB. 
The healthcare provider should order a urinalysis, a urine culture and sensitivity 
test, and a urine cytology test (if indicated, because of hematuria).  The following tests 
should be ordered if indicated, a serum creatinine test to rule out renal failure, and an 
abdominal and/or pelvic ultrasound test.  It is also important to ensure when the 
healthcare provider is performing a physical examination, to ensure that the patient is not 
in retention (palpate supra-pubically) (Barkin, 2016). Other diagnostic procedures for 
OAB include, urodynamics, uroflowmetry, urethral pressure profilometry, endoscopy/ 
cystoscopy, voiding and intake diaries, pad test, and post void residuals (Gomella, 2010).   
First line treatment is antimuscarinics such as oxybutynin, tolterodine, trospium, 
solifenacin, hyoscyamine, and fesoterodine (Gomella, 2010).  The current 
pharmacological approach to treating OAB mainly involves antimuscarinic agents, but 
the use of these agents is limited in some individuals because of the suboptimum efficacy 
or bothersome adverse events, including dry mouth, blurred vision and constipation 
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(Yamaguchi et al., 2014). Alternative approaches to managing OAB have focused on 
beta-adrenoceptors, such as mirabegron, which have a recognized role in mediating the 
relaxation of bladder smooth muscle (Yamaguchi et al., 2014). Three beta-adrenoceptor 
subtypes have been identified in the human detrusor, but it is the βᶾ-adrenoceptor subtype 
that is responsible for promoting its relaxation and urine storage, and this may also inhibit 
the activity of the bladder afferent nerves (Yamaguchi et al., 2014). 
Additional treatments include behavioral therapy such as bladder retraining, 
pelvic floor exercises (Kegel), pelvic floor biofeedback, and transvaginal/transrectal 
electrical stimulation. General prevention is consuming a high fiber diet and limiting 
consumption of caffeine and alcohol (Gomella, 2010). Caffeine is postulated to cause a 
mild diuresis, which may result in increased urinary frequency and detrusor relaxation 
during bladder filling and storage (Wells, et al., 2014). Higher caffeine intakes have been 
associated with urinary incontinence, and caffeine intake has been associated with OAB 
(Wells et al., 2014).  Other treatment options include (1) intravesical therapies (capsaicin, 
resinofentoxin), (2) estrogen (topical or oral) to increase growth of vaginal epithelium, 
increase volume of submucosal plexus, and strengthen pelvic floor musculature 
(Gomella, 2010). The prognosis varies according to the severity of disorder and 
compliance of the patient (Gomella, 2010). About 50% to 80% of patients respond to 
combination of behavioral modification, pelvic floor therapy, and pharmacotherapy 
(Gomella, 2010).  
1.2 SIGNIFICANCE 
The condition is highly prevalent and is associated with significant economic 
burden and lower health-related quality of life (Cardozo et al., 2014).  To illustrate, the 
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EPIC study, was one of the largest population based surveys that studied the prevalence 
of lower urinary tract symptom(LUTS) and OAB in five countries (Canada, United 
Kingdom, Germany, Italy and Sweden).  This study showed that the prevalence of LUTS 
suggestive of OAB was 10.8% in men and 12.8% in women (Eapen & Radomski, 2016). 
In the USA-based NOBLE study, Stewart et al (2003), estimated the prevalence of OAB 
as 16% among men and 16.9% among women, but did not collect data on the overall 
prevalence of LUTS (Coyne et al. 2008).  Epidemiological studies have demonstrated 
that the frequency of OAB ranges from 12.4% to 53.1%, depending on the target 
population and definition of OAB, and the number increases with advancing age (Hung et 
al., 2013). The total cost in the USA was estimated to be 65.9 billion in 2007, 22.1% of 
which was accounted for by indirect costs (Cardozo et al., 2014). Indirect costs include 
impaired work productivity and activity, and statistically higher rates of OAB-related 
surgery, hospitalizations, physician visits and pad use (Tang et al., 2013; Cardozo et al., 
2014). 
Urinary incontinence is associated with poorer quality of life, impaired work 
productivity and activity, and statistically high rates of OAB-related surgery, 
hospitalizations, provider visits and pad use (Cardozo et al., 2014). Despite the negative 
impact of OAB on healthcare quality of life, an online survey study conducted across 
multiple countries showed that a substantial proportion of patients never consulted a 
provider regarding their bladder symptoms (Cardozo et al., 2014). Moreover, the study 
found that those patients who did consult a provider waited a number of years before 
doing so and generally had to initiate the consultation themselves (Cruz, Denys, Signori, 
& Globe, 2012).  
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It is suggested that urinary incontinence has the potential to substantially lower 
ones’ health related quality of life (Ng Pooi Yee, Chow Yeow, & Tan Khon, 2011). 
Despite urinary incontinence being described as a problem, current research has indicated 
a low proportion of 6-12% of the population sought medical advice and treatment for 
urinary incontinence (Ng Pooi Yee, Chow Yeow, & Tan Khon, 2011). Given the high 
prevalence of OAB in women, in conjunction with the fact that many patients fail to 
mention their problems during clinical consultations, women may benefit from screening 
for symptoms of OAB, including urinary urge incontinence (Cardozo et al., 2014). 
Thus, it is important for healthcare providers to screen patients for OAB.   
Moreover, providers have an obligation to explore behavioral as well medication therapy 
in the management of OAB.  Healthcare providers in primary care settings are in a 
position to create a public health education plan to improve patient knowledge about 
OAB including nocturia and understanding the treatment options available. 
1.3 SCOPE OF PROBLEM 
 According to the Walgreens Healthcare Education department, the clinics do not 
adequately assess adult women who may potentially present with OAB issues. According 
to Walgreen data, the average age of most patients who visit the Walgreens clinics are 
between ages 18-49.  The majority of these patients are female. Walgreens Healthcare 
Clinics do not screen adult women for OAB.  However, the clinic providers treat women 
for urinary tract infections. Many times, some of these women may have normal 
urinalysis tests, but complain of nocturia and urgency. These women are not likely to 
divulge this information unless the providers ask them pointedly the critical and simple 
question: “When you get up at night to void – do you pass a lot of urine each time or just 
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a small amount?” (Barkin, 2016). Based on literature, many women believe that some 
amount of incontinence is inevitable with aging and the majority of women with these 
symptoms do not talk with their health care providers about their concerns with bladder 
function (Hartmann, McPheeters, & Biller, 2009). As a result, many women with OAB 
experience delays in treatment (Levkowicz et al., 2011). 
1.4 BEST PRACTICES 
Several articles on OAB were appraised to provide confidence to implement the 
project; the evidence was then combined with different aspects within an area of provider 
utilization and patient acceptance. The study by Sumardi et al. (2012), evaluated the test-
retest reliability of OAB Symptom Score (OABSS), which was original developed and 
validated in Japanese population. The OABSS showed excellent test-retest reliability in 
Indonesian OAB patients, and the simplicity of the tool made it useful and feasible for 
clinical practice that had limited time and resources. The results of the study suggest 
some utility for the OABSS to provide useful information on OAB symptoms which 
would otherwise have been gained from completion of a voiding diary; as such, solitary 
or complementary application of OABSS may considerably simplify the management of 
OAB (Sumardi et al., 2012).   
 The study by Basra et al. (2012), compared the value of two validated 
questionnaires: the Bladder Control Self-Assessment Questionnaire (B-SAQ) and the 
Overactive Bladder Awareness Tool (OAB-V8). Both questionnaires were found to 
perform well in identifying and screening for OAB symptoms in clinical setting. The 
OAB-V8 was validated in the USA in a predominantly primary care population; the B-
SAQ was validated in the secondary care population (Basra et al., 2012). Both the B-
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SAQ and the OAB-V8 performed well in detecting symptoms of OAB and mixed urinary 
symptoms (Basra et al., 2012). The B-SAQ performed better in detecting symptoms of 
stress incontinence than the OAB-V8 (Basra et al., 2012). However, the OAB-V8 was 
unable to screen for hematuria (Basra et al., 2012). 
 In the study by Coyne et al. (2008), the Center for Epidemiologic Studies 
Depression Scale (CES-D), the Patient Perception of Bladder Condition (PPBC), and the 
work productivity related to a specific health problem (WPAI-SHP), were questionnaires 
used to assess the prevalence and impact of OAB and lower urinary tract symptoms 
(LUTS). This study was conducted in five countries with a large sample size. The OAB 
and LUTS classifications used in this study were based entirely on patient-reported 
symptoms. This study found that the diagnosis and treatment of OAB should be 
considered in conjunction with LUTS, to maximize treatment options and optimize 
patient outcomes.  
 Cardozo et al. (2014) had 100 women complete the Actionable Bladder Symptom 
Screening Tool (ABSST). The tool was validated in non-neurogenic females and found to 
be a reliable, valid and sensitive tool for screening women with urinary urge incontinence 
and OAB (Cardozo et al., 2014). 
1.5 STATEMENT OF PURPOSE 
The purposes of this project were to (1) determine an effective standard OAB 
screening tool that could be used in a retail clinic environment and to (2) determine the 
knowledge level of providers regarding OAB, and (3) measure the provider’s perception 
of the ABSST effectiveness in assessing for OAB in patients. 
10 
 
A substantive integrative review of literature on tools that can assess OAB 
problems in adult women over age 40 years was conducted to analyze the literature for 
comparing the different tools and determine the best screening tool that providers could 
use to assess women who presented in the clinical setting. This tool was used by 
healthcare providers to screen women who may potentially have OAB and initiate 
treatment and referral as necessary.  The tool would allow healthcare providers to assist 
patients with the best practice management of non-neurogenic OAB by setting realistic 
goals with patients for improving symptom control and quality of life.  
1.6 PICOT QUESTION 
 An extensive review and analysis of literature published from 2006 through 2016 
was conducted to answer the following PICOT question: Healthcare providers providing 
primary care in Walgreens clinics (P), does an educational model to teach providers the 
use of a standard OAB screening tool (ABSST) (I), as compared to the use of no 
symptom screening tool (C), improve knowledge regarding the use of screening of OAB 
as measured by (1) the provider’s knowledge of OAB pre and post educational 
intervention, (2) the provider perception of the ABSST effectiveness in assessing for 
OAB pre and post educational intervention (O), over 3 month’s period (T)? Refer to 
Table 1.1 
Table 1.1: Evidence Based Practice Clinical Question 
Population Intervention Comparison 
Intervention 
Outcome Time 
Frame 
11 
 
Healthcare 
providers 
providing 
primary care 
in Walgreens 
clinics 
Educational 
model to teach 
providers the 
use of a 
standard OAB 
screening tool 
(ABSST)  
No use of 
symptom 
screening tool 
Improved knowledge 
regarding the use of 
the screening of OAB 
as measured by: 
• The provider’s 
knowledge of 
OAB pre-and 
post-
educational 
intervention 
• The provider’s 
perception of 
the ABSST 
effectiveness 
in assessing for 
OAB pre-and 
post-
educational 
intervention 
3months 
 
1.7 PICOT DEFINITION AND DESCRIPTIONS 
1. Adult women: any female over the age of 40 years. 
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2. Intervention:  An assessment tool that providers utilized to assess women for non-
neurogenic OAB symptoms including urinary frequency (both daytime and 
nighttime) and urgency, with or without urgency incontinence, in the absence of UTI 
or other obvious pathology that are reported as bothersome (Gormley et al., 2012). 
3. Best Practice: The use of interventions that were grounded on Evidence-based 
research and improve bladder function and quality of life. 
4. Healthcare Provider:  refers to advance practice registered nurses (APRNs) and 
physician assistants (PAs) that managed the care of women in Walgreens clinics. 
5. Non-neurogenic Overactive Bladder (OAB) is loss of bladder control because the 
bladder detrusor muscles contract often and at the wrong time ("Pri-med Institute," 
2006). This causes the sudden urge to urinate immediately ("Pri-med Institute," 
2006). Loss of bladder control is called incontinence, but “overactive bladder” refers 
specifically to “urge incontinence” ("Pri-med Institute," 2006).  The other types of 
incontinence (stress incontinence and overflow incontinence) are not caused by 
problems with the detrusor muscle ("Pri-med Institute," 2006). 
6. Assessment tools: a review literature for validated short form questionnaires to assess 
symptoms severity in women with incontinence. The assessment tool was piloted 
with providers and feedback received from the providers on the effectiveness of the 
tool in detecting OAB in women over 40 years. 
7. OAB: nocturia, frequency, urgency, detrusor muscles overactivity, urge incontinence, 
bladder control (Gormley et al., 2012). OAB is defined as bothersome urgency, 
usually associated with daytime voiding frequency (more than every 2 hours) and 
nocturia (more than one episode per night for adults under 65 years of age and three 
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or more episodes for adults aged 65 or older) with or without urge urinary 
incontinence and occurring in the absence of pathologic or metabolic conditions that 
might explain these symptoms (Gray & Moore, 2009). 
8. Nocturia:  According to the International Continence Society (ICS), nocturia is 
defined as “The complaint that the individual has to wake at night one or more times 
to void. Each void is preceded and followed by sleep.” (Barkin, 2016). 
9. Frequency: is defined as of more than eight times per day while urgency is defined as  
a strong, sudden desire to urinate (Van Kerrebroek et al., 2002; Levkowicz et al., 
2011). 
10. Detrusor muscles overactivity is defined as the occurrence of an involuntary 
contraction during the filling phase, which may be spontaneous or provoked (Abrams 
et al., 2002; Al-Ghazo et al., 2011). The urodynamic characteristics of OAB is 
detrusor overactivity (Eapen & Radomski, 2016). 
11. Urge incontinence(UI) is defined as urine loss associated with a precipitous desire to 
urinate caused by an overactive detrusor contraction (Gray & Moore, 2009). UI is 
also defined as urine leakage before one can get to the toilet (Wells et al., 2014) 
12. Bladder control is defined as having no nocturia, frequency, urgency, detrusor 
muscles 
 overactivity, or urge incontinence. 
13. Outcomes: improved knowledge regarding the use of screening of OAB as measured 
by (1) the provider’s knowledge of OAB pre-and post-educational intervention, (2) 
the provider’s perception of the ABSST effectiveness in assessing for OAB pre-and 
post-educational intervention. 
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1.8 ASSUMPTIONS 
1. OAB impairs quality of life. 
2. Providers will use the OAB tool to assess patients for OAB. 
3. Providers will use the data from the assessment tool to manage patients for OAB. 
4. Providers knowledge and comfort of managing OAB will increase. 
1.9 SUMMARY 
 This was a quality improvement project to: (1) determine an effective standard 
OAB screening tool used in a retail clinic environment and to (2) determine the 
knowledge level of providers regarding OAB, and (3) measure the provider’s perception 
of the ABSST effectiveness in assessing for OAB in patients. The ultimate goal is for 
providers to conduct a valid diagnostic process and establish treatment goals that 
maximize symptom control and patient quality of life while minimizing adverse events 
and patient burden (Gormley et al., 2012). Despite a significant reduction in health-
related quality of life in patients suffering from urinary dysfunction, many do not seek 
medical help, possibly out of embarrassment or because they do not believe that 
treatment is available, even when seen by a clinician for other conditions (Cardozo et al., 
2014). The use of a validated bladder symptom screener tool in women with incontinence 
due to OAB, presenting at the Healthcare Clinics in Walgreens may facilitate discussions 
between the provider and patient, and thereby help to identify women who could benefit 
from treatment (Cardozo et al., 2014). 
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CHAPTER 2 
LITERATURE REVIEW 
Currently, the Healthcare Clinics in Walgreens do not adequately assess adult 
women who may potentially present with overactive bladder (OAB) issues.  These 
women may not likely divulge this information unless the providers ask them pointedly. 
Many women believe that some amount of incontinence is inevitable with aging and the 
majority of women with these symptoms do not talk with their health care providers 
about their concerns with bladder function (Hartmann, McPheeters, & Biller, 2009). As a 
result, many women with OAB wait longer than needed to seek treatment (Levkowicz, 
Whitmore, & Muller, 2011). 
The purposes of this project were to (1) determine an effective standard OAB 
screening tool to be used in a retail clinic environment, and to (2) determine the 
knowledge level of providers regarding OAB, and (3) measure the provider’s perception 
of the ABSST effectiveness in assessing for OAB in patients. 
2.1 SEARCH STRATEGY 
According to Melnyk & Fineout-Overholt (2015), searching the literature back 5 
years is considered by some sufficient, this may not be adequate to discover evidence that 
can address the clinical issue. An extensive review and analysis of literature published 
from 2006 through 2016 was conducted to answer the following PICOT question: 
Healthcare providers providing primary care in Walgreens clinics (P), does an 
educational model to teach providers the use of a standard OAB screening tool (ABSST) 
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(I), as compared to the use of no symptom screening tool (C), improve knowledge 
regarding the use of screening of OAB as measured by (1) the provider’s knowledge of 
OAB pre-and post-educational intervention, (2) the provider’s perception of the ABSST 
effectiveness in assessing for OAB pre-and post-educational intervention (O), over 3 
month’s period (T)?  
The literature search strategy began with a review of library resources, with 
assistance of the librarian.  Peer-reviewed journal articles and textbooks were assessed to 
try to answer the PICOT question. A systematic search was done on nine databases: 
Google Scholar, PubMed, National Institutes of Health and Care Excellence, National 
Guideline Clearinghouse, CINAHL, Web of Science, PsyInfo, EBSCOhost, and Ovid.  
Searching subject-specific databases that index peer-reviewed research journals was the 
next step in the research of the literature. Any journal articles that were not available 
could be accessed through interlibrary loan. Tutorial videos were provided by the 
librarian for how to use Joanna Briggs Institute, Web of Science, CINAHL, and PubMed; 
and they were all carefully reviewed and used to assist in the search of the literature.  
Only databases that provided mainly full text of many types of documents were 
utilized. The first strategy was to search the literature using keywords: “nurse 
practitioner”, “provider”, “family nurse practitioner” ,“urinary incontinence”, 
“knowledge”, “perceptions”, “perceptions of OAB by NP”, “barriers”, “attitudes of 
APRNs”, “knowledge of OAB”, “barriers to assess OAB”, “overactive bladder”, “OAB 
in women”, “OAB assessment tool”, “urinary”, “nocturia”, “urinary frequency”, “urinary 
urgency”, “incontinence”, “non-neurogenic OAB symptoms”, “loss of bladder control”, 
“detrusor muscles”, “OAB questionnaires”, “assessment tools”, and “symptoms severity 
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in women with incontinence”.  Searches included searches of titles, abstracts and 
keywords. The subject headings and abstracts of the articles were reviewed using 
Medical Subject Headings (MESH). In some cases, truncation with special symbols in 
combination with words, or word parts to increase the likelihood of finding appropriate 
studies. Another strategy, utilized was the title search, which used the P, I and O terms in 
the title so as to help find any citations and studies that were useful. Subject headings, 
keywords, and Boolean operators AND or OR were used to search databases such as 
EBSCOhost. The “limit” function to narrow down a large list of citations to the more 
relevant studies. The inclusion criteria included relevant studies of nurse practitioner or 
provider knowledge and perceptions, overactive bladder assessment tools, adult women 
over 40 with non-neurogenic OAB symptoms, articles in English only, urinary 
incontinence and lower urinary tract symptoms. Articles from other countries were 
included if they were in English.  Articles that included both men and women were also 
included. The exclusion criteria included studies that had pediatric or men as the primary 
research and articles older than 10 years. Articles dealing with provider knowledge and 
perceptions of urinary incontinence, randomized studies comparing OAB medications to 
placebo were also included. Three randomized clinical trial study articles were found, 
that did not discuss an assessment tool, but focused on comparison studies of 
anticholinergic therapy, solifenacin and β3-adrenoceptor agonist mirabegron. These 
articles did have information about OAB screening tools. Refworks was used to manage 
the citations. Thirty-one articles were included in this analysis. See the Evidence Table 
1.1. Appendix B. 
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In the next step, research and non-research evidence was appraised for evidence 
level and quality (Dearholt & Dang, 2012, p. 47). See Appendix A.  According to 
Dearholt & Dang, 2012, the evidence rating is rated from Level I to Level V with a 
quality rating from   A: High, B: Good, and C: Low or Major Flaws. The articles were 
reviewed for each piece of evidence and quality. Any evidence with a quality rating of 
low-major flaws was discarded and not used in the evidence table.  Most of the articles 
the researcher found were level II or III. According to Dearholt & Dang, 2012, when 
appraising individual research studies, three major components come into play: study 
design, which has been discussed as the level of evidence; study quality, which refers to 
study method and execution, with particular attention to study limitations, and reflects the 
appraiser’s confidence the estimates of an effect are adequate to support 
recommendations (Balshem et al., 2011); and directness, or the extent to which subjects, 
interventions, and outcomes measures are similar to those of interest. 
2.2 ANALYSIS OF LITERATURE 
 After appraising the literature on OAB to provide confidence to implement the 
project, the evidence was then combined with different aspects within an area of provider 
utilization and patient acceptance. There were 31 articles whose evidence was appraised.  
According to Dearholt & Dang (2012), the John Hopkins evidence and quality guide, (see 
Appendix A), eight articles were found to have evidence level I, six had evidence level II, 
twelve had evidence level III, and four had evidence level IV and one had evidence level 
V. All articles were of good and high quality. 
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2.3 LEVEL ONE 
 The study by Sumardi et al. (2012), evaluated the test-retest reliability of OAB 
symptom Score (OABSS), which was originally developed and validated in Japanese 
population.  This test-retest reliability was examined in patients in Indonesia using the 
internal correlation coefficient and the weighted Kappa coefficients between the first and 
second applications of the OABSS.  Patients age 18 years and older with established 
OAB completed 3-day micturition diaries and questionnaires, International Prostate 
Symptom Score (IPSS), and Patient Perception of Bladder Condition (PPBC) on 2 
separate visits. It was an observational study that had 50 patients enrolled with a return 
rate of 100%. T-testing of the instrument was conducted at a level of significance of 0.05 
and internal correlation demonstrated a coefficient of 0.83. The test-retest reliability of 
the Indonesian OABSS was found to be excellent for each of the four individual items of 
the Indonesian OABSS, the weighted Kappa coefficients were 0.55-0.65, representing 
moderate to good agreement. The OABSS total score showed a moderate degree of 
correlation with the IPSS total score (Spearman correlation coefficient = 0.41 at Visit 1 
and 0.45 at Visit 2). The OABSS showed excellent reliability with an evidence level I, 
with good quality, and the simplicity of the tool made it useful and feasible for clinical 
practice that had limited time and resources. However, the generalizability of the findings 
from one hospital to another was found to be a potential threat.  Moreover, validated tools 
have demonstrated clinical use with a certain range, but one common shortcoming is they 
do not evaluate actual symptoms. 
In the study by Coyne et al. (2008), the Center for Epidemiologic Studies 
Depression Scale (CES-D), the Patient Perception of Bladder Condition (PPBC), and the 
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work productivity related to a specific health problem (WPAI-SHP), were questionnaires 
used to assess the prevalence and impact of OAB and lower urinary tract symptoms 
(LUTS). This was a symptom prevalence study (prospective study), that identified 1434 
participants. A nested case-control analysis was performed on men and women with 
(cases) and without (controls) OAB, from the EPIC study. Based on their responses to 
questions about (LUTS) cases were classified into five groups: continent OAB, OAB 
with incontinence, OAB + post-micturition, OAB + post-mictirition + voiding. A 
population based, cross sectional telephone survey of adults age over 18 years, was 
conducted in five countries (Canada, Germany, Italy, Sweden and the UK). The Center 
for Epidemiologic Studies Depression Scale (CES-D) had confirmed reliability and 
validity.  The Patient Perception of Bladder Condition (PPBC) was found to have good 
construct validity, responsiveness to change and test-retest reliability among patients with 
OAB. The OAB and LUTS classifications used in this study were based entirely on 
patient-reported symptoms. However, controls were not asked any questions, which 
limits the case-control comparisons. Another limitation was the OAB and LUTS 
classifications used were based entirely on patient self-reported symptoms; there was no 
urodynamic testing to confirm the type of LUTS, nor was there confirmation by a 
medical professional. This study found that the diagnosis and treatment of OAB should 
be considered in conjunction with LUTS, to maximize treatment options and optimize 
patient outcomes. This article was an evidence level I, of good quality. 
A systematic review (evidence level I and good quality) done by Kinsey et al. 
(2016), generated 3699 electronic searches, of which 32 articles on psychological impact 
of OAB were included in the review. The electronic databases searched were: Web of 
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Knowledge, PsycINFO, MEDLINE, and CINAHL. All the studies were cross-sectional. 
Most studies in this review were assessed using self-report questionnaire, which may 
sometimes lead to participants being included or excluded from OAB group on the basis 
of different individual views of “urgency” skewing the results. The research suggests that 
there is disagreement among physicians in the way OAB should be defined.  The lack of 
clarity about the definition of OAB may also create difficulties in researching the 
condition, particularly as OAB’s key symptoms, urgency, cannot be assessed objectively. 
According to Kinsey et al. (2016), this review provides an overview of the current 
research on the psychological impact of OAB. Psychological health should be considered 
an important aspect of managing OAB, and further research is required to determine how 
to best provide psychological care and support in this area (Kinsey et al., 2016). 
Another systematic review (evidence level I), was conducted by Gormley et al. 
(2015). The article discusses the 2014 amendments to the American Urological 
Association/Society of Urodynamics, Female Pelvic Medicine & Urogenital 
Reconstruction (AUA/SUFU) guidelines. Data extraction was conducted as part of the 
Agency for Healthcare Research and Quality Evidence Report/Technology Assessment 
Number 187 titled Treatment of Overactive Bladder in Women (2009). The report 
searched the following databases: PubMed, MEDLINE, EMBASE, and CINAHL for 
English language studies published from January 1966 to October 2008. The AUA 
conducted additional literature searches to capture populations and treatments not 
covered in detail by the AHRQ report and relevant articles published through December 
2011. The review yielded 151 treatment articles after application of inclusion/exclusion 
criteria. An additional systematic review conducted in February 2014 identified 72 
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additional articles relevant to treatment and made up the basis for the 2014 amendment.  
The amendment focused on four topic areas: mirabegron, peripheral tibial nerve 
stimulation (PTNS), sacral neuromodulation and botulinum toxin A (BTX-A). The 
additional literature provided the basis for an update of current guidelines statements as 
well as the incorporation of new guideline statements related to the overall management 
of adults with OAB symptoms. The treatments guidelines were divided in into first-, 
second-, and third-line groups. First line treatments discussed behavioral therapies may 
be combined with pharmacologic management. Second-line treatments discussed that 
clinicians should offer oral anti-muscarinics or oral βз-adrenoceptor agonists.  If a patient 
experiences inadequate symptom control and/or unacceptable adverse drug events with 
one anti-muscarinic medication, then a dose modification, or a different anti-muscarinic 
medication, or a βз-adrenoceptor agonist may be tried. Clinicians should use caution in 
prescribing these second-line treatments in the frail OAB patient.  Patients who are 
refractory to behavioral and pharmacologic therapy should be evaluated by an 
appropriate specialist if they desire additional therapy. Third-line treatment, such as 
intradetrusor onabotulinumtoxin A, PTNS, and sacral neuromodulation, required careful 
patient selection and appropriate patient counseling. The expert opinion further discussed 
that if the therapies that do not demonstrate efficacy after then adequate trial should be 
ceased. New evidence-based statements and expert opinion supplemented the original 
guidelines published in 2012, which provided guidance for the diagnosis and overall 
management of OAB in adults. 
The FINNO study by Tikkinen et al. (2009), was a case control study with 
prevalence sampling, where the authors explored the correlates for nocturia and their 
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population-level impact. Tikkinen et al. (2009), randomly identified 6000 subjects (ages 
18-79) from the Finnish Population Register (62.4% participated, 53.7% were female). 
They answered questionnaires assessing nocturia and quality of life. The factors with the 
greatest impact at the population level were (urinary) urgency (attributable 
number(AN)/1000 subjects (AN=24), benign prostatic hyperplasia (AN=19), and snoring 
(AN=16) for men and overweight and obesity (AN=40), urgency (AN=24), and snoring 
(AN=17) for women. This attributable number study generalizability was limited as it 
was done in a Finnish population and the impact measures generally are context specific. 
Alcohol consumption reporting was incomplete, yet nocturia prevalence did not vary by 
alcohol consumption among those reporting this information Although several correlates 
were identified, none accounted for a substantial proportion of the population burden, 
highlighting the multifactorial etiology of nocturia (Tikkinen et al., 2009). The 
questionnaire mailing round did not affect correlate prevalence.  However, four 
exceptions emerged (age adjusted). First-round responders reported more nocturia and 
urgency than responders in subsequent rounds (P for trend = 0.04), and first-round female 
responders were slightly less obese than those in subsequent rounds (P for trend = 0.05). 
However, the odds ratio estimates for these factors were similar for each round, 
suggesting absence or systematic error. This study was an evidence level I and of high 
quality. 
A double-blind randomized, crossover study with evidence level I and with good 
quality was done to study the effects of newly diagnosed women with OAB with a 
history of caffeine consumption (Wells et al., 2014). The women were randomly assigned 
to two groups, each group taking decaffeinated and caffeinated drinks for 14 days. The 
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periods were preceded by a 14-days run-in period and interspersed with a 14-days 
washout period.  The primary outcomes were episodes of urgency, frequency, volume per 
void, and incontinence obtained each period on 3-day bladder diaries. Secondary 
outcomes measures were OAB symptoms severity and health-related quality of life 
(QOL) recorded each period using International Consultation on Incontinence- 
Overactive Bladder Module (ICIQ-OAB-Quality of Life (ICIQ-OABqol) tools. Effects of 
caffeine reduction were measured each day using visual analogue scales. The sample size 
was small with only 11 participants completing the study. A significant reduction in 
urgency (p<0.01) and frequency (p< 0.05) of urinary voids on day 3 of the diary, total 
ICIQ-OAB score (p<0.01), and a non-significant directional change for the total ICIQ-
OABqol score (P=0.065) was found using sign tests for the period of decaffeinated 
compared to caffeinated drink intake. No significant differences were found for any 
caffeine withdrawal measures. The small sample size was a threat to the validity and 
reliability as the results could not be generalized.  Another limitation was that there were 
no power calculations undertaken in order to determine sample size. There was also no 
trial to consider the value of episodic analysis of compliance over the entire treatment 
period. Nevertheless, the pilot study demonstrated that reducing caffeine intake may 
alleviate the severity of some symptoms and health-related quality of life factors 
associated with OAB (Wells et al., 2014). 
Jafarabadi et al. (2015), evaluated the response of women over 45 years with 
OAB and detrusor overactivity to a 12-week course of oxybutynin or tolterodine 
treatment.  This randomized, double-blind, parallel group trial was designed to determine 
the effectiveness of oxybutynin (5mg immediate release {IR} tablet three times a day) 
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versus tolterodine (2 mg IR tablet every 12 hours) in a 12-week treatment of OAB in 
women over 45 years. The study was performed in a women’s clinic in Tehran, Iran.  
There were 410 patients screened and 301 randomized to oxybutynin group (n=151) and 
tolterodine group (n=151).  There was a mean improvement in terms of urgency (P=0.64) 
and urge incontinence (P=0.75. The study showed that both medications significantly 
decreased the incidence of frequency, urinary incontinence and urgency. According to the 
3-day urinary diaries, after treatment with oxybutynin, the daytime frequency and the 
nocturia episodes decreased 39.3% (P = <0.001) and 40.1% (P<0.001), respectively. In 
the tolterodine group, the daytime frequency and the nocturia episodes decreased 36.5% 
(P = 0.001) and 54.3% (P< 0.001), respectively. The evaluation of urinary urgency 
showed a significant decrease in both groups. The urinary urgency and nocturnal urinary 
urgency were decreased by 30.7% (P < 0.001) and 39.7% (P = 0.001), respectively, in the 
oxybutynin group and 28.2% (P = 0.002) and 41.2% (P < 0.001), respectively, in the 
tolterodine group.  There was a statistically significant decrease in episodes of moderate 
and severe incontinence with oxybutynin (40.6%; P < 0.001); there was also a significant 
decrease in patients treated with tolterodine (39.1%; P = 0.009). A limitation of this study 
was a small sample size, short follow-up duration and subjective nature of the follow-up. 
This study found both drugs had similar efficacy on daytime symptoms of OAB and 
similar side effects in perimenopausal patients (Jafarabadi et al., 2015). The study did, 
however, find that tolterodine was preferred for chief complaint of nocturnal frequency 
(Jafarabadi et al., 2015). This article was an evidence level I and of good quality. 
A randomized, double-blind, placebo-controlled phase III study enrolled 1139 
Japanese patients experiencing OAB symptoms for ≥ 24 weeks. The purpose of the study 
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was to evaluate the efficacy and safety of the βз-adrenoceptor agonist mirabegron, in a 
Japanese population with OAB. Men or women aged ≥ 20 years, with OAB symptoms 
for ≥ 24 weeks, entered an initial 2-week, single-blind, placebo run-in period. Key OAB-
related exclusion criteria included a diagnosis of genuine stress incontinence, an average 
total daily urine volume > 3000 ml during the 3-day pre-treatment micturition diary 
period, and a post-void residual urine volume of at least 100ml when measured before 
treatment. Patients with ≥ 8 micturitions/24 hours or ≥1 urgency incontinence episode/24 
hours were randomized to once daily placebo, mirabegron 50mg or tolterodine 4mg (as 
an active comparator, without testing for non-inferiority of efficacy and safety) for 12 
weeks. The primary endpoint was change in mean number of micturitions/24 hours from 
baseline to final assessment. The demographic and baseline characteristics were similar 
for the groups receiving placebo, mirabegron and tolterodine. Mirabegron was found to 
be significantly superior to placebo in terms of mean (SD) change from baseline in 
number of micturitions/24 hours (-1.85) [2.555] vs -1.37 [3.191]; P=0.025), incontinence 
episodes/24 hours (-1.01 [1.338] vs -0.60 [1.745]; P=0.008), and volume voided/ 
micturition (24.300 [35.4767] vs 9.715 [29.0864] ml; P<0.001). The generalizability of 
this study to other diverse populations may be a limitation. This study may have some 
bias as it was sponsored by industry. The incidence of adverse events in mirabegron 
group was similar to that of the placebo group. Most adverse events were mild and none 
were severe. Mirabegron 50mg once daily was found to be an effective treatment for 
OAB symptoms, with low occurrence of side effects (Yamaguchi et al., 2015). This 
article was an evidence level I and of good quality. 
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The SUNRISE study was a randomized, double-blind, 16-week, placebo-
controlled, rising dose trial conducted to examine the effects of the antimuscarinic agent 
solifenacin on urinary urgency. There were 863 patients in the study that was conducted 
105 centers in 14 European countries and was conducted in accordance with the 
principles of Declaration of Helsinki (1996 version) and the International Conference on 
Harmonization Guidelines for Good Clinical Practice (Cardozo et al., 2008). The primary 
efficacy variable was the change from baseline to endpoint in the number of episodes of 
severe urgency with or without urgency incontinence per 24 hours, as measured using the 
Patient Perception of Intensity of Urgency Scale, grade 3+4. The secondary efficacy 
variables included patient-reported outcomes for bladder condition, urgency bother and 
treatment satisfaction. A 3-day voiding diary was used to record micturition frequency 
and episodes of urgency and incontinence. A 7-day diary was used to assess speed of 
onset of effect. Solifenacin 5/10mg was significantly more effective than placebo in 
reducing the mean number of episodes of severe urgency with or without incontinence 
per 24 hours from baseline to endpoint (-2.6 vs 1.8, P<0.001). There were statistically 
significant differences in favor of solifenacin 5/10mg over placebo for all secondary 
variables measured at endpoint, including patient-reported outcomes. There was a 
significant improvement in urgency as early as day 3 of treatment. Treatment-emergent 
adverse events with solifenacin 5/10 mg were mainly mild or moderate in severity, and 
only led to discontinuation in 3.6% of patients.  The study was found to have potential 
bias as it was supported by industry. The study found that Solifenacin 5/10 mg 
significantly reduced the number of urgency episodes and the extent of urgency bother 
(Cardozo et al., 2008). Solifenacin was well tolerated and was found to be effective as 
 28 
 
 
early as day 3 of treatment (Cardozo et al., 2008). This article was an evidence level I and 
of good quality. 
2.4 LEVEL TWO 
Juliato et al. (2016), performed a descriptive, exploratory, cross-sectional study to 
assess OAB symptoms on quality of life in Brazilian women. The dependent variable was 
OAB and the independent variables were socio-demographic data, health related habits 
and problems with self-perception of health, and gynecological background. It was a 
simple random sample of 749 participants ages 45 to 60 years and who resided in the 
metropolitan region of Campinas.  The mean age was 52.5 and with regard to 
menopausal, 16% were premenopausal, 16% perimenopausal, and 68% postmenopausal. 
The prevalence of OAB was 7.8% with the vast majority of women having only urinary 
urgency. Only two women who responded to the interview reported urge incontinence. In 
the final statistical model, vaginal dryness (Poisson Regression 2.21; 95% CI 1.11-4.40; 
p=0.025) were associated with greater prevalence of OAB. However, the reliability of 
some variables such as genital prolapse, the presence of bacteriuria and complains of 
LUTS may have been a threat to the study.  Moreover, some women may have 
minimized urinary symptoms with in-person interview. As such, the results may have 
been incongruent as they were based on self-reporting. The study showed that health 
professionals should adopt proactive behavior in surgically menopausal women and those 
with a history of genital atrophy to identify and treat OAB, thus contributing to an 
improved quality of life and healthier aging. The study had evidence level II and good 
quality. 
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Qian-Sheng & Hann-Chorng (2010), conducted a prospective study on Chinese 
patients that showed a strong correlation between the Overactive Bladder Symptom Score 
(OABSS) and Urinary Severity Score (USS) questionnaires based on a voiding diary 
noted in patients with OAB. The changes in these two measures were similar after 
solifenacin 5mg daily for one month was given to participants. The OABSS questionnaire 
was linguistically validated. There were 170 patients recruited, 98 men and 72 women. A 
high OABSS total score was significantly associated with a high grade of USS. There 
was a significant correlation between the two scores (R²=0.5520, p<0.0001). The main 
contributions of the OABSS in patients with low USS were daytime frequency and 
nighttime frequency. The contribution of urgency and urgency urinary incontinence 
became significant in patients with high urgency grades. The changes in the USS and 
OABSS were significant at 1 month. The change in frequency was significant in the 
daytime as well as at nighttime. A limitation of the study was that the OABSS and the 
Urogenital Distress Inventory short form, measures the frequency and urgency episodes 
during a given period, but the severity of urgency is not assessed as a quantitative 
measure of reflecting real life conditions. The findings from these articles were evidence 
level II and good quality. 
 Hung et al. (2011), performed a randomized clinical trial on 60 patients with 
OAB who visited different hospitals in Taiwan. These patients were tested using the 
Chinese OABSS. Patients were randomized either incontinent (OAB wet, n=31) or 
continent (OAB dry, n=29). The test-retest reliability of the Chinese OABSS was 
moderate to good, with weighted kappa coefficients of 0.515-0.721 for each symptom 
score and 0.610 for the total symptom score. Each symptom score correlated positively 
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with the total OABSS (Spearman’s rho 0.365-0.793) and was internally consistent 
(Cronbach’s alpha 0.674). The distribution of the OABSS showed clear separation 
between OAB wet (average 11.4, range 7-15) and OAB dry (average 7.97, range 4-10) 
subgroups (Wilcoxon exact test, p<0.05).  In addition, the OABSS items correlated 
positively with the corresponding bladder diary variables (Spearman’s rho 0.504-0.879) 
and the degrees of agreement improved with study visits except for nighttime frequency. 
The Chinese OABSS tended to underestimate the frequency of nighttime voiding. The 
Chinese OABSS was developed and validated as a reliable instrument for assessing OAB 
symptoms. OABSS can be an alternative to, but not a replacement for, 3-day bladder 
diary for assessing patients. This was an evidence level II and of high quality. 
Cardozo et al. (2014), had 100 women complete the Actionable Bladder Symptom 
Screening Tool (ABSST). The ABSST was initially developed to identify patients with 
multiple sclerosis (MS) who could benefit from lower urinary tract assessment and 
treatment. This was a prospective, observational study performed in 6 gynecological 
clinics located in the USA. The women completed the ABSST, OAB Questionnaire Short 
Form (OAB-q SF), and the patient global impression of severity (PGI-S) scale. Half of 
the sample had urinary urgency incontinence (UUI), while the other half did not. 
Descriptive statistics, reliability, and validity were examined, as was sensitivity and 
specificity of the previous cut-off score established in patients with multiple sclerosis. 
Fifty-three women with UUI/OAB and 47 controls took part (71% Caucasian). Patients 
with UUI/OAB were older (54.6 vs 40.4years), had a higher body mass index (31.1 vs 
26.4 kg/m²), and more comorbid conditions.  The Cronbach’s alpha reliability of ABSST 
was 0.90. High correlations with OAB-q SF Symptom Bother and Health Related Quality 
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of Life (r=0.83 and -0.81 respectively) supported concurrent validity.  Using the PGI-S 
severity scores as a reference, the ABSST was able to distinguish patients with differing 
severity levels (known-group validity).  The study found that a score of 3 on ABSST may 
highlight the presence of bladder symptoms consistent with OAB and facilitate critical 
communication between the patient and their healthcare provider and further evaluation 
when warranted. The tool was validated in non-neurogenic females and found to be a 
reliable, valid and sensitive tool for screening women with urinary urge incontinence and 
OAB (Cardozo et al., 2014). The results from this study demonstrated that a cut-off 
ABSST score of 3 distinguished between patients who should be treated for urge urinary 
incontinence or OAB vs those who did not require treatment. This article was evidence 
level II and of good quality. 
A mixed-method qualitative/quantitative needs assessment of patients with 
overactive bladder and/or urinary symptoms was conducted by Filipetto et al. (2014). 
Primary care providers may lack training in OAB or lack clinical awareness of effective 
evaluation and management strategies. Inadequate communication between patients and 
providers has limited successful diagnosis, treatment, and management of OAB. Another 
barrier to effective management of OAB is poor patient adherence or persistence to 
treatment. The causes of non-adherence are multifactorial and may include unclear or 
unrealistic treatment goals, side effects or inconvenience of therapy, cost, or simply 
forgetting to follow the treatment regimen. A sample of 194 interviewees were 
prescreened for a history of OAB and/or urinary incontinence. The data analyses for 
survey responses was conducted using SPSS. Descriptive statistics such as mean and 
frequencies were provided. Differences in knowledge scores for respondent gender, 
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respondents age (41-60 and ≥ 61 years), provider gender, and provider specialty were 
determined using analysis of covariance (ANCOVA) to control for the lag time between 
the respondents first noticed symptoms and when he/she talked with a provider about 
their symptoms. Analysis of variance (ANOVA) was used to determine the difference in 
knowledge score with frequency of communication between the patient and provider and 
type of educational material utilized. On average, respondents had experienced urinary 
and bladder symptoms for 9 years (SD=9.3) while only being under a provider’s care for 
these symptoms for 5.8 (SD=6.0) years, resulting in an average time gap of 3.5 years 
between symptom onset and treatment initiation. The survey results showed that only 
14% of survey participants reported that ‘my provider asked me about urinary or bladder 
symptoms’. Interviewees reported that they felt providers were quick to prescribe 
medication even when the patient did not necessarily think it was needed. Only 29% and 
31% of surveyed participants reported being provided bladder training and pelvic floor 
exercises, respectively. Interviewees reported overall dissatisfaction with clinicians’ 
frequency and quality of communication regarding OAB. Forty-one percent said they 
discussed urinary or bladder symptoms ‘occasionally’, while 32% reported discussions 
‘nearly every visit’. These findings were similar to interview responses where follow-up 
conversations initiated by either patient or provider after initial diagnosis and treatment 
rarely occurred. Patients preferred regular discussions on OAB with their provider, with 
75% of those surveyed rating this issue as ‘very important’. Limitations to this study was 
the survey was not pilot tested and was not validated. The responses were developed 
using responses from the qualitative interviews. Participants were also recruited using a 
company that compiles panels of participants. This study may have limited 
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generalizability due to selection bias of participants. This study was an evidence level II 
and of good quality. 
2.5 LEVEL THREE 
The study by Basra et al. (2012), compared the value of two validated 
questionnaires: Bladder Control Self-Assessment Questionnaire (B-SAQ) and the 
Overactive Bladder Awareness Tool (OAB-V8). This was a comparison study whose aim 
was to compare the value of two validated questionnaires: Bladder Control Self-
Assessment Questionnaire (B-SAQ) and the Overactive Bladder Awareness Tool (OAB-
V8). Two hundred and twenty-three women were recruited on the basis of their 
presenting symptoms. The mean age of the women was 49 years (range 19-84). Only 
fully completed questionnaires were used for statistical analysis and 219 responses were 
used for data analysis. The receiver operating curve (ROC) identifying stress 
incontinence was 0.85 and 0.68 for the B-SAQ and OAB-V8, respectively, which shows 
that the B-SAQ is a good test and the AOB-V8 is poor test for stress incontinence. 
Cohen’s Kappa calculations in patients with a clinical diagnosis of OAB showed values 
of 0.2 for both B-SAQ and OAB-V8 questionnaires (P=.01); indicating fair agreement 
between both questionnaires and the clinical diagnosis. The B-SAQ lower urinary tract 
screening questionnaire was found to be a better test for stress and mixed urinary 
incontinence identification than OAB-V8. The study was found to have some selection 
bias as all patients were from general gynecology and urology clinics and not primary 
care settings. Limitation of the study were only English-speaking patients were included; 
and OAB-V8 was found to be a poor test for stress incontinence and a fair test for mixed 
incontinence; and OAB-V8 was too specific and may lead to exclusion of a large affected 
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population.  The study had an evidence level III and good quality.  Both questionnaires 
were found to perform well in identifying and screening for OAB symptoms in clinical 
setting.  
 A Belgian study done by de Ridder et al. (2013), used the validated Bladder 
Control Self-Assessment Questionnaire (B-SAQ) and complemented with a question on 
stress urinary incontinence (SUI) and bladder bother to assess the prevalence of OAB.  
This epidemiological study had general practitioners collect data on OAB and SUI 
prospectively on women 40 years and older during a regular visit for any reason. The 
presence of mild bladder control symptoms (BCS) was defined as an overall B-SAQ 
symptom score (OSS) ≥ 4 and an overall bother score (OBS) ≥ 1. The data was collected 
on 7193 women, with a mean (SD) age of 61.0 (12.6) years. About 33.9% had mild BCS. 
Most women reported overall mild OAB symptoms (46.9) and 34.9% had moderate-to-
very severe symptoms. The prevalence of moderate-severe urgency, frequency or 
nocturia was higher than that of moderate-severe incontinence. Urgency and nocturia 
were considered the most bothersome symptoms. Moderate-severe stress urinary 
incontinence affected 17.7% of women. About 16.4% of women reported to be 
moderately-severely bothered by their bladder in everyday life. The risk of severe 
symptoms and bother increased with age. About 10% of women had clinically significant 
BCS (OSS ≥ 7 and OBS ≥ 4). A limitation of the study was some women may have felt 
hindered or embarrassed to indicate their problems in the presence of the provider, 
causing underreporting. The B-SAQ is not a diagnostic questionnaire and does not assess 
whether the symptoms experienced are actually caused by OAB or whether other pelvic 
disorders are present. The study found that a significant proportion of women aged 40 
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years and older do not only have OAB symptoms, but also consider these bothersome in 
daily life. This article was evidence level III with good quality. 
 Fujimura et al. (2011), had 318 Japanese female patients, ages ranging from 15-91 
years complete three questionnaires: Core lower urinary tract symptoms (CLSS); 
International Prostate Symptom Score (IPSS); and OABSS. The quality of life (QOL) 
was determined as per IPSS quality of life index.  The clinical diagnoses were OAB, 
mixed incontinence, pelvic organ prolapse, interstitial cystitis, bacterial cystitis, 
underactive bladder and other. All symptoms scores were significantly increased in 
symptomatic women. The CLSS described the symptom profile of patients with distinct 
conditions. The scores of corresponding symptoms on the three questionnaires were 
significantly correlated (r=0.51-0.85; all p < 0.0001). Multivariate logistic regression 
modeling proved five CLSS symptoms (daytime frequency, nocturia, urgency 
incontinence, straining, and urethral pain) as independent predictors of poor QOL, with 
hazard ratios ranging from 2.0 to 4.2. The IPSS included only two (urgency and 
straining) significant symptoms. The IPSS was designed for men with BPH and may have 
limited ability to illustrate female LUTS, such as incontinence symptoms. The IPSS alone 
was found not to fully evaluate female LUTS, with a possible negative impact on quality 
of life. Using the CLSS questionnaire was found to enable simple and comprehensive 
assessment of female LUTS. This comparative study was found to have evidence level III 
with good quality. 
Jongen et al. (2015), had 141 multiple sclerosis (MS) patients (ages ranging from 
24 to 73 years), complete the ABSST. This observational non-interventional web based 
study, assessed retest reliability and concurrent validity of a Dutch version of the English 
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ABSST. The test compared the test performance of the simplified scoring with a cut-off 
point 3, with that of a cut-off point 2, using cut-off point 6 as the gold standard. A total 
score of ≥ 3 showed sensitivity of 0.79 and a specificity of 0.98 with respect to the 
clinician-based assessment of whether or not treatment was needed. Their findings 
suggest that in MS patients the simplified ABSST scoring is more accurate with cut-off 
point 2 than with cut-off point 3, especially by substantially reducing false negative 
outcomes; and that in MS the original ABSST scoring seemed preferable (Jongen et al., 
2015).However, in a study on women with incontinence due to OAB, it was 
demonstrated that the use of the ABSST with a cut-off score 3 strongly distinguishes 
between patients who should be treated versus those who do not require treatment. This 
article was evidence level III and of high quality. However, in a study in women with 
incontinence due to OAB, it was demonstrated that the use of the ABSST with cut-off 
score 3 strongly distinguishes between patients who should be treated versus those who 
do not require treatment (Cardozo et al., 2014). 
Lekskulchal et al. (2008), retrospectively reviewed records of a largely Caucasian 
female population, who had undergone an interview, clinical examination, multichannel 
urodynamic studies and translabial ultrasound examination. The detrusor wall thickness 
measurements were taken at the bladder dome, after bladder emptying. The receiver-
operator characteristics(ROC) analysis was used to identify the optimal cut-off of 
detrusor wall thickness in predicting detrusor overactivity.  The researchers reviewed 686 
records of women who had attended a tertiary urodynamic center. They found that the 
average detrusor wall thickness in the detrusor overactivity group was 4.7+/- 1.9 mm 
(mean +/- SD), compared with 4.1 +/- 1.6 mm in the non-detrusor overactivity group (p< 
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0.001). Using a cut-off of detrusor wall thickness of 5.0 mm gave a sensitivity of 37% 
and a specificity of 79% for diagnosing detrusor overactivity. The ROC analysis revealed 
an area under the curve (AUC) of 0.606 (95% CI 0.56-0.65). This diagnostic method did 
not yield high specificity or sensitivity. The researchers did not use a transvaginal 
ultrasound and only measured the dome. Lekskulchal et al. (2008), found that 
measurement of detrusor wall thickness should not be used as a diagnostic parameter for 
detrusor over-activity in women. 
Palma et al. (2013), performed an epidemiological study to verify the presence of 
OAB symptoms in premenopausal women and related them with child-bearing data. 
There were 1052 women of child-bearing age (20-45 years) in Brazil, who were asked to 
complete the International Consultation on Incontinence Questionnaire- Overactive 
Bladder (ICIQ-OAB) questionnaire. A validated ICIQ-OAB Portuguese version, with 
specific questionnaire for the specific demographics was utilized. Multiparous and 
primiparous women showed significantly higher scores in the ICIQ-OAB questionnaire 
than nulliparous women. Multiparous women presented more frequency than nulliparous 
women (P < 0.0001). No significant difference was found in urgency (P = 0.0682), and 
multiparous women presented more urgency incontinence than nulliparous ones (P= 
0.0313). The study was performed in mostly public places and as such made it impossible 
to perform physical assessments in participants. Their study found that nulliparous 
women presented with less OAB symptoms than primiparous women; while multiparous 
women symptoms were more than the other two groups (Palma et al.,2013). There were 
no significant differences (P = 0.0743), between the mode of delivery (cesarean or 
vaginal) (Palma et al., 2013). This was an evidence level III and of good quality. 
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A retrospective study was done to evaluate the relationship between urodynamic 
detrusor overactivity (DO) and OAB symptoms in men and women by Al-Ghazo et al., 
2011. Two hundred and nine patients’ records (117 men and 92 women) in a tertiary 
referral center in Jordan were reviewed for urodynamic evaluation of OAB syndrome 
symptoms with the presence or absence of DO. Incidence of DO was 76.1% and 58.7% in 
male and female OAB patients, respectively. Of men 63% and 61% of women with 
urgency (OAB dry) had DO, while 93% of men and 69.8% of women with urgency and 
urgency urinary incontinence (OAB wet) had DO. Of men, 58% who were OAB wet had 
stress urinary incontinence symptom with 26.4% having urodynamic stress incontinence. 
While 6% of men and 6.5% of women with OAB symptoms had urodynamic diagnosis of 
voiding difficulties with post-void residual greater than 100ml.  Combination of 
symptoms is more accurate in predicting DO in OAB patients. The multivariate disease 
model for males included urge urinary incontinence (UUI) and urgency while for females 
it included UUI and nocturia. The results were statistically evaluated using Mann-
Whitney and Fisher’s exact probability tests for comparison of the findings between DO 
and no DO patients, and for comparison between symptoms and urodynamic findings. 
The results showed that there was a better correlation between OAB symptoms and the 
urodynamic diagnosis of detrusor overactivity in men than in women, more so in OAB 
wet than in OAB dry (Al-Ghazo et al., 2011). Limitations to the study compared 
subjective symptoms with objective parameters; follow-up data was lacking in some 
patients; and there was not adequate information regarding whether or not urodynamic 
findings altered management for these patients. This was an evidence level III and of 
good quality. 
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Reynolds et al. (2015), performed a systematic review and meta-analysis of the 
original research on community dwelling women with non-neurogenic OAB undergoing 
pharmacotherapy with medication available in the USA. They reviewed randomized 
controlled trial for meta-analysis and cohort, case-control, and case series for harms data. 
Five data sources were reviewed, and they included MEDLINE, EMBASE, Cumulative 
Index of Nursing and Allied Health Literature, and ClinicalTrials.gov. The objective of 
the review was to summarize evidence about reduction in voiding and resolution of urine 
loss in OAB comparing data from the active drug arms with the placebo arms of 
randomized trials (Reynolds et al., 2015). Multiple team members performed data 
extraction independently with secondary review of data entry to ensure quality and 
validity. This article was an evidence level III and of good quality.  No individual 
medication demonstrated superiority over another and anticholinergic management for 
OAB showed modest and rarely full resolution of symptoms (Reynolds et al., 2015). 
A cross-sectional, descriptive, correlational design was used to study to examine 
the level of knowledge and the attitudes and perceptions of APRNs regarding urinary 
incontinence in older adult women by Keilman & Dunn, (2010). Eligible participants had 
completed a master’s degree in nursing from an accredited university, had achieved 
national certification as a nurse practitioner, clinical nurse specialist, or midwife, and 
worked with older adult women. The study sample was 54 or 75% response rate, with 
initially 72 APRNs initially agreeing to participate. Approximately 57% (n=31) of the 
APRNs reported they diagnose UI in their clinical practice. Of the APRNs who diagnose 
UI, 60% also treat, manage, educate, and counsel patients regarding with condition.  
Approximately 54% (n=29) of the APRNs answered they were taught about UI in their 
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graduate program. Only 48% felt their education on the topic was adequate. This group of 
APRNs reported learning more about UI through attending conferences where UI was 
offered as a topic (n=30, 72.2%), consulting a UI specialist (n=21, 38.9%), or acquiring 
specific information through professional journals (n=48, 88.9%). UI guidelines were 
used regularly in practice by only 24.1% (n=13) of the APRNs. Most of the participants 
understood that UI is not a normal part of the aging process (M=1.87, SD=1.03). All 
participants (N=54) strongly agreed that UI was an important health concern that should 
be handled by APRNs. Thirty-eight of the APRNs (70.3%) reported they always asked 
about UI when performing a health assessment. However, the participants did not 
necessarily feel confident in their assessment/diagnostic skills related to UI (M=3.50, 
SD=0.95) and in managing and/or treating UI independently (M=3.06, SD=1.05). The 
respondents also knew education was a crucial component in the management of UI 
(M=4.61, SD=0.50). Most of the APRNs (M=4.02, SD=0.63) recognized that prompted 
voided improves symptoms of urge and mixed UI and can be recommended as a 
noninvasive treatment. Respondents were not sure of the pharmacologic effects on 
symptoms of detrusor overactivity in women (M=3.41, SD=0.81) and were not aware of 
the pharmaceutical classifications of drugs that could potentially cause UI (M=2.94, 
SD=1.05). Participants also reported not feeling comfortable assessing older women’s 
motivation for learning (M=3.87, SD=0.78). Providing anticipatory guidance and/or 
counseling for women with UI was not strong with this group of APRNs (M=3.28, 
SD=1.10). An education index (EI) was computed that reflected the type of education of 
the APRNs reported receiving on UI. A statistically positive correlation was found 
between EI and age (r=0.47). APRNs that were older reported higher levels of education 
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regarding women with UI than younger APRNs. In addition, a statistically significant 
correlation was found between the total scale score and EI (r=0.40), the knowledge 
subscale score and EI (r=0.27), and the Attitudes/Perceptions subscale score and EI 
(r=0.51). APRNs who reported a higher level of education regarding UI had more 
accurate perceptions, more positive attitudes, and more knowledge regarding older adult 
women with UI than those who reported lesser level of education. The reliability of the 
KAPUIOW scale was estimated by Cronbach’s alpha. Total scale estimate was α= 0.86, 
with α=0.81 for the Attitudes/Perception subscale, and α=0.77 for the knowledge 
subscale. Limitations to this study was it was self-reported data, lengthy questionnaire 
that took approximately 1-2 hours to complete and the small sample size that was not 
randomly sampled. According to Keilman & Dunn (2010), the single most important 
action that APRNs can take is to ask every older adult about UI and then follow with the 
basic approaches to evaluation and management of UI. 
Nguyen et al. (2016), investigated family physicians’ knowledge of, attitudes 
towards, and understanding of UI, as well as their perceptions of barriers to continence 
care, as a foundation for designing interventions to improve service provision for those in 
northern Alberta who suffer from UI. A descriptive survey using a standardized 
instrument was used. The survey instrument was complete either by telephone interview 
or a paper copy faxed back to the researcher. Hundred and fifty-eight participants in 
Alberta, Canada, were randomly selected from the publicly available directory published 
by the College of Physicians and Surgeons of Alberta using a computer-generated 
random-number list. UI was thought to affect quality of life to some extent or a great 
extent by 85.5% of physicians, ranking behind depression, arthritis, and chronic pain. 
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Among the 158 participants, 53.8% (85 of 158) indicated that they proactively discussed 
incontinence with most or all of the patients they suspected had incontinence problems; 
29.7% (47of 158) indicated that they proactively discussed incontinence with some of 
their patients, and 15.2% (24 of 158) indicated that did not discuss incontinence with 
anyone unless the patients raised the issue themselves. After initial management, such as 
providing lifestyle advice, prescribing medication, recommending incontinence products, 
or providing referral to specialist, 78.5% (124 of 158) of physicians sometimes, if not 
always, arranged follow-up appointments specifically to deal with the incontinence; 
21.5% (34 of 158) rarely if ever arranged follow-up. Reasons for lack of confidence in 
management included concerns about the level of training, drug side effects, a lack of 
support services in the area, and the general embarrassment around UI. In total, 70.9% 
(112 of 158) of family physicians reported that improving the treatment and management 
of patients with incontinence was a fairly high if not a high priority to them personally, 
with 25.9% (41 of 158) reporting it to be either a fairly low or a low priority. Limitations 
to the study was the response rate of the physicians was low and the researchers finding 
may not be generalizable. This article was an evidence level III and of good quality. 
Another study by Duralde et al. (2016), sought to conduct an observational cohort 
study to identify clinical and sociodemographic determinants of patient-provider 
discussion and treatment of incontinence among ethnically diverse, community-dwelling 
women. The women were aged 40-80 years enrolled in Kaiser Permanente Northern 
California. Clinical severity, type, treatment, and discussion of incontinence were 
assessed by structured questionnaires. Mean age of the participants was 59.9 years and 
55% were racial/ethnic minorities (171 black, 233 Latina, 133 Asian or Native 
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American). Fifty-five percent reported discussing their incontinence with a health care 
provider, 36% within 1 year of symptom onset, and with only 3% indicating that their 
provider initiated the discussion.   More than half (52%) reported being at least 
moderately bothered by their incontinence. Of these women, 324 (65%) discussed their 
incontinence with a clinician, with 200 (40%) doing so within 1 year of symptom onset. 
In a multivariate analysis, women were less likely to have discussed their incontinence if 
they had a household income <$30,000 vs ≥ 120,000/year (adjusted odds ratio [AOR], 
0.49, 95% confidence interval (CI), 0.28-0.86) or were diabetic (AOR, 0.71, 95% CI, 
0.51-0.99). They were more likely to have discussed incontinence if they had clinically 
severe incontinence (AOR, 3.09, 95% CI, 1.89-5.07), depression (AOR, 1.71, 95% CI, 
1.20-2.44), pelvic organ prolapse (AOR, 1.98, 95% CI,1.13-3.46), or arthritis (AOR, 
1.44, 95% CI, 1.06-1.95). Among the subset of women reporting at least moderate 
subjective bother from incontinence, black race (AOR, 0.45 95% CI, 0.25-0.82, vs white 
race) and income < $30000/ year (AOR, 0.37, 95% CI 0.17-0.81, vs ≥ $120000/year) 
were associated with a reduced likelihood of discussing incontinence. Those with 
clinically severe incontinence (AOR, 2.93, 95% CI, 1.53-5.61, vs low to moderate 
incontinence by the Sandvik scale) were more likely to discuss it with a clinician.  A 
limitation of the study was that it relied on participant report for incontinence status. The 
study did not include women who had previously suffered from incontinence, underwent 
evaluation, and were successfully treated or those with less frequent incontinence. The 
study findings suggest that even among women with frequent incontinence and 
streamline and affordable access to primary care and specialist services, the rates of 
patient-provider discussion of incontinence remain low, and rates of provider initiated 
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screening for incontinence are even lower. This was an evidence level III and of good 
quality. 
Teunissen et al. (2015), conducted an observational study to determine the 
effectiveness of introducing a nurse practitioner in UI care and to explore women’s 
reasons for not completing treatment. Sixteen nurse practitioners working with a GP’s 
office in the Netherlands, undertook a training program in which they learned how to 
manage female patients with UI. All patients were examined and referred by the General 
Practitioner (GP) to the NP working in the same practice.  At baseline the severity of the 
UI (Sandvik-score), the impact of the quality of life (IIQ) and the impressed severity 
(PGIS) was measured and repeated after three months. Differences were tested by the 
paired t and the NcNemar test. Reasons for not completing treatment were documented 
by the nurse practitioner and differences between the group that completed treatment and 
the drop-out group were tested. Hundred and three women were included, mean age 55 
years (SD 12.6). The Sandvik severity categories improved signinficantly (P<0.001), as 
did the impact on daily life (2.54 points, P=0.012). Among the IIQ score the impact on 
daily activities increased 0.73 points (P=0.032), on social functioning 0.60 points 
(P=0.030) and on emotional well-being 0.63 points (P=0.031). The PGIS -score improved 
in 41.3% of the patients. The most important reasons for not completing the treatment 
were lack of improvement of the UI and difficulties in performing the exercises. Women 
who withdrew from guidance by the nurse practitioner perceived more impact on daily 
life (P=0.036), in particular on the scores for social functioning (P=0.015) and emotional 
well-being (P=0.015). Limitations to the study were dropout rate in this study was 32% 
which is considered high; no control group was involved as a RCT which received care 
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by the GP and the training program for patients with UI is time consuming, and not 
always easy to sustain and difficult to implement in daily life. Treatment by a trained NP 
seems to have a small positive affect the severity of the UI and the impact on the quality 
of life. NPs involved in the care of patients generally leads to an improvement of health 
outcomes and patient satisfaction. Women who did not complete treatment suffer from 
more impact on quality of life, experience not enough improvement and mention 
difficulties in performing exercises. This was an evidence level III and of good quality. 
2.6 LEVEL FOUR 
 Barkin (2016), discusses the pervasiveness of nocturia in men and women who 
present with LUTS. Barkin (2016) article is an evidence level IV and of good quality. Dr. 
Barkin gives his expert opinion in this article, exploring the different causes and types of 
nocturia, then describes how to diagnose different types of nocturia (including use of 
frequency-volume charts), and discusses different approaches to managing nocturia 
(including the use of desmopressin), depending on the type and cause. The article 
discusses the importance of taking a patient’s history to determine the onset and severity 
of nocturia, and also find out if nocturia is consistent or intermittent. Clinicians should 
rule out the other medical and non-medical causes of LUTS.  All appropriate tests – 
urinalysis, urine culture and sensitivity test, urine cytology test (if indicated), serum 
creatinine test to rule out renal failure (if indicated), abdominal/or pelvic ultrasound (if 
indicated), and frequency-volume charts. Barkin (2016), finds that nocturia is pervasive 
in both genders who present with LUTS. Once it is determined that a patient has 
nocturnal polyuria based on the frequency-volume chart, clinicians can then safely offer a 
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new, low-dose, effective synthetic oral disintegrating tablet of desmopressin (Nocdurna), 
which has few side effects (Barkin, 2016). 
An article by Carcio (2014), takes a nurse practitioner perspective on OAB. This 
article is a level IV and of good quality. OAB is not life threatening, but it is lifestyle 
threatening. Carcio (2014), discusses the importance APRNs identifying patients using 
assessment of health history, a focused examination, and office based tests. Fifty percent 
of women with bladder problems do not mention them at patient visits. The article 
discusses a survey done by the National Association of Nurse Practitioners in Women’s 
Health that surveyed 300 APRNs, and found that although most respondents could 
identify common symptoms of OAB and its’ adverse effect on quality of life, more than 
half reported that they lacked confidence in their ability to accurately identify OAB and 
more than half reported lacking sufficient knowledge to effectively treat OAB.  APRNs 
are ideally suited to educate patients about OAB, as well as diagnose and treat OAB. If 
the patients are more knowledgeable about OAB, they would recognize it when it arises 
and understand that treatment is available. With continued emphasis on OAB in academic 
programs and national conferences, APRNs can educate themselves to face this challenge 
Eapen & Radomski (2015), discuss four studies, the EPIC study, the National 
Overactive Bladder Evaluation(NOBLE) study, the Epidemiology of Lower Urinary 
Tract Symptoms (EpiLUTS) study, and the MILSOM study, that assess the impact of 
OAB symptoms, their findings and prevalence and impact on quality of life. According to 
the EPIC study which was conducted in five countries, showed the prevalence of OAB 
and its symptoms increases with increasing age in both genders. Looking specifically at 
urinary incontinence (UI), women had a much higher rate of any UI (urge, mixed, stress 
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and other) than men (13.1% versus 5.4%). The NOBLE study showed an overall OAB 
prevalence of approximately 16% with no significant differences between the two sexes 
(16% in men, 16.9% in women). The study also found an association between OAB with 
UI and body mass index (BMI)in women but not men. Women with BMI > 30 were 2.2 
times more likely to have OAB with UI than women with BMI <24. The EpiLUTS study 
conducted in the United States, United Kingdom and Sweden, showed the prevalence of 
OAB symptoms “sometimes” and “often” were 27.2% and 15.8% respectively, whereas 
in women, the prevalence of OAB symptoms “sometimes” and “often” was 43.1% and 
32.6%, respectively. Women had an overall higher prevalence of symptoms such as 
urgency, UI or both. The MILSOM study conducted in France, Germany, Italy, Spain, 
Sweden and United Kingdom, found an overall prevalence of OAB symptoms of 16.6%. 
In the MILSOM study, the overall prevalence of frequency and urgency were comparable 
irrespective of gender. These studies also found that older patients (over age 65) were 
more likely to consult a clinician than younger patients with OAB. Treatment for OAB 
should take on a multidisplinary approach with the implementation of lifestyle 
modifications, behavioral therapies and pharmacotherapy for the most optimal outcome 
(Eapen & Radomski, 2015). This article was an evidence level IV and of high quality.  
A study by Alber-Heitner et al.(2010), explored the experiences and attitudes of 
nurse specialists in primary care regarding their role in care for patients with urinary 
incontinence (UI), thereby identifying facilitators and barriers for wider implementation. 
This study was a level IV and of good quality.  A focus group was conducted with six 
female nurse practitioner specialists who were trained in caring for patients with UI. The 
study was carried out from May 2005 until March 2008 in four Dutch regions. These 
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nurse specialists followed patients in a RCT (n=384) for 12 months. At the end of the 
intervention period, nurse specialist experiences and attitudes were explored in one focus 
group study. Prior to the focus group study, a short questionnaire was sent to the 
participants to collect demographic data, education and nursing experience. To increase 
dependability and confirmability, the interview was transcribed verbatim. To improve 
consistency and reliability of the analyses, the external moderator and the researcher 
analyzed the transcript independently of each other. The findings showed that most nurse 
specialists main reason to participate was to enhance their professional role, provide more 
than patient care, develop a new specialty and look for new challenges. Nurse specialists 
felt that most patients with UI were satisfied and happy with their care and therefore 
seemed to accept this care by nurse specialists. The trained nurse specialist appeared to 
feel competent and satisfied to support physicians in care for patients with UI. There 
were some limitations to this study. The researchers chose only one a qualitative focus 
group discussion with only six nurse specialist. Because the nurse specialists knew the 
researchers had an interest in the intervention they may have made socially desirable 
comments, and as such creating a bias. The limited number of nurse specialists may limit 
the generalizability of the results to similar situations in the primary care setting in a new 
context. 
2.7 LEVEL FIVE 
 A descriptive cross-sectional study was performed by Levokowicz et al. (2011), 
1111 American women internet users (ages 40-65), were surveyed online. A sample of 
611 women in same age bracket with symptoms of OAB was surveyed regarding their 
experiences and attitudes about treatment. Women with nocturia in the study tended to 
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prolong seeking treatment.  They found women with OAB, including nocturia, were more 
likely than women with OAB, excluding nocturia, to alter their behavior in social 
situations, refrain from physical activity and intimacy, and cancel social plans because of 
their condition.  The results of this study showed that women with OAB almost always 
got up to urinate at night, but 1 in 5 (n=121 of 611 [20%]) respondents typically 
experienced severe nocturia, necessitating four or more trips to the bathroom during the 
night. Most women surveyed (n=586 of 611 [96%]) got up at least one time during the 
night to urinate. Despite their more severe symptoms, respondents with OAB including 
nocturia, surprisingly were no more likely to consider themselves proactive about seeking 
treatment for their symptoms than women without nocturia. In fact, nearly 2 in 5 (n=172 
of 478 [36%] of women with nocturia surveyed had never sought treatment for symptoms 
of OAB, whereas 29% (n=39 of 133) of those with OAB but without nocturia reported 
they had not sought treatment. Interestingly, those who had nocturia, 76% (n=365 of 478) 
reported that they waited longer than they should to consult a provider versus 65% (n=86 
of 133) of women without nocturia. Roughly one-third of women with OAB in the 
sample survey experienced nocturia regardless of whether or not they were in treatment; 
149 of 478 (31%) were in treatment, 157 of 478 (33%) had stopped treatment, and 172 of 
478 (36%) had never treated their OAB. Moreover, 63% (n=316 of 500) of nationally 
representative American women reported that not getting enough sleep throws off their 
sense of “normalcy.”  In addition, 60% (n=300 of 500) of women reported that when one 
aspect of life is thrown off, it disrupts other areas of life. The results of this study suggest 
how nocturia, in particular, impacts quality of life considerations, and thus, could 
represent a factor disrupting a person’s sense of normalcy.  A limitation of this study, is 
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participants had to have access and knowledge of a computer to answer the survey 
questions.  The generalizability of this survey may be questioned as it may not be 
representative of the general US population in the target age group and across all desired 
demographics (Levokowicz et al., 2011). They found more public health education was 
needed to improve consumer knowledge about OAB including nocturia and 
understanding of all treatment options for its symptoms. The article evidence level was V 
and good quality.    
2.8 SYNTHESIS OF THE LITERATURE 
 A review of the literature was conducted and evidence table developed to enable 
an understanding of the studies and to determine their evidence level and quality per the 
John Hopkins evidence guidelines (Dearholt & Dang, 2012). After reviewing several 
articles, a hierarchy of baseline characteristics and outcome measures were developed: 
nocturia, frequency, urgency, detrusor muscle overactivity, urge incontinence, bladder 
control, quality of life, urodynamic measures and assessment tools. All articles were 
reviewed for validity and reliability. The evidence table is presented in its’ entirety in 
Appendix B.  
 The evidence table was created to support a systematic tabulation and assessment 
of study characteristics including, (1) a brief reference, type of study and quality rating, 
(2) methods, (3) threats to validity/reliability, (4) sample, sample size and setting, (5) 
study findings that help answer the evidence based practice question, (6) limitations, and 
(7) conclusions. This allowed for identification of common threads in reporting across the 
articles. The experience of having OAB is a constellation of self-reported events, 
symptoms, and the impact they have on an individual’s life (Hartmann et al., 2009). 
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Thus, measures of quality of life, interference with daily activities, degree of distress 
from symptoms, and satisfaction with the outcomes of treatment are also common and 
helpful metrics in this literature (Hartmann et al., 2009). 
2.9 SUMMARY 
Despite the evidence showing the impact of OAB on quality of life, many women 
delay seeking treatment for their symptoms (Eapen & Radomski, 2015; Levokowicz et 
al., 2011). Four studies, the EPIC study (Coyne et al., 2008), the National Overactive 
Bladder Evaluation(NOBLE) study, the Epidemiology of Lower Urinary Tract Symptoms 
(EpiLUTS) study, and the MILSOM study, assessed the impact of OAB symptoms on 
quality of life (Eapen & Radomski, 2016). The EPIC study showed a prevalence of LUTS 
suggestive of OAB 10.8% in men and 12.8% in women. The NOBLE study showed a 
prevalence of 16% in men and women. The EpiLUTS study found an overall higher 
prevalence of symptoms such as urgency, UI or both in women. The MILSOM study 
found a prevalence of 15.6% in men and 17.4% in women with OAB symptoms.  
Various articles have discussed validated OAB screening tools that have been 
retested in various countries and populations. Some tools are more specific to OAB 
symptoms while other tools assess urinary incontinence. The ABSST, OABSS, CES-D, 
IPBC, PPBC, WPAI-SHP, CLSS, B-SAQ, OAB-V8, IPSS, ICIQ-OAB-Quality of life, 
are all validated screening tools that have been used in several settings to assess patients 
with urinary incontinence and OAB symptoms (Basra et al., 2012; Cardozo et al., 2014; 
Coyne et al., 2008; De Ridder et al., 2013; Fujimara et al.,2011; Hung et al., 2011; Quian-
Sheng & Hann-Chorng, 2010; Sumardi et al., 2012).  
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Wells et al., (2014), pilot study demonstrated that reducing caffeine intake may 
alleviate the severity of some symptoms. Juliato et al. (2016), study showed that when 
clinicians are assessing women who are menopausal, premenopausal, peri-menopausal or 
post-menopausal; they should adopt a proactive behavior in surgically menopausal 
women and those with a history of genital atrophy to identify and treat OAB symptoms. 
Palmas et al. (2013), found that there was no significant difference (P=0.0743) in OAB 
symptoms, between mode of delivery (cesarean or vaginal). Lekskulchai & Dietz (2008), 
found that when evaluating detrusor overactivity, the measurement of detrusor wall 
thickness should not be used as a diagnostic parameter. Al-Ghazo et al. (2011), did 
however find a better correlation in detrusor overactivity between OAB symptoms and 
the urodynamic diagnosis of detrusor overactivity in men than in women, more in OAB 
wet than in OAB dry. 
Oral antimuscarinics agent, such as tolterodine, and solifenacin were not found to 
demonstrate superiority over another in the systematic review done, and anticholinergic 
agents showed modest and rarely full resolution of symptoms (Reynolds et al., 2015). 
The efficacy of a βз-adrenoceptor agonist mirabegron 50mg was found to be effective in 
treatment of OAB symptoms, with a low occurrence of side effects in a Japanese 
population (Yamaguchi et al, 2014).  
The National Association of Nurse Practitioners in Women’s Health (NPWH) 
surveyed 300 NPs to ascertain their own level of recognition and treatment of OAB in 
their practice, and found most respondents could identify common symptoms of OAB 
and its adverse effects on quality of life (Carcio, 2014). However, more than half reported 
that they lacked confidence in their ability to accurately identify OAB and more than half 
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reported lacking sufficient knowledge to effectively treat OAB (Carcio, 2014). Barriers to 
changing practice may include a lack of provider confidence in discussing UI, lack of 
training in clinical examination, and diagnosis and treatment of OAB. APRNs who 
reported a higher level of education regarding UI had more accurate perceptions, more 
positive attitudes, and more knowledge regarding older adult women with UI than those 
who reported lesser levels of education (Keilman & Dunn, 2010). APRNs can make a 
difference in the management of UI in women if they are taught the essentials and UI and 
OAB practice guidelines, and have the assessment tools at hand to quickly assess patients 
for UI and OAB (Keilman & Dunn, 2010).  With proper screening for OAB, 
communication between provider and patient about OAB, most, if not all, of the patients 
with this condition can be identified and treated (Albers-Heitner et al., 2010; Carcio, 
2014; Duralde et al., 2016; Filipetto et al., 2014; Keilman & Dunn, 2010; Nguyen et al., 
2013; Teunissen et al., 2015). 
2.10 DISCUSSION OF BEST PRACTICE 
 A review of current literature supports OAB screening by primary care providers 
to aid in recognizing OAB early and initiating appropriate treatments, thus decreasing the 
time women wait to seek treatment (Barkin, 2016; Basra et al., 2012; Cardozo et al., 
2014; Coyne et al.,2008; De Ridder et al., 2013; Eapen & Radomski, 2016; Fujimura et 
al., 2011; Hung et al., 2011; Jongen et al., 2015; Juliato et al., 2016; Kinsey et al., 2016; 
Levkowicz et al., 2011; Palma et al., 2013; Quian-Sheng & Hann-Chorng, 2010; Sumardi 
et al., 2012; Tikkinen et al., 2009).  The potential impact of this quality improvement 
project was to increase the provider’s knowledge about OAB symptoms; and assess the 
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provider perception of the ABSST effectiveness in assessing OAB symptoms in their 
patients’.  
Successful OAB treatment requires a willing participant who is informed  
and engaged in the treatment process, understands that OAB has a variable and chronic 
course likely requiring multiple management strategies over time with no single ideal 
treatment and understands that treatment vary in invasiveness, risk of adverse effects and 
reversibility (Gormley et al., 2012). Most OAB treatments improve patient symptoms but 
are unlikely to eliminate all symptoms (Gormley et al., 2012). Explaining what is normal 
can help the patient understand their condition and give a comparator for establishing 
mutually-identified and realistic goals for treatment (Gormley et al., 2012). Education 
empowers the patient to participate in their treatment, an essential factor when 
interventions rely on behavior change. 
 It is believed that the use of a simple urinary symptom screener in primary care 
settings, may facilitate discussions between the patient and healthcare provider regarding 
OAB, and thereby help to identify women who could benefit from treatment (Cardozo et 
al., 2014). A validated OAB screening tool would be useful to healthcare providers in 
monitoring disease progression, as well as response to treatment. 
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CHAPTER 3 
METHODS 
 The purpose of this chapter is to present the methodology used to conduct 
the DNP project. The methodology included description of the design, units of analysis, 
sample, setting, outcomes to measure, the theoretical framework utilized, strategies to 
reduce barriers and increase support, the procedure, and the data analysis. The purposes 
of this project were to (1) determine an effective standard OAB screening tool to be used 
in a retail clinic environment (see Appendix A), (2) determine the knowledge level of 
providers regarding OAB, and (3) measure provider’s perception of the ABSST 
effectiveness in assessing for OAB in patients. 
3.1 DESIGN 
This descriptive exploratory pre- and post-test design assessed the knowledge 
level of providers regarding OAB. The investigator conducted a pre- and post-test design 
to ascertain the providers’ perception of the ABSST effectiveness in assessing for OAB 
following an educational model to teach how to use the ABSST. 
3.2 UNIT OF ANALYSIS 
The researcher utilized descriptive statistical analysis to describe the sample of 
providers. Most providers in the Walgreens clinic are advance practice nurse practitioners 
(APRNs). T-testing was used to assess the means, and descriptive statistics was used to 
analyze data pre- and post-test design for measuring the provider’s knowledge level and 
perception of the effectiveness in assessing for OAB using the ABSST. The descriptive 
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statistics demographic data included years in practice, gender, age, and role (NP, PA). 
The provider’s knowledge and perception of the screening tool effectiveness 
survey (see appendix B), assessed the provider’s pre-and post-knowledge of OAB. The 
survey also captured data regarding the perceptions of the providers in the ABSST 
effectiveness in assessing for OAB. The combined survey consisted of seven questions 
on OAB and as based on a five-point Likert Scale ranging from Strongly Agree (5) to 
Strongly Disagree (1). For example, a question asked the providers if OAB condition 
affects many women globally and in the U.S.A.  Another question asked the provider if 
women with urinary incontinence problems often seek treatment immediately. The 
providers were asked to utilize the ABSST tool and rate its’ effectiveness in highlighting 
the presence of OAB symptoms and whether it facilitated communication between them 
and the patient. Barriers to providers initiating the conversation with patients was also 
assessed using a five-point Likert scale. This tool was not a validated research tool and 
had no psychometric findings in the literature. 
3.3 SAMPLE 
The sample size included 153 providers, who were asked to utilize the Actionable 
Bladder Symptom Screener Tool (ABSST) (see Appendix C) with at least 50% of their 
patients whom they saw for UTI symptoms, who meet the inclusion criteria.   Inclusion 
criteria included providers with prescriptive authority directly involved in providing 
episodic and primary care to adults in Walgreens clinics. Another inclusion criteria, was 
providers who would be able to utilize the language line for patients whom English is a 
second language, to assist in answering the questions on the tool. Fulltime, part-time 
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providers and providers who worked as needed, and had access to a computer for the 
online training module, either in the clinic or from home were also be included.  
The investigator reached out to the Walgreens education team, the Atlanta market 
educator, and asked their assistance in gaining access to all Walgreen providers’ emails.  
3.4 INSTITUTIONAL BOARD APPROVAL 
 Upon receiving approval from USC IRB, written information about the study was 
sent by the researcher to potential participants via Walgreens email.  The email invited 
the potential subjects to participate in the evidence based project. In the email, the 
researcher explained the purpose of the quality improvement project, the educational 
module, the pre- and post-test data collection procedures. The subjects were also given 
time frames to complete surveys and estimated time to complete the pretest survey, 
educational modules, and post-test survey. A link for the online Class Climate survey for 
providers to access to complete their pre-test knowledge and post-test of OAB was 
provided. The survey also captured data pre-test regarding the perceptions of the provider 
in the ABSST effectiveness in assessing for OAB, if any. Participation in the survey was 
voluntary and all responses were anonymous. Participation implied consent to participate. 
The researcher used the subject providers’ mother’s birthdate, using month and year, as 
in 10-1940, for example, to be able to link the pre-and post-survey. The pre-and post-
surveys was merged by their mother’s birthdate. 
3.5 SETTING 
The setting for the DNP project and implementation of the OAB assessment tool 
was online via Walgreens email server. There were over 400 clinic sites throughout the 
country. Walgreens retail clinics provide a range of services from immunizations, 
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physicals, treatment of acute illnesses to chronic disease management. The clinics 
provide care to male and female patients from ages 18 months and older. 
3.6 DATA COLLECTION PROCEDURE 
 There were two phases for the data collection procedure. The first phase included 
a pre-test survey which the provider completed online via Class Climate survey. The 
provider’s knowledge and perception of the screening tool effectiveness survey (see 
appendix B), was distributed online via Class Climate to assess the provider’s pre-test 
knowledge of OAB. The survey also captured data pre-test regarding the perceptions of 
the provider in the ABSST effectiveness in assessing for OAB, if any.  
Once the provider subject completed the pre-test, they were provided a link to 
access and complete the educational component of the program. This was conducted via 
Grand Rounds on the online educational department website, to teach providers strategies 
for managing OAB in women presenting to the clinics. The ABSST was also presented to 
the providers as a validated tool that could be utilized to screen for OAB symptoms. The 
ABSST is a validated tool with psychometric properties and findings in the literature 
(Cardozo et al., 2014; Jongen et al., 2015). The subject providers were asked to provide 
their mother’s birthdate, using the month and year only, to link the pre-and post-survey to 
the same provider. 
The researcher with the assistance of the educational team at the Walgreens 
clinics presented a Grand Rounds educational session on OAB via the online meeting 
center called Genesys (See Appendix H). All providers were invited to view and listen to 
the power point presentation recorded on October 27th, 2016. The presentation was 
approximately 40 minutes in length. The providers who participated in the OAB grand 
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round session were eligible for one credit hour of continuing education (CE) credit 
offered by Rush University. Rush University is accredited as a provider of continuing 
nursing education by the American Nurses Credentialing Center’s Commission on 
Accreditation (ANCC). Providers subjects who participated in the grand rounds were 
asked to email the date of completion to the researcher. 
Once the educational module was completed, the providers were asked to 
complete an online post-test survey, the provider’s knowledge and perception of the 
screening tool effectiveness survey (see appendix D), via Class Climate survey. They 
were able to access the post-test survey by a link that was emailed to all subjects who 
were initially invited to participate in the project. Once the participant linked with Class 
Climate survey, each participant would receive a written introduction again about the 
survey that explained the purpose of the project, protection of subjects, and consent. All 
responses were anonymous. The providers were asked to provide their mother’s 
birthdate, asking only for the month and year, to link the pre- and post- survey. 
Participation was voluntary in the survey and implied consent. 
Once the subject completed the module, a second online post-test survey was sent 
to the same group of potential subjects. The provider’s knowledge and perception of the 
screening tool effectiveness post-test survey (see Appendix C) was distributed online via 
Class Climate to assess the provider’s post-test knowledge of OAB. The survey also 
captured data post-test regarding the perceptions of the provider in the ABSST 
effectiveness in assessing for OAB, if any. All responses were anonymous for pre- and 
post-test. However, the researcher asked the providers for the mother’s birthdate, asking 
only for the month and year, to link the pre- and post-test to each provider. Participation 
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was voluntary in the survey and implied consent. Providers did not receive any financial 
incentive to participate. 
3.7 OUTCOMES MEASURED 
The outcomes measured were increased knowledge regarding the use of screening 
of OAB as measured by (1) the provider’s knowledge of OAB pre-and post-educational 
intervention, (2) the provider’s perception of the ABSST effectiveness in assessing for 
OAB pre- and post-educational intervention. 
3.8 THEORETICAL FRAMEWORK 
This project was based on the theoretical framework of the Model for Evidence-
based Practice Change (Rosswurm & Larrabee, 1999). There are six steps that help the 
DNP student progress through evidence-based project, on improving outcomes for 
patients with OAB.  
Step 1. Assess the need for change in practice 
The identified problem was that providers in the Walgreens Healthcare Clinics may not 
routinely screen women who may potentially present with OAB symptoms.  A standard 
OAB assessment tool was utilized by the providers to assess women over 40 years of age 
who may potentially need further treatment or referral. The Healthcare Clinics at 
Walgreens are now able to manage primary care problems and having a validated, 
standard OAB assessment tool, would further assist providers in screening their patients. 
There was no data provided by Walgreens as to how many women present with OAB 
symptoms. Having a standard OAB assessment tool that is simple may potentially 
increase awareness by providers of the problem and help patients improve their quality of 
life. 
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Step 2. Locate the best evidence 
The evidence that was used was a validated, standard OAB assessment tool.  Sources of 
evidence included electronic bibliographic databases, websites, journals and textbooks. 
The databases utilized were CINAHL, Joanna Briggs, NIH, Google Scholar, National 
Guidelines Clearinghouse, PubMed, The Cochrane Collaboration, Web of Science and 
Turning Research into Practice (TRIP) database. The John Hopkins Evidence Level and 
Quality Guide was used evaluate the evidence of the sources. The John Hopkins Nursing 
Evidence-Based Practice process occurs in three phases and can be simply described as 
Practice question, Evidence, and Translation (PET), which uses a five-level scale to 
determine the type, level, and quality of evidence (Dearholt & Dang, 2012). 
Step 3: Critically Analyze the Evidence 
Most articles were appraised and judged for their evidence and found to be of good 
quality but the levels of articles ranged from level I through level V. Issues that promote 
the feasibility of this EBP project are that the study can be conducted in about 3 months 
and the researcher can potentially get good sample size of providers to participate, and 
approval has been obtained from the Walgreens education team and the chief nursing 
officer (CNO). Of concern to the researcher a good sample size of provider participation. 
Another concern will be provider acceptance of the ABSST.  
Step 4: Design Practice Change 
An OAB assessment tool was provided to the providers in the retail setting.   
The researcher involved the CNO and market educators to champion the project  
with the providers. Providers were notified via email (see Appendix C) of the study and 
request participation in the study. Providers who accepted to be in the study were asked 
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to participate in an educational session known as Grand Rounds, and an anonymous Class 
Climate pre-and post-survey that was sent to each provider to assess improved knowledge 
after utilizing the standard OAB screening tool. 
Step 5: Implement and Evaluate Change in Practice 
The researcher assessed provider knowledge and got feedback  
on the effectiveness of the OAB tool, using Class Climate survey.   The  
providers’ feedback was used to make minor adjustments in the implementation  
plan, if necessary ((Melnyk & Fineout-Overholt, 2015, p. 289). Based on the feedback of 
the providers, Walgreens would be asked to adapt, adopt, or reject the new OAB 
assessment tool. 
Step 6: Integrate and Maintain Change in Practice 
3.9 STRATEGIES TO REDUCE BARRIERS AND INCREASE SUPPORT 
A major advantage of survey research was that there was the potential for a large 
sample size due to the fact that Walgreens clinics were in multiple market. According 
to Melynk & Fineout-Overholt (2015), before embarking on a study, important questions 
to ask regarding feasibility are: 
1. Can the study be conducted in a reasonable amount of time? 
2. Are there an adequate number of potential subjects to recruit into the study? 
3. Have the settings for recruitment been identified and is accessibility a concern? 
4. Does the lead person (PI) have sufficient time and expertise to spearhead the effort? 
5. Are there major ethical or legal constraints to undertaking this study? 
6. Are there adequate resources available at the institution or clinical site to conduct the     
study? If the answer is no, what is the potential for obtaining funding? 
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Five issues that promoted the feasibility of this evidence based project were: (1) 
 could the study be conducted in about 3 months or less, (2) would the providers in the 
clinics can complete the online educational modules, (3) would the providers complete 
the Class Climate survey online, (4) how would the investigator obtain emails for 
providers who are employed in the Walgreens Clinics for provider recruitment, and (5) 
would the same providers complete the online survey pre- and post. 
 The answers to all five issues was yes. The researcher anticipated it may take 
more time to carry out the project than originally projected and had incorporated a buffer 
period (i.e., extra time) in case of IRB approval delay, access to subject recruitment took 
longer than anticipated. Walgreens education team provided the emails for all providers 
working in the clinics. The market educators, Walgreens IRB team, and Chief Nursing 
Officer approval of the project also facilitated the researcher’s consideration in whether it 
would be feasible. The researcher anticipated provider “buy-in” to the project.    
3.10 DATA ANALYSIS 
Once the survey data was returned, the researcher, in collaboration with a 
statistician, reviewed the data and, created data in the form that would be useable in SAS 
9.4 for analysis. The researcher utilized descriptive statistical analysis to describe the 
sample. Descriptive statistics include frequency tables for categorical variables and 
means, standard deviation, and range for continuous variables. Matched-paired t-test was 
used to examine the increase of knowledge after the introduction of the education tool. 
Also, inferential statistics including parametric test (t-test) and non-parametric test (sign 
ranked test) were used to examine the difference in means for knowledge and perception 
of the providers over a 3-month period for this quality improvement study. 
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3.11 SUMMARY 
Once all the data for the study was collected and analyzed, the researcher planned 
to share the recommendations about the adaptability of the OAB tool in the clinics with 
the market educators, chief nursing officer and the providers. The researcher also shared 
the findings with University of South Carolina College of Nursing and planned to 
publish. The researcher used the data gained from the survey to design an in-service 
education workshop to enhance the providers’ knowledge and skills in this area. This in-
service was conducted via Genesys (an online center utilized by providers for educational 
needs at the Walgreens retail clinic setting). The researcher would continue to 
communicate with the champions and participants and keep them abreast of the progress 
being made and actions that have resulted from the research. The researcher would ensure 
the relationship was maintained after research was concluded by giving feedback to the 
participants. 
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CHAPTER 4 
RESULTS 
The purpose of this project was to (1) determine an effective standard screening 
tool to be used in a retail clinic environment, (2) determine the knowledge level of 
providers regarding OAB, and (3) measure provider’s perception of the ABSST 
effectiveness in assessing for OAB in patients. Descriptive statistics were used to 
describe the sample. Inferential statistics included parametric test (T-test) and non-
parametric test (sign ranked test) to examine the difference in means for providers’ 
knowledge of OAB and perception of their effectiveness in assessing OAB pre-and post-
intervention. This quality improvement project was conducted over a 3-month period. 
The researcher obtained IRB approval from both Healthcare Clinics in Walgreens 
and University of South Carolina prior to initiating the study in the clinic setting. The 
researcher then obtained support from the clinic stakeholders – the market educators, 
providers and assistant area directors – to encourage participation.  After obtaining 
providers’ email from the Healthcare Clinic Directors, the initial recruitment invite with 
the consent and Class Climate survey was sent on December 2nd, 2016 (See Appendix E). 
The recruitment phase was completed on December 23rd, 2016. Those providers who 
emailed the researcher upon completing the pre-survey, were then asked to complete the 
educational module on OAB online (See Appendix H) and email the researcher. 
Thereafter, the providers were sent the ABSST (See Appendix C), and asked to use with 
their patients that met the criteria for 4 weeks. The researcher then sent out weekly 
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remainder emails (See Appendix F) to participants to continue using the tool with  
patients’ who met the criteria. After the utilizing the ABSST in the clinic for 4 weeks, the 
participants were sent the post survey (See Appendix G). The providers were sent 
reminders every 3 days to complete the post survey with the final day on February 16th, 
2016. The purpose of this chapter was to present the findings of the project. 
4.1 DESCRIPTION OF SAMPLE 
Over 1000 potential providers were targeted to participate and of those, 153 
providers agreed to participate but only 52 providers completed the study including the 
pre- and post-surveys, the educational module, and utilized the ABSST tool with their 
patients that met the criteria. The mean age of the sample was 50 years old. See Table 4.1 
for characteristics of the respondents who completed the pre-survey and post-survey. 
Table 4.1 Frequency and percentage of respondents to the online pre-survey and post-
survey  
Characteristic Pre-survey (N=153) 
N                 % 
Post survey (N=52)  
N                  % 
Gender    
Male 8                5.52 1                     2 
Female 136           93.79 49                 98 
Age Range    
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25-35 17             11.26 2                    3.9 
36-45 41             27.16 19                37.92 
46-55 47             31.13 16             31.37 
>55 46             30.46 14             27.45 
Years of NP Practice    
1-3 years 39                26 10              19.23 
4-7 years 39                26 14              26.92 
>8 years 72               48 28              53.85 
Title    
NP 145            96.03 49                 98 
PA 6               3.97 1                     2 
 
Findings indicated that 16 participants correctly linked their pre- and post-survey 
using their mother’s date of birth. See Table 4.2 for characteristics of the 16 matched 
respondents pre-survey and post-survey. 
Table 4.2 Frequency and percentage of the 16 matched respondents pre-survey and post-
survey  
Characteristic  Pre-survey (N=16) 
N                 % 
Post-survey (N=16) 
N                 % 
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Gender    
Male 1                 6.67 1                 6.25 
Female 14               93.33 15              93.75 
Age Range    
25-35 years 3               18.75 1                  6.25 
36-45 years 6               37.50 7                 43.75 
46-55 years 4                   25 5                31.25 
>56 years 3               18.75 3                18.75 
Years of NP Practice    
1-3 years 5               31.25 4                   25 
4-7 years 6               37.50 4                    25 
>8 years 5                31.25 8                   50 
Title    
NP 15               93.75 14                93.33 
PA 1                 6.25 1                    6.67 
 
4.2 KNOWLEDGE OF OAB 
 The knowledge of the participants was assessed utilizing Class Climate pre-and 
post-survey (See Appendix D). Findings indicated between age groups, there were no   
statistically significant mean differences in pre-and post-survey (N= 151 pre-survey, and 
N=51 post-survey). Moreover, there were no statistically significant mean differences in 
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mean age between pre-and post-survey (N= 151 pre-survey, and N=51 post-survey). See 
Table 4.3 for survey items pre-and post-survey. 
Table 4.3.  Sample (N), Mean, Standard Deviation (STD) for pre-and post-survey 
between age groups 
Survey 
Item 
Pre 
  N        Mean        STD 
Post 
N       Mean         STD 
T-test 
 (p-value) 
OAB is a 
common 
condition 
affecting 
many 
women 
globally and 
in the US 
 153        4.16         .86  52          4.35          .71     0.154 
Women 
with urinary 
incontinence 
problems 
often seek 
treatment 
immediately 
150         2.07          .81 49            1.90         .65     0.171 
P value <0.05     
4.3 PROVIDER’S PERCEPTION OF THE SCREENING TOOL EFFECTIVENESS 
 The results of the T-test indicated significant mean differences for pre-and post-
intervention for ABSST effectiveness (P<0.0001) (N=148 pre-survey and N= 51 post-
survey), effectiveness in facilitating critical communication (P <0.0001) (N=145 pre-
survey and N=52 post-survey), and patient uncomfortable bringing up the topic 
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(P=0.0244) (N= 152 pre-survey and N= 52 post-survey). The results did not reveal any 
statistically significant difference for survey items (1) OAB is a common condition 
affecting many women globally and in the US (N= 153 pre-survey and N= 52 post-
survey); (2) women with urinary incontinence problems often seek treatment immediately 
(N= 150 pre-survey and N= 49 post-survey). See Table 4.4 for survey items pre-and post-
survey. 
Table 4.4 Sample (N), Mean, Standard Deviation (STD) for pre-and post-survey between 
age groups 
Survey Item Pre 
 25 years ≥ 56 years 
N           Mean       STD 
Post 
25 years ≥ 56 years 
N          Mean     STD 
T-test 
(p-value) 
The validated 
overactive 
bladder 
screening tool 
(ABSST) is 
effective in 
highlighting the 
presence of 
bladder 
symptoms 
consistent with 
OAB 
148          3.56      .69      51         4.14         .89 <0.0001* 
The ABSST is 
effective in 
facilitating 
145          3.57      .74      52        4.21          .78 <0.0001* 
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critical 
communication 
between patient 
and provider 
Lack of 
provider 
information 
about OAB 
symptoms 
151           3.73     .79      51        3.82          .77 0.4556 
Not enough 
time 
152           3.89     .86      52         4.02         .90 0.3482 
Patients are 
uncomfortable 
bringing up the 
topic  
152           4.03     .75     52          4.29         .61 0.0244* 
*P value <0.05 
 Non-parametric results were similar to the T-test results. Findings indicated that 
the mean differences between pre-and post-survey and provider age groups were not 
significantly different (p=0.943). Results indicated significant differences for ABSST 
effectiveness (P<0.0001), effectiveness in facilitating critical communication (P 
<0.0001), and patient uncomfortable bringing up the topic (P=0.0109) among provider-
age groups pre-and post-intervention. The results did not reveal any statistically 
significant differences between other survey items in Table 4.5 by age group. See Table 
4.5 for non-parametric sample (N), mean, standard deviation (STD), and Wilcoxon Test 
for survey items pre-and post by age groups. 
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Table 4.5 Non-parametric sample (N), mean, standard deviation (STD) for pre-and post-
survey between age groups 
Survey Item Pre 
 25 years ≥ 56 years 
N         Mean       STD 
Post 
25 years ≥ 56 years 
N           Mean     STD 
Wilcoxon Two-
sample test 
 (p-value) 
OAB is a 
common 
condition 
affecting many 
women 
globally and in 
the US 
153   100.06      332.29     52      111.66      332.29 0.0878 
Women with 
urinary 
incontinence 
problems often 
seek treatment 
immediately 
150    102.31    301.51 49       92.93       301.51 0.1256 
The validated 
overactive 
bladder 
screening tool 
(ABSST) is 
effective in 
highlighting 
the presence of 
bladder 
symptoms 
148    88.59     325.94 51     133.11      325.94 <0.0001* 
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consistent with 
OAB 
The ABSST is 
effective in 
facilitating 
critical 
communication 
between 
patient and 
provider 
145    86.98    321.57 52       132.50      321.57     <0.0001* 
Lack of 
provider 
information 
about OAB 
symptoms 
151     99.73     306.70 51       106.75       306.70  0.1916 
Not enough 
time 
152     99.91     336.98 52       110.07      336.99 0.1218 
Patients are 
uncomfortable 
bringing up the 
topic  
152     97.76      313.99 52       116.36      313.99 0.0109* 
*P<0.05 
 The matched paired for 16 participants showed an increased mean score for the 
providers’ knowledge between pre-and post-survey (N=16). The result of matched-paired 
T-test (p = .0306) and sign rank test (p = .0451) were similar (N=16). The results 
revealed on average a 2.38-unit increase in the provider’s knowledge from pre-survey to 
post-survey (N=16). See Table 4.6 for mean knowledge scores. 
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Table 4.6 Mean, STD, and 95% CI for the difference knowledge scores (post – pre) 
Variable                                                                                       95% CI 
N              Mean                   STD                     Mean                   P value 
Total OAB 16             2.38                      3.98               0.25 – 4.4                 0.0306* 
*P<0.05 
For providers’ age group, mean scores were different pre-and post-testing but they 
were not statistically significant for age groups 25-35, 36-45 and 46-55 (N=3, N=6, N=4 
respectively). For providers’ greater than 56 years of age, there was a statistically 
significant increase in the mean score of 5 and p=0.0340 (N= 3), indicating an increase in 
the provider’s knowledge and use of the OAB post intervention. See Table 4.7 below for 
the total OAB scale for age groups. 
Table 4.7. The total OAB scale for age 
Variable 25-35 years 
N Mean STD 
36-45 years 
N Mean STD 
46-55 years 
N Mean STD 
>56 years  
N Mean STD 
P  
value 
Total 
OAB 
3    -2        1  6   4.50   4.04 4   0.50   2.38 3    5        3         0.0340* 
*P<0.05      
Providers’ years of experience was not statistically significant for mean score 
differences in pre-and post-testing.  However, providers’ years or experience in the 
primary care setting for the matched paired design showed an increased mean score for 
all experience groups 1-3 years, 4-7 years and greater than 8 years between pre-and post-
testing. Providers with more than 8 years of experience had the largest increase in mean 
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score (3.60), even though it was not statistically significant p=0.6737 (N=5). See Table 
4.8 below for the total OAB scale for number of years in primary care setting. 
Table 4.8 The total OAB scale for number of years in primary care setting 
Years in 
Primary 
Care 
Setting 
1-3 years 
N       Mean    STD 
4-7 years 
N       Mean    
STD 
8 years or more 
N       Mean       STD 
 
P value 
Total 
OAB 
5        2.4         5.22 6       1.33    4.03 5        3.60           2.88       0.6737 
P<0.05 
4.4 ANALYSIS OF PICO 
 Among healthcare providers providing primary care in Walgreens clinics, does an 
educational model to teach providers the use of a standard OAB screening tool (ABSST), 
as compared to the use of no symptom screening tool, improve knowledge regarding the 
use of screening of OAB? The project PICOT sought to measure by (1) the provider’s 
knowledge of OAB pre-and post-educational intervention, (2) the provider perception of 
the ABSST effectiveness in assessing for OAB pre-and post-educational intervention, 
over a 3-month period.  
The post survey was emailed to79 participants upon utilizing the OAB tool for 
one month in the clinic with 52 participants completing the survey. Upon analyzing the 
pre-and post-survey data, only 16 participants correctly linked from the pre- and post-
survey using their mother’s date of birth.  Both the researcher and the statistician 
reviewed the data for accuracy and gaps. Table 4.9 and Table 4.10 show the results by 
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percentages of responses for the pre-and post-survey by the respondents (N= 153 for pre, 
N = 52 post).  
Table 4.9. Percentage of responses to the OAB and perceptions of ABSST effectiveness 
pre-survey(N=153) 
Survey Item SD                D               N              A                 SA 
OAB is a common condition affecting many 
women globally and in the U.S 
2.61           1.96             8.50         50.98            35.95 
Women with urinary incontinence problems 
often seek treatment immediately 
19.33        62.67           10.67         6.00              1.33 
The validated OAB screening tool (ABSST) is 
effective in highlighting the presence of 
bladder symptoms consistent with OAB 
1.35           0.68             45.27        45.95             6.76 
The ABSST is effective in facilitating critical 
communication between patient and provider 
2.76          0.69               39.31         51.03           6.21 
Lack of provider information about OAB 
symptoms 
0.66          9.27               16.56         63.58           9.93 
Not enough time 0.66          7.24               17.11         52.63          22.37 
Patients are uncomfortable bringng up the 
topic of OAB  
1.32          3.29                 9.21         63.82          22.37     
 
 
 
Table 4.10. Percentage of responses to the OAB and perceptions of ABSST effectiveness 
post-survey (N=52) 
Survey Item SD                D               N              A                 SA 
OAB is a common condition affecting many 
women globally and in the U.S 
1.92          1.92               0            53.86             42.31   
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Women with urinary incontinence problems 
often seek treatment immediately 
24.49         63.27          10.20         2.04               0 
The validated OAB screening tool (ABSST) is 
effective in highlighting the presence of 
bladder symptoms consistent with OAB 
3.92              0             9.80           50.98             35.29 
The ABSST is effective in facilitating critical 
communication between patient and provider 
1.92              0                0               51.92          36.54           
Lack of provider information about OAB 
symptoms 
0                9.80             9.80           68.63          11.76 
Not enough time 0                9.62             9.62           50               30.77 
Patients are uncomfortable bringng up the 
topic of OAB  
0                1.92            1.92          61.54           34.62     
 
Table 4.11 and Table 4.12 show results by percentage of matched responses pre-
and post-survey by respondents (N=16).  
Table 4.11. Percentage of responses to the OAB and perceptions of ABSST effectiveness 
pre-survey (N=16) 
Survey Item SD                D               N              A                 SA 
OAB is a common condition affecting many 
women globally and in the U.S 
0                   0              6.25          31.25          62.50 
Women with urinary incontinence problems 
often seek treatment immediately 
37.50          50               0              12.50           0 
The validated OAB screening tool (ABSST) 
is effective in highlighting the presence of 
bladder symptoms consistent with OAB 
0                  0               42.86         35.71            21.43 
The ABSST is effective in facilitating critical 
communication between patient and provider 
0                  0                50              42.86            7.14 
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Lack of provider information about OAB 
symptoms 
0                6.67              20             66.67             6.67 
Not enough time 0                  0                  25             50                 25 
Patients are uncomfortable bringng up the 
topic of OAB 
0                  0                12.50           56.25         31.25 
 
Table 4.12. Percentage of responses to the OAB and perceptions of ABSST effectiveness 
post-survey (N=16) 
Survey Item SD                D               N              A                 SA 
OAB is a common condition affecting many 
women globally and in the U.S 
0                   0                0            56.25            43.75 
Women with urinary incontinence problems 
often seek treatment immediately 
31.25           50             18.75            0                 0 
 The validated OAB screening tool (ABSST) 
is effective in highlighting the presence of 
bladder symptoms consistent with OAB 
0             0              12.50              50                37.50 
The ABSST is effective in facilitating critical 
communication between patient and provider 
0             0               12.50             31.25             56.25 
Lack of provider information about OAB 
symptoms 
0             0                18.75             62.50            18.75  
Not enough time 0            25               12.50             37.50            25 
Patients are uncomfortable bringng up the 
topic of OAB ͨ 
0             0                 6.25              56.25           37.50 
 
The results from the T test pre-to post survey revealed a statistically significant 
increase in the ABSST effectiveness in highlighting OAB symptoms (p<0.0001) (N=148 
pre-survey and N=51 post survey); and a statistically significant increase in the ABSST 
facilitating communication (p<0.0001) (N=145 pre-survey and N=52 post survey). The 
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results demonstrated that patients are uncomfortable approaching and discussing OAB 
(p=0.0109) (N= 152 pre-survey and N=52 post survey). Other survey items were not 
statistically significant. See Table 4.13 for N, mean, STD pre-and post for each survey 
item. 
Table 4.13. The N, mean, STD pre- and post for each survey item 
Survey Item   Pre                                 
N             Mean           STD 
Post 
N              Mean           STD 
OAB is a common condition 
affecting many women 
globally and in the U.S 
153           4.16            0.86 52             4.45              0.71 
Women with urinary 
incontinence problems often 
seek treatment immediately 
150           2.07             0.81 49             1.90              0.65 
The validated OAB 
screening tool (ABSST) is 
effective in highlighting the 
presence of bladder 
symptoms consistent with 
OABª 
148           3.56            0.69 51              4.14              0.89 
The ABSST is effective in 
facilitating critical 
communication between 
patient and provider ᵇ 
145           3.57            0.74 52              4.21             0.78 
Lack of provider information 
about OAB symptoms 
151            3.73            0.79 51              3.82             0.77 
Not enough time 152            3.89            0.86 52               4.02             0.90 
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Patients are uncomfortable 
bringng up the topic of OAB 
 ͨ 
152            4.03             0.75 52               4.29              0.61 
a. P value = <0.0001  b. P value = <0.0001    c. P value = 0.0109 
The results revealed a significant change at a 95% confidence interval that the total mean 
difference between pre and post survey for matched T-test is between 0.2536 and 4.4964, 
with p=0.0306 (N=16). This findings indicates that providers’ knowledge and awareness 
of OAB symptoms and screening in adult women were increased following an 
educational online module. See Table 4.14 for N, mean, STD pre-and post-total OAB 
survey pre-and post. 
Table 4.14. The N, mean, STD pre-and post-total OAB survey difference pre-and post. 
Survey N                          Mean                     STD P value 
Total OAB 16                         2.375                   3.981      0.0306* 
*P<0.05 
The two questions that sought to measure provider knowledge pre to  post 
educational module were not statistically significant. See Table 4.14 for the N, mean, 
STD for survey items measuring provider knowledge pre- and post survey. 
Table 4.15. The N, mean, STD for survey items measuring provider knowledge pre- and 
post survey  
 
Survey Item 
Pre 
N            Mean         STD 
Post 
N         Mean      STD 
 
P value 
OAB is a common 
condition affecting 
many women globally 
and in the U.S 
153         4.16          0.86 52         4.35        0.71 0.1542 
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Women with urinary 
incontinence problems 
often seek treatment 
immediately 
150          2.07          0.81 49         1.90         0.65 0.1713 
P<0.05 
The two questions that sought to measure the provider perception of the ABSST 
effectiveness in assessing for OAB in patients were statistically significant (N=148; 
N=145 pre survey and N=51; N=52 post survey). The validated overactive bladder 
screening tool (ABSST) was found to be statistically significant in  hightlighting the 
presence of bladder symptoms consistent with OAB at a 95% confidence interval (-
0.8163 - -0.3366) with p< 0.0001 (N=148 pre-survey and N=51 post survey). The 
ABSST is effective in facilitating critical communication between patient and provider 
was signigicant at 95% confidence interval (-0.8787 - -0.3995, p<0.0001) (N=145 pre-
survey and N=52 post survey). See Table 4.16 for the N, mean, STD for survey items 
measuring provider perception pre- and post survey. 
Table 4.16. The N, mean, STD for survey items measuring provider perception pre- and 
post survey  
 
Survey Item 
Pre 
N        Mean   STD 
Post 
N        Mean      STD 
 
P value 
The validated OAB 
screening tool 
(ABSST) is 
effective in 
highlighting the 
presence of bladder 
symptoms 
148      3.56      0.69 51         4.14        0.89 <0.0001* 
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consistent with 
OAB 
The ABSST is 
effective in 
facilitating critical 
communication 
between patient and 
provider  
145     3.57       0.74 52         4.21        0.78 <0.0001* 
*P<0.05 
The researcher noted some limitations to the study. The small sample size could 
not provide a robust analysis of the study. The recruitment phase was conducted during 
vacation time and during company restructuring which may have affected the reponse 
rate. The study required the providers to complete a pre survey and educational teaching 
module, utilize the ABSST tool in clinic, and then complete the post survey. Complicated 
and time consuming steps may have also impacted the response rate leading to a more 
than 50% attrition rate. While surveys are are direct  measures that are versatile, they are 
prone to bias when respondents provide the socially acceptable answer rather than their 
true opinion (Moran et al., 2014). 
4.5 SUMMARY 
Most women with OAB symptoms do not discuss with their healthcare providers 
bladder dysfunction and providers may not systematically inquire (Hartmann, 
McPheeters, & Biller, 2009). The rising prevalence of OAB creates a burden for 
individuals and society and increases the potential for impaired functional status and 
lower health-related quality of life (Barile et al., 2015). The use of a validated bladder 
symptom screener tool in women over 40 years of age presenting in the Healthcare 
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Clinics in Walgreens was found to facilitate discussion between the provider and patient, 
and thereby identify women who could benefit from treatment or referral. Assessment of 
OAB symptoms in women is an important component of chronic disease management. 
This study created an awareness in the providers who did not routinely screen their 
patients for OAB symptoms.  It was found that at a 95% confidence interval there was a 
statistically significant increase (p< 0.0001) in the ABSST effectiveness in highlighting 
the presence of bladder symptoms consistent with OAB (N=145 pre-survey and N=52 
post survey). In regards to provider knowledge level assessing for OAB in patient; there 
was significant increase following the educational module (p=0.0004) (N=153 pre-survey 
and N=52 post-survey). 
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CHAPTER 5 
DISCUSSION 
The prevalence of OAB in the United States is 16.9 percent in women, according 
to the NOBLE study (Eapen & Radomski, 2016). The rising prevalence of OAB creates a 
burden for individuals and society and increases the potential for impaired functional 
status and lower health-related quality of life (Barile et al., 2015). The evaluation of OAB 
symptoms by providers should be addressed as part of the routine primary care visit, 
however, it is often not assessed or documented. This quality improvement project goal 
was to create an awareness of the importance of routinely screening patients for OAB 
symptoms in primary care settings. The use of the ABSST could facilitate further 
discussion between provider and patient. The study created an awareness in the providers 
who did not routinely screen their patients for OAB symptoms. The ABSST was effective 
in highlighting OAB symptoms.  The ABSST questionnaire is an option available for 
providers to use in clinic to evaluate symptoms of OAB. The OAB grand rounds 
educational module (See Appendix H), which the participants viewed, discussed how to 
use the questionnaire and the criteria for treatment or referral. 
The researcher cited some limitations to the study project. The small sample size 
could not provide a robust analysis of the study. There were more female respondents 
than males, and there were more NPs respondents than PAs.There were no physician 
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participants in the study. A large and fairly equal sample size based on the characteristics 
would have helped the study findings. Another limitation was the recruitment phase was 
conducted during vacation time for providers and during company restructuring, which 
may have affected the reponse rate. The study required the providers to complete a pre 
survey, educational teaching module, utilize the ABSST tool in clinic, and complete a 
post survey. Complicated and time consuming steps may have also impacted the response 
rate leading to more than 50% attrition rate.  Some of the providers did not complete the 
survey correctly, lending the study to an even smaller matched sample size from pre to 
post survey. The researcher did not record how often the providers used the tool with 
their patients. However, the researcher did ask the providers to use it with at least 50% of 
their female patients who met the criteria. The researcher was not able to match the 
provider with the survey they completed, as it was anonymous.  The study was for a 3-
month period; and a longer time in clinic may also have lent  itself to a more robust 
study. While surveys are direct  measures that are versatile, they are prone to bias when 
respondents provide the socially acceptable answer rather than their true opinion (Moran 
et al., 2014).  
The focus of the DNP degree is expertise in clinical practice (Chism, 2013). This  
quality improvement project is inclusive of the Essentials of Doctoral Education for 
Advance Nursing Practice as outlined by the American Association of Colleges of 
Nursing (2006). Each Essential is addressed as it relates to this quality improvement 
scholarly project. The purpose of this chapter is show how the the Essentials of Doctoral 
Education in Advance Nursing Practice guided the DNP graduate. According to 
Donabedian (1990), seven attributes of health care define its quality: (a) efficacy: the 
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ability of care to improve health; (b) effectiveness: how well health improvements are 
realized; (c) efficiency: the facility to obtain the best health improvements at the lowest 
cost; (d) optimally: balancing costs and benefits; (e) acceptability: taking into account 
patient preferences; (f) legitimacy: accord with social preferences concerning all the 
above; and (g) equity: fair distribution of care (Holly, 2014). 
5.1 THE SCIENTIFIC UNDERPINNING FOR PRACTICE 
 This was addressed as evidenced by the research of a reliable and validated 
questionnaire; and peer reviewed journals, articles and textbooks that identify science 
based theories and concepts related to the prevalence of OAB symptoms in women over 
40 years. The project addressed Essential I through developing an educational module on 
OAB that the providers were able to access via the Healthcare clinic webbased 
educational forum and then utilizing the ABSST in clinic setting. The pre and post survey 
data showed statitical significance in the ABSST effectiveness  and ABSST facilitating 
communication between patient  and provider. There was no statistical significance found 
in increasing the knowledge of providers from pre to post testing. This quality 
improvement project was implemented through researching science based evidence and 
concepts to identify health care delivery  actions and strategies to facilitate better 
assessment of OAB symptoms. 
5.2 ORGANIZATIONAL AND SYSTEMS LEADERSHIP FOR QUALITY 
IMPROVEMENT AND SYSTEMS THINKING  
  This was integrated in this project through the researcher identifying a need for a 
quick and simple questionnaire in clinic to assess for OAB symptoms for women who 
may not necessarily have urinary tract infections, and present for primary care in the 
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Healthcare clinics. Encouraging providers to be proactive in inquiring about OAB 
symptoms in their patients, may lead to a improvement in health related quality of life of 
the women whose symptoms are addressed promptly.   
5.3 CLINICAL SCHOLARSHIP AND ANALYTICAL METHODS FOR EVIDENCE-
BASED PRACTICE 
For this quality improvement project, the researcher critically evaluated existing 
literature and determined the best evidence for practice and the implementation and in 
clinic setting. The researcher presented an educational module on the Walgreens 
Healthcare University site entitled “Overactive Bladder: Strategies for Assessment and 
Managing Symptoms”  See Appendix H for powerpoint presentation done on October 
27th 2016. The pre and post survey data were compared to determine the impact of the 
educational module presented. The questions that sought to measure provider knowledge 
pre to post educational module were not statistically significant. However the two 
questions that sought to measure the provider perception of the ABSST effectiveness in 
assessing for OAB in patients were statitically significant. Based on the significance of 
the ABSST effectiveness, continued reinforcement to utilize the questionnaire needs to be 
encouraged in assessing symptoms and educating patients. 
5.4 INFORMATION SYSTEM/TECHNOLOGY AND PATIENT CARE 
TECHNOLOGY FOR THE IMPROVEMENT AND TRANSFORMATION OF 
HEALTH  
The DNP graduate is required to be knowledgeable and proficient in information 
technology regarding how to use powerpoint presentation in a virtual classroom. This 
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quality improvement utilized web-based communication such as email and the online 
educational module which was done using powerpoint presentation. The information 
technology was a cost effective and  critical component to send out the pre survey, post 
survey via the work emails. 
5.5 HEALTHCARE POLICY FOR ADVOCACY IN HEALTH CARE 
 DNP graduates are in a position to be powerful advocates for healthcare policy 
through their practice experiences at all levels.This quality improvement project 
discussed health polices related to OAB symptoms, promotion of health for patients, and 
reinforced to providers the importance to screen and educate their patients. Furthermore, 
doctoral prepared advance nurse practitioners are in a position to advance the health of 
populations by influencing politicians through organizing communities, advocating for 
healthy public policy, promoting effective regulation, and pursuing fair taxation and 
public service (Davidson, 2014). 
5.6 INTERPROFESSIONAL COLLABORATION FOR IMPROVING PATIENT AND 
POPULATION HEALTH  
The researcher participated in effective communication with the leadership team, 
education team and IRB team at Walgreens Healthcare clinics for the need to implement 
the quality improvement project in the Walgreens clinics. Approval was then given to 
proceed with study in the clinics.The results of the pre and post survey showed that the 
ABSST was an effective tool in facilitating critical communication. The researcher 
communicated with the Walgreens education team the quality improvement study 
findings;  and encouraged them to make the ABSST tool easily accessible online for 
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providers who may chose to use it to screen their patients for OAB symptoms. The 
director for education and development at the Healthcare Clinics thought it was a great 
project and stated she would share the tool with the EPIC and clinical practice teams to 
see if it could possibly be added to the EPIC electronic medical record, in the future. 
5.7 CLINICAL PREVENTION AND POPULATION HEALTH FOR IMPROVING 
THE NATION’S HEALTH 
 There are a number of major underlying causes of health disparities, determinants 
of population health, which lead to health inequalities (Davidson, 2014). Improving 
patient experience of care, reducing per capita cost and improving population health are 
described as the Triple Aim by the Institute for Healthcare Improvement and are a 
roadmap to assess overall population health. (Stiefel & Nolan, 2012). Urinary 
incontinence (UI) and OAB are common conditions affecting women in the United States 
(Newman & Wein, 2009). Most health care providers often times fail to screen for UI and 
OAB (Newman & Wein, 2009). The retail clinics in Walgreens are anexcellent entry 
point of intervention for women who may present with OAB. Individual health is 
influenced by whether an individual can afford the care and cope with the stigma that for 
some causes embrassment and shame. This often times leads to a delay in seeking 
treatment from their providers. Provider support is essential in education patients about 
their health conditions. 
5.8 ADVANCED NURSING PRACTICE  
This was demonstrated with this quality improvement project through 
comprehensively assessing the health and illness parameters related to OAB in women 
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and interventions and treatments that can be incorporated in assisting this population. The 
educational module assisted providers in the use of the ABSST, which in turn they could 
utilize with their patients to screen for OAB symptoms. 
5.9 FURTHER STUDIES 
More studies need to be conducted in both male and female patients utilizing the 
ABSST and comparing it to other reliable and validated questionnaires. Further studies 
assessing perceptions of physicians, physician assistants and nurse practitioners in acute 
care, urgent care, primary care and retail settings, in regard to OAB symptoms in their 
patients would also be beneficial. Moreover, further research aimed at identifying 
patients who may have OAB symptoms is needed, to help reduce the delay in seeking 
treatment from their providers. 
5.10 RECOMMENDATIONS 
Further recommendations for this study would include replicating this study with 
a larger sample, as well as expanding the content to assess all adults, both male and 
female. Many studies have found the prevalence of OAB and it symptoms increases with 
age in both genders (Eapen & Radomski, 2016).  The utilization of the ABSST helped 
facilitate an increased awareness by the providers at the Healthcare Clinics in Walgreens, 
to rountinely screen their patients for OAB symptoms. The educational module on OAB 
showed no significance for providers increasing their level of knowledge. However, 
provider support is essential in educating and screening  patients about their OAB 
condition. Patient awareness of symptoms can reduce stress and improve quality of life. 
 91 
 
 
Providers need to be encouraged to routinely screen their patients for OAB symptoms 
and incoporate it into their daily practice. 
5.11 PRACTICE IMPLICATIONS 
 This study represents an initial starting entry point in raising awareness about the 
prevalence of OAB and importance of providers initiating the discussion with their 
patients. This can empower patients to know when to seek help from their providers. This 
results suggest that the ABSST is likely to improve patient outcomes for patients who are 
screened and if criteria met, treatment is started early. The rising prevalence of OAB 
creates a burden for individuals and society and increases the potential for impaired 
functional status and lower health-related quality of life (Barile et al., 2015). The indirect 
costs include impaired work productivity and activity, clinically and statistically poorer 
general  and disease-specific health related quality of lif, and statistically higher rates of 
OAB-related surgery, hospitalizations, physician visits and pad use (Cardozo et al., 
2014). The study results suggest that the use of ABSST in adult patients can lead to 
enhancing patient care and an increased patient awareness of OAB symptoms. 
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APPENDIX A: EVIDENCE LEVEL AND QUALITY GUIDE 
 
Evidence Levels Quality Guides 
Level I 
Experimental study, randomized controlled trial (RCT) 
Systematic review of RCTs, with or without meta-analysis 
A High quality: Consistent, generalizable results; sufficient 
sample size for the study design; adequate control; definitive 
conclusions; consistent recommendations based on 
comprehensive literature review that includes thorough reference 
to scientific evidence 
 
B Good quality: Reasonably consistent results; sufficient 
sample size for the study design; some control, fairly definitive 
conclusions; reasonably consistent recommendations based on 
fairly comprehensive literature review that includes some 
reference to scientific evidence 
 
C Low quality or major flaws: Little evidence with 
inconsistent results; insufficient sample size for the study design; 
conclusions cannot be drawn 
 
Level II 
Quasi-experimental study 
Systematic review of combination of RCTs and quasi-
experimental, or quasi-experimental studies only, with or 
without meta-analysis 
Level III 
Non-experimental study 
Systematic review of a combination of RCTs, quasi-
experimental 
and non-experimental studies, or non-experimental studies only, 
with or without meta-analysis 
Qualitative study or systematic review with or without a meta-
synthesis 
  
 
9
9
 
Level IV 
Opinion of respected authorities and/or nationally recognized 
expert committees/consensus panels based on scientific evidence 
 
Includes: 
• Clinical practice guidelines 
• Consensus panels 
A. High quality: Material officially sponsored by a 
professional, public, private organization, or government 
agency; documentation of a systematic literature search 
strategy; consistent results with sufficient numbers of 
well-designed studies; criteria-based evaluation of 
overall scientific strength and quality or included studies 
and definitive conclusions; national expertise is clearly 
evident; developed or revised within the last 5 years 
B. Good quality: Material officially sponsored by a 
professional, public, private organization, or government 
agency; reasonably thorough and appropriate systematic 
literature search strategy; reasonably consistent results, 
sufficient numbers of well-designed studies; evaluation 
of strength and limitations of included studies with fairly 
definitive conclusions; national expertise is clearly 
evident; developed or revised within the last 5 years 
 
C. Low quality or major flaws: Material not sponsored by 
an official organization or agency; undefined, poorly 
defined, or limited literature search strategy; no 
evaluation of strengths and limitations of included 
studies, insufficient evidence with inconsistent results, 
conclusions cannot be drawn; not revised within the last 
5 years 
Level V 
Based on experiential and non-research evidence 
Includes: 
• Literature reviews 
• Quality improvement, program or financial evaluation 
• Case reports 
Organizational Experience: 
 
A High quality: Clear aims and objectives; consistent results 
across multiple settings; formal quality improvement, financial 
or program evaluation methods used; definitive conclusions; 
consistent recommendations with thorough reference to 
scientific evidence 
  
 
1
0
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• Opinion of nationally recognized expert(s) based on 
experiential evidence 
 
B Good quality: Clear aims and objectives; consistent results in 
a single setting; formal quality improvement or financial or 
program evaluation methods used; reasonably consistent 
recommendations with some reference to scientific evaluation 
 
C Low quality or major flaws: Unclear or missing aims and 
objectives; inconsistent results; poorly defined quality 
improvement, financial or program evaluation methods; 
recommendations cannot be made 
 
Literature Review, Expert Opinion, Case Report, 
Community Standard, Clinician Experience, Consumer 
Preference: 
 
A High quality: Expertise is clearly evident; draws definitive 
conclusions; provides scientific rationale; thought leader(s) in 
the field 
 
B Good quality: Expertise appears to be credible; draws fairly 
definitive conclusions; provides logical argument for opinions 
 
C Low quality or major flaws: Expertise is not discernable or 
is dubious; conclusions cannot be drawn 
 
©The Johns Hopkins Hospital/The John Hopkins University 
Adapted from Dearholt, S.L., & Dang, D. (2012). John Hopkins Nursing Evidence-Base Practice: Model and Guidelines (2nd ed.). 
Indianapolis, IN: Sigma Theta Tau International. 
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APPENDIX B: EVIDENCE TABLE 
 
Arti-
cle  
# 
Brief 
Reference, 
Type of 
Study, 
Quality 
rating 
Methods Threats to 
validity/ 
reliability 
Sample, 
Sample Size & 
Setting 
Study findings 
that help answer 
The EBP question 
Limitations Conclusi-
ons 
1. Sumardi, R., 
Mochtar, 
C.A., Junizaf, 
Santoso, B.I., 
Tjahjodjati, 
Purwara, B. 
H., 
Hardjowijoto,
S., Paraton, 
H., Yunaidi, 
D.A.(2012). 
Test-retest 
reliability of 
the Indonesian 
Observational  
Study to evaluate 
test-retest 
reliability of 
OAB symptom 
Score (OABSS) 
translated from 
the original 
Japanese 
OABSS. 
Developed by the 
Japanese 
Neurogenic 
Threats to 
the validity 
could be 
generalizati-
on of the 
findings from 
one hospital 
to another. 
Initially 
study done 
with 
Japanese 
patients, and 
as such, there 
84 subjects 
screened. 
50 patients 
enrolled in the 
study and the 
return rated of 
questionnaire 
was 100%. 
Exclusion 
criteria used 
was for any 
patients with 
(1) significant 
Descriptive 
statistics. 
All statistical tests 
were two-tailed and 
conducted with a 
significant level of 
0.05. 
All analyses used 
the Statistical 
Package of Social 
Sciences (SPSS). 
 
The 3-day 
micturition 
diaries can be 
troublesome 
for some 
patients and 
data are not 
immediately 
amenable for 
statistical 
analysis in the 
research 
setting. 
The test-
retest 
reliability 
was 
excellent 
for 
OABSS 
total 
score. 
The 
simplicity 
of this tool 
might 
make it 
  
 
1
0
2
 
version of the 
overactive 
bladder 
symptom 
score 
(OABSS) and 
its correlation 
with standard 
assessment 
tools. The 
Indonesian 
Journal of 
Internal 
Medicine, 
44(3):214-221 
Retrieved 
from 
http://www-
ncbi-nlm-nih-
gov.pallas2tcl.
sc.edu/pubme
d/22983076 
 
Observational  
Bladder Society, 
the OABSS was 
validated in 
Japanese 
population and 
translated to local 
languages of 
interest. 
Patients ≥ 18 
years with 
established 
overactive 
bladder, (OAB) 
completed 3-day 
micturition 
diaries and 
questionnaires 
for the OABSS, 
International 
Prostate 
Symptom Score 
(IPSS), and 
Patient 
Perception of 
Bladder 
Condition 
was concern 
about 
translation to 
local 
language of 
interest 
stress 
incontinence or 
mixed 
stress/urge 
incontinence as 
the 
predominant 
factor, (2) 
indwelling 
catheter, (3) 
symptomatic 
urinary tract 
infection (4) 
previous pelvic 
radiation 
therapy or 
current 
malignant  
disease of the 
pelvic organs, 
(5) treatment 
for OAB that 
started, 
stopped or 
changed within 
4 weeks of the 
screening 
Internal correlation 
coefficient (ICC) 
was 0.83.   
The test-retest 
reliability of the 
Indonesian OABSS 
was found to be 
excellent and for 
each of the four 
individual items of 
the Indonesian 
OABSS, the 
weighted Kappa 
coefficients were 
0.55-0.66, 
representing 
moderate to good 
agreement. 
The correlations 
with a 3-day 
micturition diary of 
total pads used 
based on 3-day 
micturition diary of 
total pads used, 
Validated tools 
have 
demonstrated 
clinical use 
with a certain 
range, but one 
common 
shortcoming is 
that they do 
not evaluate 
actual 
symptoms. 
 
 
 
 
useful and 
feasible 
for 
clinical 
practice 
that has 
limited 
time and 
resources.  
 
 
  
 
1
0
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Study 
Evidence 
Level: IIb 
Quality: Good 
(PPBC) on 2 
separate visits.  
Test-retest 
reliability was 
examined using 
the internal 
correlation 
coefficient (ICC) 
and weighted 
Kappa 
coefficients 
between the first 
and second 
applications of 
the OABSS. 
Pearson or 
Spearman 
correlation 
coefficients were 
calculated to test 
the correlation of 
OABSS with 
IPSSS, IPSS 
Quality of Life 
(QOL) item, 
PPBC and 
period, (6) 
diabetic  
neuropathy, 
and (7) 
patient’s 
receiving 
certain drugs 
such as 
anticholinergic 
or 
antispasmodic 
drugs. 
Recruited from 
3 hospitals in 
Indonesia from 
12/11/09 to 
9/20/10 
 
 
total voided volume 
and frequency of 
nocturia were weak 
(Pearson correlation 
coefficient were 
0.22—0.44 at Visit 
1, and 0.10-0.27 at 
Visit 2). 
The OABSS total 
score showed a 
moderate degree of 
correlation with the 
IPSS total score 
(Spearman 
correlation 
coefficient = 0.41 at 
Visit 1 and 0.45 at 
Visit 2). 
  
 
1
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clinical variables 
of the 3-day 
voiding dairy. 
2 Basra, R.K., 
Cortes, E., 
Khullar, V., & 
Kelleher, C. 
(2012). A 
comparison 
study of two 
lower urinary 
tract 
symptoms 
screening 
tools in 
clinical 
practice: The 
B-SAQ and 
OAB-V8 
questionnaires
. Journal of 
Obstetrics and 
Gynaecology, 
32(7), 666-
671).  
The aim of the 
study was to 
compare the 
value of two 
validated 
questionnaires: 
Bladder Control 
Self- Assessment 
Questionnaire 
(B-SAQ) and the 
Overactive 
Bladder 
Awareness Tool 
(OAB-V8). 
 Patient were not 
recruited on the 
basis of 
presenting 
symptoms. All 
female patients 
attending the 
clinics were 
Threats to 
the validity 
was the 
selection bias 
as all patients 
were from 
general 
gynecology 
and urology 
clinics and 
not primary 
care setting. 
223 women 
participated 
and were 
recruited from 
general 
gynecology 
and 
urogynecology 
clinics in two 
London 
teaching 
hospitals. 
The mean age 
of women was 
49 years (range 
19-84).  
 
Study results were 
analyzed using 
SPSS version 15. 
Only fully 
completed 
questionnaires were 
used for statistical 
analysis and 219 
responses were 
used for data 
analysis. (Four 
patients left 
incomplete 
responses). 
The receiver 
operating curve 
(ROC) curve 
identifying stress 
incontinence was 
0.85 and 0.68 for 
the B-SAQ and 
OAB-V8, 
Patients unable 
to read or 
understand 
English were 
excluded. 
OAB-V8 is a 
poor test for 
stress 
incontinence 
and a fair test 
for mixed 
incontinence. 
A condition 
specific 
questionnaire 
such as OAB-
V8 may be too 
specific and 
lead to 
exclusion of a 
The study 
confirms 
that both 
the B-
SAQ and 
OAB-V8 
perform 
well in 
identifyin
g OAB 
symptoms
, and as 
such, are 
suitable to 
screen for 
OAB in 
both the 
clinical 
and 
research 
setting. 
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Retrieved 
from 
http://dx.doi.o
rg/10.3109/01
443615.2012.
696158 
 
Comparison 
Study 
Evidence 
Level: IIIb 
Quality: Good 
 
handed the study 
pack consisting 
of a patient 
information 
leaflet and 
consent form, 
standardized 
questionnaire 
detailing 
patient’s 
demographic data 
and the B-SAQ 
and OAB-V8 
questionnaire. 
B-SAQ is an 8-
item 
questionnaire that 
evaluates the 
symptoms of 
urinary 
frequency, 
urgency, nocturia 
and urinary 
incontinence and 
associated bother. 
respectively, which 
shows that the B-
SAQ is a good test 
and the OAB-V8 is 
poor test for stress 
incontinence. 
Cohen’s Kappa 
calculations in 
patients with a 
clinical diagnosis of 
OAB showed 
values of 0.2 for 
both B-SAQ and 
OAB-V8 
questionnaires 
(p<0.01); indicating 
fair agreement 
between both 
questionnaires and 
the clinical 
diagnosis. 
The B-SAQ lower 
urinary tracts 
screening 
questionnaire was 
large affected 
population. 
. 
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The OAB-V8 is 
an 8-item 
questionnaire that 
assesses 
symptom bother 
and quality of life 
(QoL) impact of 
OAB.  
 
Data was 
collected from 
patients who 
agreed to take 
part in the study. 
All patients fully 
completed the B-
SAQ 
questionnaire 
found to be a better 
test for stress and 
mixed urinary 
incontinence 
identification than 
the OAB-V8. 
 
3 Juliato, C.R., 
Baccaro, L.F., 
Pedro, A.O., 
Costa-Paiva, 
L., Lui-Filho, 
J., Pinto-Neto, 
A.M.(2016). 
A descriptive, 
exploratory, 
cross-sectional 
study. 
The dependent 
variable was 
Threat to the 
reliability 
was some 
variables 
such as 
genital 
prolapse, the 
820 women 
invited to 
participate. 
749 women 
participated. 
Mean age was 52.5. 
With regard to 
menopausal, 16% 
were 
premenopausal, 
16% 
perimenopausal and 
Some women 
may minimize 
urinary 
symptoms with 
in-person 
interviews. 
Health 
profession
als should 
adopt 
proactive 
behavior 
in 
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Subjective 
urinary 
urgency in 
middle age 
women:  A 
population-
based study. 
Maturitas, 
85(82-87). 
Retrieved 
from 
http://www-
ncbi-nlm-nih-
gov.pallas2.tcl
.sc.edu/pubme
d/26857885 
 
Descriptive, 
exploratory, 
cross-sectional 
study 
 
Evidence 
Level: IIb 
OAB and the 
independent 
variables were 
sociodemographi
c data, health 
related habits and 
problems, self-
perception of 
health, and 
gynecological 
background. 
 All analyses 
were performed 
using IBM SPSS 
version 20 and 
Stata version 7. 
Bivariate analysis 
using the chi-
square test, and 
Poisson 
regression using 
back selection 
criteria. 
 
presence of 
bacteriuria 
and 
complains 
associated to 
lower urinary 
tract 
symptom. 
 
 Inclusion 
criteria were 
native 
Brazilian 
women, aged 
45-60 years 
and residing in 
the 
metropolitan 
region of 
Campinas. 
 
68% 
postmenopausal. 
The prevalence of 
OAB was 7.8%. 
The vast majority 
of women had only 
urinary urgency. 
Only two women 
who responded to 
the interview 
reported urge 
incontinence. In the 
final statistical 
model, vaginal 
dryness (Poisson 
Regression 2.21; 
95% Clinical 
Interval 1.11-4.40; 
p=0.025) were 
associated with 
greater prevalence 
of OAB. 
 
The results 
were based on 
self-reporting 
and 
uncertainties 
may have 
occurred. 
 
 
surgically 
menopaus
al women 
and those 
with a 
history of 
genital 
atrophy to 
identify 
and treat 
OAB, thus 
contributi
ng to an 
improved 
quality of 
lift and 
healthier 
aging. 
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Quality: Good Simple random 
sampling 
4. Coyne, K.S., 
Sexton, C.C., 
Irwin, D.E., 
Kopp, Z.S., 
Kelleher, C.J., 
Milsom, I. 
(2008). The 
impact of 
overactive 
bladder, 
incontinence 
and other 
lower urinary 
tract 
symptoms on 
quality of life, 
work 
productivity, 
sexuality and 
emotional 
well-being in 
men and 
women: 
results from 
A nested case-
control analysis 
was performed 
on men and 
women with 
(cases) and 
without 
(controls) OAB, 
from the EPIC 
study. Based on 
their responses to 
questions about 
lower urinary 
tract symptoms 
(LUTS) cases 
were classified 
into five groups: 
continent OAB, 
OAB with 
incontinence, 
OAB + 
postmicturition, 
OAB + voiding, 
and OAB 
The CES-D 
scale has 
confirmed 
reliability 
and validity 
and has been 
used in both 
continent and 
incontinent 
OAB 
populations. 
The PPBC 
has a good 
construct 
validity, 
responsivene
ss to change, 
and test-
retest 
reliability 
among 
patients with 
OAB. 
Of the EPIC 
participants, 
1434 identified 
OAB cases 
were matched 
by age, gender 
and country, 
with 1434 
designated as 
controls. 
A population-
based, cross 
sectional 
telephone 
survey of 
adults aged 
over 18, was 
conducted in in 
five countries 
(Canada, 
Germany, 
Italy, Sweden, 
and the UK). 
Comorbid 
conditions differed 
significantly by 
case/control status, 
with cases reporting 
significantly greater 
rates of chronic 
constipation, 
asthma, diabetes, 
high blood 
pressure, bladder or 
prostate cancer, 
neurological 
conditions and 
depression.  
There were 
significant 
differences between 
cases and controls 
in all reported 
LUTS.  
The OAB + 
postmicturition + 
Many 
questionnaires 
used to 
evaluate the 
impact of 
LUTS were 
OAB-specific, 
as an objective 
of this study 
was to explore 
the prevalence 
and impact of 
OAB. It is 
possible that 
the use of a 
less OAB-
specific 
measures 
would yield a 
different 
pattern of 
results. 
The 
diagnosis 
and 
treatment 
of OAB 
should be 
considered 
in 
conjunctio
n with 
LUTS, to 
maximize 
treatment 
options 
and 
optimize 
patient 
outcomes. 
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the EPIC 
study. BJU 
International 
101(1388-
1395). 
Retrieved 
from 
http://scholar.
google.com 
doi:10.1111/j.
1464-
410X.2008.07
60x 
 
Symptom 
prevalence 
study 
(prospective 
cohort). 
 
Evidence 
Level: Ib 
+postmicturition 
+ voiding. Both 
control and cases 
were asked 
questions about 
symptom bother 
(OAB-q), generic 
quality of life 
QoL (EQ-5D), 
work 
productivity 
(Work 
Productivity and 
Activity 
Impairment, 
WPAI), 
depressive 
symptoms 
(Center for 
Epidemiologic 
Studies 
Depression Scale, 
CES-D), sexual 
satisfaction, and 
erectile 
dysfunction (men 
only) using the 
No threats to 
validity/relia
bility were 
noted 
voiding group 
reported 
significantly greater 
symptom bother, 
worse HRQoL, 
higher rates of 
depression and 
decreased 
enjoyment of 
sexual activity, than 
the other 
subgroups. 
Controls were 
not asked any 
questions, 
which limits 
the case-
control 
comparisons. 
The OAB and 
LUTS 
classifications 
used are based 
entirely on 
patient-
reported 
symptoms; 
there was no 
urodynamic 
testing to 
confirm the 
type of LUTS, 
nor was there 
confirmation 
by a medical 
professional. 
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Quality: Good 
 
Massachusetts 
Male Aging 
Study. Case 
answered 
additional 
condition-
specific questions 
HRQol (OAB-q 
short form), 
Patient 
Perception of 
Bladder 
Condition, 
PPBC, and work 
productivity 
related to a 
specific health 
problem (WPAI-
SHP). General 
linear models 
were used to 
evaluate group 
differences. 
5. de Ridder, D., 
Roumeguere, 
T., Kaufman, 
Data on OAB 
and SUI were 
prospectively 
Possible 
threat was 
the external 
Data was 
collected on 
7193 women, 
About 33.9% had 
mild BCS. Most 
women reported 
The study 
population 
consisted of 
A 
significant 
proportion 
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L. (2013). 
Overactive 
bladder 
symptoms, 
stress urinary 
incontinence 
and associated 
bother in 
women aged 
40 and above; 
a Belgian 
epidemiologic
al survey. 
International 
Journal of 
Clinical 
Practice,67(3)
,198-208. 
Retrieved 
from 
https://eds.b.e
bscohost.com.
pallas2tcl.sc.e
du/ehost 
doi:http://dx.d
oi.org.pallas2t
collected among 
women ≥ 40 
years by general 
practitioners 
(GP) during a 
regular visit for 
any reason. The 
validated Bladder 
Control Self-
Assessment 
Questionnaire 
(B-SAQ) was 
used and 
complemented 
with a question 
on SUI and 
bladder bother. 
The presence of 
mild bladder 
control 
symptoms (BCS) 
was defined as an 
overall B-SAQ 
symptom score 
(OSS) ≥ 4 and an 
validity of 
the 
conclusions, 
involve 
generalizatio
ns of 
research 
findings to 
other 
settings. 
with a mean 
(SD) age of 
61.0 (12.6) 
years 
overall mild OAB 
symptoms (46.9) 
and 34.9% had 
moderate-to-(very) 
severe symptoms. 
The prevalence of 
moderate-severe 
urgency, frequency 
or nocturia was 
higher than that of 
moderate-severe 
incontinence. 
Urgency and 
nocturia were 
considered the most 
bothersome 
symptoms.  
Moderate-severe 
stress urinary 
incontinence (SUI) 
affected 17.7% of 
women. About 
16.4% of women 
reported to be 
moderately-
severely bothered 
by their bladder in 
women aged 
≥40 years who 
visited a GP 
for any reason. 
This sample 
may not be 
representative 
of the general 
population of 
women ≥40 
year and may 
over-represent 
women with 
co-morbidities.  
Women may 
have also felt 
hindered or 
embarrassed to 
indicate their 
problems in the 
presence of the 
GP, causing 
underreporting. 
The B-SAQ is 
not a 
of women 
aged 40 
years and 
older do 
not only 
have OAB 
symptoms
, but also 
consider 
these 
botherso-
me in 
daily life. 
Physicians 
should be 
proactive 
and 
engage in 
conversati
ons about 
bladder 
control 
symptoms 
and 
available 
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cl.sc.edu/10.1
111/ijcp.1201
5 
Epidemiologic
al study 
Evidence 
Level: IIIb 
Quality: Good 
overall bother 
score OBS ≥1.  
Descriptive 
statistics were 
performed.  
everyday life. The 
risk of severe 
symptoms and 
bother increased 
with age. About 
10% of women had 
clinically 
significant BCS 
(OSS ≥ 7 and OBS 
≥ 4). 
diagnostic 
questionnaire 
and does not 
assess whether 
the symptoms 
experienced 
are actually 
caused by 
OAB or 
whether other 
pelvic 
disorders are 
present. 
treatment 
options. 
6. Qian-Sheng, 
K., Hann-
Chorng, K. 
(2010). Strong 
correlation 
between the 
overactive 
bladder 
symptom 
score and 
urgency 
severity score 
in assessment 
Patients with 
clinical 
symptoms of 
frequency and 
urgency were 
prospectively 
enrolled in this 
study. The 
Chinese version 
of the OABSS 
questionnaire, 
which has been 
linguistically 
The OABSS 
questionnaire 
was 
linguistically 
validated 
A total of 170 
patients were 
enrolled - 98 
men and 72 
women with a 
mean age of 
64.1 years. 
A high OABSS 
total score was 
significantly 
associated with a 
high grade of USS. 
There was a 
significant 
correlation between 
the two scores 
(R²=0.5520, 
p<0.0001). The 
main contributions 
of the OABSS in 
The OABSS 
and the 
Urogenital 
Distress 
Inventory short 
form (UDI-6), 
measure the 
frequency and 
urgency 
episodes 
during a given 
period, but the 
severity of 
A strong 
correlation 
between 
the 
OABSS 
and USS 
based on a 
voiding 
diary was 
noted in 
patients 
with OAB 
and the 
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of patients 
with 
overactive 
bladder 
syndrome. Tzu 
Chi Medical 
Journal,22(2), 
82-86. 
Retrieved 
from 
Retrieved 
from 
http://scholar.
google.com 
http://www.tz
uchimedjnl.co
m/ 
doi:10.1016/s1
016-
3190(10)6004
5-6 
Prospective 
study 
validated, and the 
urgency severity 
score (USS) 
based on a 3-day 
voiding diary 
were recorded at 
baseline. Patients 
with clinically 
diagnosed OAB 
were treated with 
solifenacin 5mg 
daily for 1 
month, and the 
OABSS and USS 
were repeated at 
1 week and 1 
month. The 
OABSS and USS 
were compared at 
baseline, 1 week 
and 1 month after 
treatment. 
patients with a low 
USS were daytime 
frequency and 
nighttime 
frequency. The 
contribution of 
urgency and 
urgency urinary 
incontinence 
became significant 
in patients with 
high urgency 
grades.  The 
changes in the USS 
and OABSS were 
significant at 1 
month. The change 
in frequency was 
significant in the 
daytime as well as 
at nighttime. 
urgency is not 
assessed as a 
quantitative 
measure 
reflecting real 
life conditions. 
changes in 
these two 
measures 
were 
similar 
after 
solifenac-
in 
treatment. 
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Evidence 
Level: IIb 
Quality: Good 
7. Tikkinen, 
K.A., 
Auvinen, A., 
Johnson, 
T.M., Wiess, 
J.P., Keranen, 
T., Tiitinen, 
A., Polo, O., 
Partinen,M.,  
Tammela, 
T.L. (2009). A 
systematic 
evaluation of 
factors 
associated 
with nocturia 
– The 
population 
based FINNO 
study. 
American 
Journal of 
In a case-control 
with prevalence 
sampling, the 
authors explored 
the correlates for 
nocturia and their 
population-level 
impact. 
Questionnaires 
contained items 
on medical 
conditions, 
medications, 
lifestyle, 
sociodemographi
c and 
reproductive 
factors, urinary 
symptoms, and 
snoring. Nocturia 
was defined as 
≥2 voids/night. In 
Threats to 
the validity 
include of 
self-report 
has not been 
established 
for all 
characteristic
s considered. 
The Finnish 
population 
may not be 
directly 
generalizable 
to other 
ethnicities 
because 
impact 
measures 
generally are 
6000 subjects 
(aged 18-79) 
were randomly 
identified from 
the Finnish 
Population 
Register 
(62.4% 
participated, 
53.7% were 
female) 
The factors with the 
greatest impact at 
the population level 
were (urinary) 
urgency 
(attributable 
number/1000 
subjects (AN=24), 
benign prostatic 
hyperplasia 
(AN=19), and 
snoring (AN=16) 
for men and 
overweight and 
obesity (AN=40), 
urgency (AN=24), 
and snoring 
(AN=17) for 
women. 
Correlates included 
prostate cancer and 
antidepressant use 
Alcohol 
consumption 
reporting was 
incomplete, yet 
nocturia 
prevalence did 
not vary by 
alcohol 
consumption 
among those 
reporting this 
information. 
There was no 
information on 
physical 
activity, 
although 
physical 
activity has not 
previously 
Although 
several 
correlates 
were 
identified, 
none 
accounted 
for a 
substantial 
proportion 
of the 
population 
burden, 
highlighti
ng the 
multifacto
rial 
etiology 
of 
nocturia. 
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Epidemiology, 
170(3), 361-
368. 
Retrieved 
from 
https://eds.b.e
bscohost.com.
pallas2tcl.sc.e
du/ehost/detail 
Doi: 
http://dx.doi.o
rg.pallas2.tcl.s
c.edu/aje/kwp
133 
Case-control 
study 
Evidence 
Level: 1a 
Quality: High 
age-adjusted 
analyses, factors 
associated with 
nocturia were 
entered into a 
multivariate 
model. Backward 
elimination was 
used to select 
variables for the 
final model, with 
adjustments for 
confounding. 
context 
specific.  
for men, coronary 
artery disease and 
diabetes for 
women, and restless 
legs syndrome and 
obesity for both 
sexes. 
been related to 
nocturia. 
 
8. Barkin, J. 
(2016). 
Nocturia: 
diagnosis and 
The article 
explores the 
different causes 
and types of 
None noted The article 
discussed a 
study based on 
a survey of 
When taking a 
patient history, it is 
important to 
determine the onset 
None noted Nocturia 
is 
pervasive 
in men 
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management 
for the 
primary care 
physicians. 
The Canadian 
Journal of 
Urology, 
23(1),16-19. 
Retrieved 
from 
www.ncbi-
nlm-
nih.gov.pallas
2.tcl.sc.edu/pu
bmed/269245
91 
Evidence level 
IVa 
Clinical 
practice 
guidelines 
nocturia, then 
describes how to 
diagnose 
different types of 
nocturia 
(including use of 
frequency-
volume charts), 
and last, 
discusses 
different 
approaches to 
managing 
nocturia 
(including the use 
of desmopressin), 
depending on the 
type and cause. 
more than 
1400 people 
diagnosed with 
OAB. 
and severity of the 
nocturia, and also 
find out if nocturia 
is consistent or 
intermittent. 
Physicians need to 
look for any 
medical conditions 
or drugs that may 
cause nocturia. 
Physicians should 
then order all 
appropriate tests- 
urinalysis, urine 
culture and 
sensitivity test, 
urine cytology test 
(if indicated), 
serum creatinine 
test to rule out renal 
failure (indicated), 
order abdominal/or 
pelvic ultrasound 
(if indicated), and 
and 
women 
who 
present 
with 
LUTS. 
Providers 
need to 
rule out 
the other 
medical 
and non-
medical 
causes of 
LUTS. 
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frequency-volume 
charts. 
9. Hung, M.J., 
Chou, C.L., 
Yen, T.W., 
Chuang, Y.C., 
Meng, E., 
Huang, S.S., 
Kuo, H.C. 
(2011). 
Development 
and validation 
of the Chinese 
overactive 
bladder 
symptom 
score for 
assessing 
overactive 
bladder 
syndrome in a 
RESORT 
study. Journal 
of the 
Formosan 
Medical 
The Chinese 
OABSS was 
developed by 
linguistic 
validation of the 
original version. 
It reliability and 
validity and 
correlations with 
a 3-day bladder 
diary were tested 
on patients with 
OAB in a 
multicenter study 
conducted in 
Taiwan (the 
RESORT study). 
A threat to 
the Chinese 
OABSS it 
may not be 
generalizable 
to other 
Mandarin-
speaking 
areas due to 
the 
difference in 
simplified 
and 
traditional 
Chinese 
characters. 
60 patients 
with OAB who 
visited 
different 
hospitals in 
Taiwan were 
enrolled in the 
study. Patients 
were 
randomized 
either 
incontinent 
(OAB wet, 
n=31) or 
continent 
(OAB dry, 
n=29) 
The test-retest 
reliability of the 
Chinese OABSS 
was moderate to 
good, with 
weighted kappa 
coefficients of 
0.515-0.721 for 
each symptom 
score and 0.610 for 
the total symptom 
score. Each 
symptom score 
correlated 
positively with the 
total OABSS 
(Spearman’s rho 
0.365-0.793) and 
was internally 
consistent 
(Cronbach’s alpha 
0.674). The 
distribution of the 
OABSS showed a 
One concern is 
that the 
Chinese 
OABSS was 
developed and 
validated in 
Taiwan using 
Taiwanese 
patients and 
traditional 
Chinese 
characters.  
There are, 
however many 
differences 
between 
simplified 
Chinese and 
traditional 
Chinese 
characters. It 
cannot be 
applied 
directly to 
The 
Chinese 
OABSS 
has been 
developed 
and 
validated 
as a 
reliable 
instrument 
for 
assessing 
OAB 
symptoms
. OABSS 
can be an 
alternative 
to, but not 
a 
replaceme
nt for, a 3-
day 
bladder 
diary for 
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Association, 
112, 276-282. 
Retrieved 
from 
http://scholar.
google.com 
Doi:10.1016/j.
jfma.2011.09.
020 
Randomized 
clinical trial 
Evidence 
level: IIa 
Quality: High 
clear separation 
between OAB wet 
(average 11.4, 
range 7-15) and 
OAB dry (average 
7.97, range 4-10) 
subgroups 
(Wilcoxon exact 
test, p<0.05). In 
addition, the 
OABSS items 
correlated 
positively with the 
corresponding 
bladder diary 
variables 
(Spearman’s rho 
0.504-0.879) and 
the degrees of 
agreement 
improved with 
study visits except 
for nighttime 
frequency. The 
Chinese OABSS 
tended to 
underestimate the 
other 
Mandarin-
speaking areas. 
assessing 
patients. 
  
 
1
1
9
 
frequency of 
nighttime voiding. 
10. Lekskulchal, 
O., Dietz, H.P. 
(2008). 
Detrusor wall 
thickness as a 
test for 
detrusor 
overactivity in 
women. 
Uitrasound 
Obstetrics & 
Gynecology, 
32(4):535-
539. 
Retrieved 
from 
http:eds.b.ebsc
ohost.com.pall
as2tcl.sc.edu/e
host/detail/det
ail 
Records of 
women were 
retrospectively 
reviewed. The 
patients had 
undergone an 
interview, 
clinical 
examination, 
multichannel 
urodynamic 
studies and 
translabial 
ultrasound 
examination. 
Detrusor wall 
thickness 
measurements 
were taken at the 
bladder dome, 
after bladder 
emptying. 
Receiver-
operator 
It was largely 
a Caucasian 
population 
and there 
may be 
generalizabili
ty issues to 
other races. 
686 women’s 
who attended a 
tertiary 
urodynamic 
service from 
November 
2002 to 
January 2006 
Average detrusor 
wall thickness in 
the detrusor 
overactivity group 
was 4.7+/- 1.9mm 
(mean +/- SD), 
compared to 4.1 +/- 
1.6mm in the non-
detrusor 
overactivity group 
(p<0.001). Using a 
cut-off of detrusor 
wall thickness of 
5.0mm gave a 
sensitivity of 37% 
and a specificity of 
79% for diagnosing 
detrusor 
overactivity. The 
ROC analysis 
revealed an area 
under the curve 
(AUC) of 0.606 
Urodynamic 
testing is 
invasive, 
expensive, 
time 
consuming and 
may be 
technically 
difficult. 
The diagnostic 
method did not 
yield high 
specificity or 
sensitivity. 
The 
researchers did 
not use a 
transvaginal 
ultrasound and 
only measured 
the dome. 
Measurem
ent of 
detrusor 
wall 
thickness 
should not 
be used as 
a 
diagnostic 
parameter 
for 
detrusor 
overactivit
y in 
women. 
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Retrospectivel
y Review 
study 
Evidence 
Level: IIIb 
Quality: Good 
characteristics 
(ROC) analysis 
was used to 
identify the 
optimal cut-off of 
detrusor wall 
thickness in 
predicting 
detrusor 
overactivity. 
(95% CI, 0.56-
0.65). 
 
11. Levokowicz, 
R., Whitmore, 
K. E., Muller, 
N. (2011). 
Overactive 
bladder and 
nocturia in 
middle-age 
American 
women: 
Symptoms and 
impact are 
significant. 
Urologic 
Nursing. 
American women 
internet users 
were surveyed 
online from 
March 18th to 
March 31st 2009. 
In addition, a 
sample of 611 
women were 
surveyed in 
regards to their 
experiences and 
attitudes about 
treatment. 
Threats to 
the validity 
were 
generalizabili
ty may be 
questioned 
because the 
sample was 
drawn from 
female users 
of the 
internet and 
may not be 
representativ
e of the 
general US 
1111 women 
ages, 40 to 65 
years of age, 
online users 
Women with 
nocturia in this 
study tended to 
prolong seeking 
treatment.  Women 
with OAB, 
including nocturia, 
were more likely 
than women with 
OAB, excluding 
nocturia , to alter 
their behavior in 
social situations, 
refrain from 
physical activity 
and intimacy, and 
Participants 
need to be able 
to have access 
and knowledge 
of a computer 
to answer 
survey 
questions 
More 
public 
health 
education 
is needed 
to 
improve 
consumer 
knowledg
e about 
OAB 
including 
nocturia 
and 
understan
ding of all 
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31(2):106-
111. 
Retrieved 
from 
http://eds.b.eb
scohost.com.p
allas2.tcl.sc.ed
u/ehost/detail 
Descriptive, 
cross-sectional 
survey 
Evidence 
Level: Vb 
Quality: Good 
population in 
the target age 
group and 
across all 
desired 
demographic
s 
cancel social plans 
because of their 
condition. 
treatment 
options 
for its 
symptoms
. 
12. Wells, M. J., 
Jamieson, K., 
Markham, T. 
C.W., Green, 
S.M, Fader, 
M. J. (2014). 
The effects of 
caffeinated 
versus 
Newly diagnosed 
women with 
OAB and a 
history of 
caffeine 
consumption 
were randomly 
allocated two 
groups. Each 
Threats to 
the validity/ 
reliability the 
small sample 
size and 
generalizabili
ty of the 
findings 
14 recruited, 
but 11 
completed the 
study 
 
A significant 
reduction in 
urgency (p<.01) 
and frequency 
(p<.05) of urinary 
voids on day 3 of 
the diary, total 
ICIQ-OAB score 
(p<.01), and a non-
Small sample 
size of 11 
participants. 
No power 
calculations 
were 
undertaken in 
order to 
The pilot 
study 
demonstra
ted that 
reducing 
caffeine 
intake 
may 
alleviate 
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decaffeinated 
drinks on 
overactive 
bladder. 
Journal of 
Wound, 
Ostomy & 
Continence 
Nursing. 
41(4)371-378. 
Retrieved 
from 
http://ovidssp.t
x.ovid.com.pal
las2.tcl.sc.edu/
sp-3.18.Ob 
Double-blind, 
randomized, 
crossover 
study 
Evidence 
Level: Ib 
Quality: Good 
group taking 
decaffeinated and 
caffeinated 
drinks for 14 
days.  The 
periods were 
preceded by a 14-
day run-in period 
and interspersed 
with a 14-day 
washout period. 
Primary 
outcomes were 
episodes of 
urgency, 
frequency, 
volume per void, 
and incontinence 
obtained each 
period on 3-day 
bladder diaries.  
Secondary 
outcomes 
measures were 
OAB symptoms 
severity and 
health-related 
significant 
directional change 
for the total ICIQ-
OABqol score 
(P=.065) was found 
using sign tests for 
the period of 
decaffeinated 
compared to 
caffeinated drink 
intake. No 
significant 
differences were 
found for any 
caffeine withdrawal 
measures. 
determine 
sample size. 
The trial did 
not consider 
the value of 
episodic 
analysis of 
compliance 
over the entire 
treatment 
period. 
the 
severity of 
some 
symptoms 
and 
health-
related 
QOL 
factors 
associated 
with 
OAB. 
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quality of life 
(QOL) recorded 
each period using 
International 
Consultation on 
Incontinence-
Overactive 
Bladder Module 
(ICIQ-OAB-
Quality of Life 
(ICIQ-OABqol) 
tools. Effects of 
caffeine 
reduction were 
measured each 
day using visual 
analogue scales. 
13. Gormley, 
E.A., 
Lightner, D.J., 
Faraday, M., 
Vasavada, 
S.P. (2015). 
Diagnosis and 
treatment of 
overactive 
Data extraction 
conducted as part 
of the Agency for 
Healthcare 
Research and 
Quality Evidence 
Report/Technolo
gy Assessment 
Number 187 
None noted The reviewed 
yielded 151 
treatment 
articles after 
application of 
inclusion/ 
exclusion 
criteria. A 
systematic 
The amendment 
focused on four 
topic areas: 
mirabegron, 
peripheral tibial 
nerve stimulation, 
sacral 
neuromodulation 
and BTX-A. The 
None noted New 
evidence-
based 
statements 
and expert 
opinion 
supplemen
t the 
original 
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bladder (non-
neurogenic) in 
adults: 
AUA/SUFU 
guidelines 
amendment. 
The Journal of 
Urology. 193, 
1572-1580. 
Retrieved 
from OVID 
http://dx.doi.o
rg/10.1016/j.ju
ro.2015.01.08
7 
Systematic 
review 
Evidence 
Level Ib 
Quality: Good 
titled Treatment 
of Overactive 
Bladder in 
Women (2009). 
That report 
searched 
PubMed, 
MEDLINE, 
EMBASE and 
CINAHL for 
English language 
studies published 
from January 
1966 to October 
2008. The AUA 
conducted 
additional 
literature 
searches to 
capture 
populations and 
treatments not 
covered in detail 
by the AHRQ 
report and 
relevant articles 
published 
review 
conducted in 
February 2014 
identified 72 
additional 
articles 
relevant to 
treatment and 
made up the 
basis of the 
2014 
amendment. 
additional literature 
provided the basis 
for an updated of 
current guidelines 
statements as well 
as the incorporation 
of new guideline 
statements related 
to the overall 
management of 
adults with OAB 
symptoms. 
guidelines 
published 
in 2012, 
which 
provided 
guidance 
for the 
diagnosis 
and 
overall 
manageme
nt of OAB 
in adults. 
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through 
December 2011.   
14. Fujimura, T., 
Kume, H., 
Tsurumaki, 
Y., 
Yoshimura, Y, 
Hosoda, C., 
Suzuki, M., 
Fukuhara, H., 
Enomoto, Y., 
Nishimatsu, 
H., Homma, 
Y. (2011). 
Core lower 
urinary tract 
symptom 
score (CLSS) 
for the 
assessment of 
female lower 
urinary tract 
symptoms: A 
comparative 
study. 
International 
Three 
questionnaires: 
Core lower 
urinary tract 
symptoms 
(CLSS); 
International 
Prostate 
Symptom Score 
(IPSS); and 
Overactive 
Bladder 
Symptom Score 
(OABSS), were 
completed. 
Quality of life 
(QOL) was 
determined as per 
IPSS quality of 
life Index. The 
clinical diagnoses 
were overactive 
bladder, mixed 
incontinence, 
Japanese 
women were 
studied and 
the 
generalizabili
ty of this 
study is 
called to 
question. 
 
318 female 
patients, ages 
ranging from 
15 -91. 
All symptom scores 
were significantly 
increased in 
symptomatic 
women. The CLSS 
described the 
symptom profile of 
patients with 
distinct conditions. 
The scores of 
corresponding 
symptoms on the 
three questionnaires 
were significantly 
correlated (r=0.51-
0.85; all P<0.0001). 
Multivariate 
logistic regression 
modeling proved 
five CLSS 
symptoms (daytime 
frequency, nocturia, 
urgency 
incontinence, 
The IPSS was 
designed for 
men with BPH 
and may have 
a limited 
ability to 
illustrate 
female LUTS, 
such as 
incontinence 
symptoms. 
The Bristol 
Female Lower 
Urinary Tract 
Symptoms 
(BFLUTS) is a 
questionnaire 
for women, but 
may not be 
readily 
accepted for 
daily use by 
clinicians 
The IPSS 
alone does 
not fully 
evaluate 
female 
LUTS, 
with a 
possible 
negative 
impact on 
QOL. 
Using the 
CLSS 
questionna
ire would 
enable a 
simple 
and 
comprehe
nsive 
assessmen
t of female 
LUTS. 
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Journal of 
Urology, 
18(11)778-
784. 
Retrieved 
from Web of 
Science 
http://apps.we
bofknowledge.
com.pallas2.tc
l.sc.edu/full_r
ecord.do?prod
uct=WOS&se
arch-mode 
Comparative 
Study 
 
Evidence 
Level: IIIb 
Quality: Good 
 
stress 
incontinence, 
pelvic organ 
prolapse, 
interstitial 
cystitis, bacterial 
cystitis, 
underactive 
bladder and 
other. Simple 
statistics and the 
relationship 
between 
symptom scores 
and poor QOL 
(QOL Index≥4) 
were examined. 
straining, and 
urethral pain) as 
independent 
predictors of poor 
QOL, with hazard 
ratios ranging from 
2.0 to 4.2. The IPSS 
included only two 
(urgency and 
straining) 
significant 
symptoms. 
owing to a 
large burden. 
  
 
1
2
7
 
15. Kinsey, D., 
Pretorius, S., 
Glover, L., 
Alexander, T. 
(2016). The 
psychological 
impact of 
overactive 
bladder: A 
systematic 
review. 
Journal of 
Health 
Psychology, 
21(1)69-81. 
Retrieve from 
PsycINFO 
http://sagepub.
co.uk/journals
Permissions.n
av 
Systematic 
review 
Electronic 
databases (Web 
of Knowledge, 
PsycINFO, 
MEDLINE and 
CINAHL) were 
searched for 
published articles 
evaluating the 
impact of OAB 
on psychological 
well-being. 
All studies were 
cross-sectional. 
Most studies 
in this review 
were 
assessed 
using self-
report 
questionnaire
s. This may 
have led to 
participants 
being 
included/ 
excluded 
from OAB 
group on the 
basis of 
different 
individual 
views of 
“urgency”, 
skewing the 
results. 
Electronic 
searches 
generated 3699 
results. 
32 articles on 
psychological 
impact of OAB 
were included 
in the review. 
Majority of studies 
investigated nine 
areas: depression, 
anxiety, 
embarrassment/ 
shame, self-esteem, 
sleep, relationships 
and impact on 
others, sexual 
relationships, social 
life and QoL. 
Research has 
suggested that 
there is 
disagreement 
among 
physicians I 
the way OAB 
is and should 
be defined. 
The lack of 
clarity about 
the definition 
of OAB may 
also create 
difficulties in 
researching the 
condition, 
particularly as 
OAB’s key 
symptom, 
urgency, 
cannot be 
assessed 
objectively. 
This 
review 
provides 
an 
overview 
of the 
current 
research 
on the 
psycholog
ical 
impact of 
OAB. 
Psycholog
ical health 
should be 
considered 
an 
important 
aspect of 
managing 
OAB, and 
further 
research is 
required 
to 
determine 
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Evidence 
Level: Ib 
Quality: Good 
how to 
best 
provide 
psycholog
ical care 
and 
support in 
this area. 
16. Cardozo, L., 
Staskin, D., 
Currie, B., 
Wiklund, I., 
Globe, D., 
Signori, M., 
Dmochowski, 
R., 
MacDiarmid, 
S., Nitti, 
V.W., 
Noblett, K. 
(2014). 
Validation of 
a bladder 
symptom 
screening tool 
in women 
Prospective, 
observational 
study. 
100 women 
completed the 
Actionable 
Bladder 
Symptoms 
Screener Tool 
(ABSST), OAB 
Questionnaire 
Short Form 
(OAB-q SF), and 
a patient global 
impression of 
severity (PGI-S) 
scale. Half of the 
A subset of 
10 patients 
with OAB 
and UUI also 
participated 
in a one-to-
one cognitive 
interview 
during the 
study visit. 
This is too 
small a 
sample size 
to draw 
definitive 
conclusions 
and as a such 
the 
100 women 
from six 
gynecological 
clinics located 
in the USA. 
Clinic staff 
identified 
potential study 
participants 
through 
database and 
chart reviews 
and then, using 
a standard 
recruitment 
and screening 
script, 
contacted 
53 women with 
UUI/OAB and 47 
controls took part 
(71& Caucasian).  
Patients with 
UUI/OAB were 
older (54.6 vs 40.4 
years), had a higher 
body mass index 
(31.1 vs 
26.4kg/m²), and 
more comorbid 
conditions. The 
Cronbach’s alpha 
reliability of 
ABSST was 0.90. 
High correlations 
with OAB-q SF 
Qualitative 
results should 
be interpreted 
with some 
caution, as it is 
difficult to 
draw definitive 
conclusions 
around content 
validity with a 
sample of 10 
patients.  
The women 
enrolled in the 
study 
represented a 
group of 
The 
previous 
MS 
ABSST 
scoring 
algorithm 
was 
validated 
in a non-
neurogeni
c female 
population
. ABSST 
is a 
reliable, 
valid, and 
sensitive 
tool for 
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with 
incontinence 
due to 
overactive 
bladder. 
International 
Urogynecolog
ic Journal, 
25:1655-
1663. 
Retrieved 
from Web of 
Science. 
Doi:10.1007/s
001192-014-
2417-7 
 
Evidence 
Level: IIb 
Quality: Good 
 
sample had 
urinary urgency 
incontinence 
(UUI), while the 
other half did not. 
Descriptive 
statistics, 
reliability, and 
validity were 
examined, as was 
sensitivity and 
specificity of the 
previous cut-off 
score established 
in patients with 
multiple sclerosis. 
IRB was 
approved for 6 
clinics. 
generalizabili
ty to lower 
educated 
women is 
limited. Most 
women who 
participated 
were 
relatively 
highly 
educated. 
However, the 
results 
showed that 
the ABSST 
was a 
reliable 
instrument, 
as 
demonstrated 
by its high 
internal 
consistency 
coefficient. 
prospective 
participants to 
gauge interest 
in participation 
and ascertain 
eligibility for 
the study. 
Symptom Bother 
and Health Related 
Quality of Life 
(r=0.83 and -0.81 
respectively) 
supported 
concurrent validity. 
Using the PGI-S 
severity scores as a 
reference, the 
ABSST was able to 
distinguish patients 
with differing 
severity levels 
(known-group 
validity). Physician 
assessment of the 
need for further 
evaluation/treatmen
t showed sensitivity 
(79%) and 
specificity (98%), 
supporting a cut-off 
score of greater 
than or equal to 3. 
patients who 
were relatively 
well educated 
and also 
willing to 
discuss their 
lower urinary 
tract symptoms 
in a research 
setting. 
Study 
participants’ 
responses may 
not be 
reflective of 
patients who 
have not 
presented for 
treatment 
and/or who 
would be less 
willing to 
discuss their 
symptoms with 
women 
with 
UUI/OAB
. 
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 a healthcare 
provider. 
The diagnosis 
of OAB was 
based on the 
clinician’s 
report without 
a consistent 
definition 
across 
clinicians. 
There was no 
inter-rater 
reliability of 
diagnosis or 
referral for 
treatment was 
evaluated. 
 
17. Jongen, P.J., 
Blok, B.F., 
Heesakkers, 
J.P., Heerings, 
M., Lemmens, 
Observational 
non-
interventional 
web-based study 
Generalizabil
ity of results 
as this were 
patients with 
multiple 
141 MS 
patients from 
Netherlands. 
106 females 
and 35 males. 
For cut-off point 3 
the outcomes (Test 
1 and 2) were: Test 
Positive (TP) 
43.26%, 40.88%; 
Data was 
acquired via 
patient self-
report. 
The study 
findings 
suggest 
that in MS 
patients 
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W.A., 
Donders, R. 
(2015). 
Simplified 
scoring of the 
Actionable 8-
item 
screening 
questionnaire 
for 
neurogenic 
bladder 
overactivity in 
multiple 
sclerosis: a 
comparative 
analysis of 
test 
performance 
at different 
cut-off points. 
BMC 
Urology, 15 
(106). 
Retrieved 
from 
Assessed the test-
retest reliability 
and concurrent 
validity of a 
Dutch version of 
the English 
Actionable 
questionnaire. 
Compared the test 
performance of 
the simplified 
scoring with cut-
off point 3 with 
that of cut-off 
point 2, using the 
original scoring 
with cut-off point 
6 as a gold 
standard. 
Associations 
between positive 
test result and 
urological 
treatment, and 
bladder-specific 
sclerosis 
(MS) in 
Netherlands. 
Ages ranged 
from 24 years 
to 73 years. 
Recruited from 
January 2015 
to May 2015. 
Patients gave 
informed 
consent prior 
to participating 
in web-based 
study. 
Inclusion 
criteria used: 
(1) have an MS 
diagnosis (2) 
no relapse in 
last 30 days (3) 
willing and 
able to comply 
with 
requirement of 
the protocol, 
i.e. online 
completion of 
questionnaires 
Test negative (TN) 
29.79%, 32.85%; 
False Positive (FP) 
0.00%, 0.00%; 
False Negative 
(FN)26.95%, 
26.28%; Sensitivity 
0.62, 0.61; 
Specificity 1.00, 
1.00; Positive 
Predictive Value 
(PPV) 1.00, 1.00; 
Negative Predictive 
Value (NPV) 0.53, 
0.55; Accuracy 
0.73, 0.74; and for 
cut-off point 2: TP 
59.97%, 59.85%; 
TN 26.95%, 
31.39%; FP 2.84%, 
1.46%; FN 10.63%, 
7.30%; Sensitivity 
0.85, 0.89; 
Specificity 0.90, 
0.96; PPV 0.95, 
0.98; NPV 0.72, 
Given 
prevalence of 
cognitive 
impairments in 
MS patients, 
this may 
interfere with 
the quality of 
the data and 
conclusions. 
 
the 
simplified 
Actionabl
e scoring 
is more 
accurate 
with cut-
off point 
2, by 
reducing 
false 
negative 
outcomes; 
while in 
OAB 
patients a 
cut-off 
point of 3 
strongly 
distinguis
hes 
between 
patients 
who 
should be 
treated vs. 
those who 
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bmcurol.biom
edcentral.com
/articles/10.11
86/s12894-
015-0100-z 
 
Observational 
study 
Evidence 
Level: 
IIIa 
Quality: High 
 
 
  
drug treatment 
were calculated. 
and having the 
Expanded 
Disability 
Status Scale 
score assessed 
by phone. 
 
0.81; Accuracy 
0.87, 0.91.  
Cut-off 3 
completely 
prevented FP 
outcomes, but 
wrongly classified 
26% of the patients 
as negative (FN). 
Cut-off 2 reduced 
the FN to 7-10%, 
with low FP values 
(2.84-1.46%). 
With cut-off 2, the 
percentage of 
patients screened 
positive was higher 
in the Progressive 
group (75%) than in 
the Relapsing 
Remitting group 
(56.25%) 
(P=0.0331), which 
do not 
require 
treatment. 
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was not the case 
with cut-off 3. 
Only a positive test 
according to the 
original scoring 
was associated with 
both urological 
treatment 
(P=0.0119) and 
bladder-specific 
medication 
(P=0.0328). 
18. Eapen, R.S., 
Radomski, S. 
B. (2016). 
Gender 
differences in 
overactive 
bladder. The 
Canadian 
Journal of 
Urology, 
23(1):2-9.  
The article 
discusses various 
LUTS and OAB 
studies and 
describes ways to 
evaluate and treat 
patients who 
present with 
symptoms 
suggestive of 
OAB. 
None noted The article 
discussed fours 
studies OAB 
symptoms, 
their findings 
and prevalence 
and impact on 
quality of life. 
Prevalence of OAB 
and its symptoms 
increases with 
increasing age in 
both genders. 
Urinary urge 
incontinence more 
common in women. 
Treatment should 
take on a 
multidisplinary 
approach with 
None noted OAB is 
common 
in both 
men and 
women.  
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Retrieved 
from google 
scholar. 
Clinical 
practice 
guidelines 
Evidence 
level IVa 
Quality: High 
implementation of 
lifestyle 
modification s and 
behavioral therapies 
alongside 
pharmacotherapy  
for most optimal 
outcome. 
19. Jafarabadi, 
M., 
Jafarabadi, L., 
Shariat, M., 
Rabie 
Salehi,G., 
Haghollahi, 
F., Rashidi, 
B.H.(2015). 
Considering 
the prominent 
complaint as a 
guide in 
medical 
therapy for 
Randomized, 
double-blind, 
parallel group 
trial 
The study was 
designed to 
determine the 
effectiveness of 
oxybutynin (5mg 
immediate 
release{IR} 
tablet, three times 
a day) versus 
tolterodine (2mg 
Generalizabil
ity of study 
findings to 
other 
countries 
with diverse 
populations. 
This study 
was 
performed on 
patients in a 
women’s 
clinic in 
Tehran, Iran. 
410 patients 
screened 
301 
randomized. 
151 and 150 
patients in the 
oxybutynin 
and tolterodine 
groups, 
respectively. 
Exclusion 
criteria: 
lactation, 
Mean 
improvements in 
the terms of 
urgency (P=0.64) 
and urge 
incontinence 
(P=0.75) showed an 
insignificantly 
larger score in 
patients who were 
treated by 
oxybutynin.  
Improvement in 
night-time urinary 
Small sample 
size, short 
follow-up 
duration and 
the subjective 
nature of the 
follow up 
Oxybutyni
n and 
tolterodine 
showed 
similar 
efficacy 
on 
daytime 
symptoms 
of 
overactive 
bladder 
and 
similar 
side 
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overactive 
bladder 
syndrome in 
women over 
45 years. 
Journal of 
Obstetrics & 
Gynaecology 
Research, 
41(1):120-126 
DOI:http://dx.
doi.org.pallas
2.tcl.sc.edu/10
.1111/jog.124
83 
Randomized 
clinic trial 
study 
Evidence 
Level: Ib 
Quality: Good 
IR tablet every 12 
hours) in a 12-
week treatment of 
OAB in women 
over 45 years. 
suspicion of 
pregnancy, 
glaucoma, 
acute or 
repetitive 
urinary 
infection, 
significant 
stress urinary 
incontinence, 
myasthenia 
gravis, 
neuropathy, 
mental 
disorder, gross 
renal, hepatitis 
or 
cardiovascular 
disorders, 
obstruction in 
urinary bladder 
outlet, history 
of 
genitourinary 
operations, 
interstitial 
cystitis, 
urgency and 
nocturia (41.2% 
and 54.3% vs 
39.7% and 40.1% 
in oxybutynin vs 
tolterodine groups, 
respectively) were 
shown to be more 
improved by 
tolterodine in 
comparision to 
oxybutynin (P=0.72 
and 0.04 for night-
time urinary 
urgency and 
nocturia, 
respectively) 
Discontinuation of 
treatment due to 
adverse events was 
not significantly 
different in the two 
groups. 
 
effects in 
perimenop
ausal 
patients.  
For 
patient 
with the 
chief 
complaint 
of 
nocturnal 
frequency, 
prescriptio
n of 
tolterodine 
is 
preferably 
suggested. 
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unexplained 
hematuria, 
urinary 
catheterization, 
concomitant 
antimuscarinic 
medication, 
electrostimulati
on therapy or 
bladder 
training, 
allergy to 
oxybutynin or 
tolterodine, or 
treatment with 
this drugs in 
the 3 months 
before 
randomization 
and exposure 
to any other 
investigational 
drug in the 
preceding 2 
months 
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20. Palma, T., 
Raimondi, M., 
Souto, S., 
Fozzatti, C., 
Palma, P., 
Riccetto, C. 
(2013). 
Prospective 
study of 
prevalence of 
overactive 
bladder 
symptoms and 
child-bearing 
in women in 
reproductive 
age. Journal 
of Obstetrics 
& 
Gynaecology 
Research, 
39(8):1324-
1329. 
DOI: 
http://dx.doi.o
rg.pallas2tcl.s
Premenopausal 
women were 
interviewed to 
ascertain the 
prevalence of 
OAB symptoms. 
Patients were 
approached to 
complete the 
International 
Consultation on 
Incontinence 
Questionnare-
Overactive 
Bladder (ICIQ-
OAB) 
questionnaire. 
A validated ICIQ-
OAB Portuguese 
version, with 
specific 
questionnaire for 
the demographics. 
 
External 
validity due 
to 
generalizatio
n of results 
as 
questionnaire 
performed in 
public 
places. 
1052 women 
of child-
bearing age 
(20-45 years) 
in Campinas, 
Brazil, 
1400 
questionnaires 
were filled. 
348 were 
excluded as 
they did not 
meet the 
inclusion 
criteria. 
Exclusion 
criteria: 
diabetes 
mellitus, 
chronic lung 
disease, history 
of recurrent 
urinary tract 
infections, 
current urinary 
Multiparous and 
primiparous women 
showed 
significantly higher 
scores in the ICIQ-
OAB questionnaire 
than nulliparous 
women, 
Multiparous women 
presented more 
frequency than 
nulliparous women 
(P<0.0001). 
No significant 
difference was 
found in urgency 
(P=0.0682), and 
multiparous women 
presented more 
urgency 
incontinence than 
nulliparous ones 
(P=0.0313). 
The non-
parametric 
analysis. 
Study 
performed in 
mostly public 
places, which 
made it 
impossible to 
perform 
physical 
assessments in 
participants. 
Data relied on 
the information 
given by the 
women in the 
questionnaires. 
Nulliparou
s women 
presented 
fewer 
OAB 
symptoms 
than 
primiparo
us women.  
Multiparo
us women 
presented 
more 
symptoms 
than the 
other two 
groups. 
No 
significant 
difference
s between 
cesarean 
and 
vaginal 
delivery, 
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c.edu/10.1111
/jog.12063 
Epidemiologi
cal study 
Evidence 
Level:IIIb 
Quality: Good 
 tract infection, 
neurological 
diseases and 
other 
conditions that 
can predispose 
to neurogenic 
detrusor 
overactivity, 
and patients 
who underwent 
surgery for 
urinary 
incontinence 
and other 
major pelvic 
surgery. 
 
but the 
scores of 
women 
who had 
vaginal 
delivery 
were 
higher 
than those 
who had 
cesareans.  
Both types 
of 
delivery 
were 
related to 
higher 
ICIQ-
OAB 
questionna
ire scores 
than those 
of 
nulliparou
s women. 
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21. Al-Ghazo, 
M.A., 
Ghalayani, I. 
F., Al-Azab, 
R., Hani, O. 
B., Matani, 
Y.S., Haddad, 
Y. (2011). 
Urodynamic 
detrusor 
overactivity in 
patients with 
overactive 
bladder 
symptoms. 
International 
Neurourology 
Journal, 
15:48-54. 
A study to 
evaluate the 
relationship 
between 
urodynamic 
detrusor 
overactivity (DO) 
and OAB 
symptoms in men 
and women. 
Records were 
reviewed of 
patients who 
attended a tertiary 
referral center for 
urodynamic 
evaluation of 
OAB syndrome 
symptoms with 
Generalizabil
ity of the 
results to the 
entire 
population  
Results 
reviewed of 
209 adult non-
neurogenic 
patients (117 
men and 92 
women) in a 
urodynamic 
specialist 
referral testing 
center. 
Performed 
between 
February 2002 
and February 
2007. 
Exclusion 
criteria: 
neurological, 
Incidence of DO 
was 76.1% and 
58.7% in male and 
female OAB 
patients, 
respectively. 
Of men 63% and 
61% of women 
with urgency (OAB 
dry) had DO, while 
93% of men and 
69.8% of women 
with urgency and 
urgency urinary 
incontinence (OAB 
wet) had DO. 
Of women, 58% 
who were OAB wet 
had stress urinary 
The study was 
retrospective. 
A validated 
urgency scale 
that measures 
urgency rather 
than bladder 
sensation was 
needed. 
The study 
compares 
subjective 
symptoms with 
objective 
parameters. 
Follow-up data 
was lacking in 
some patients. 
There was 
better 
correlation 
in results 
between 
OAB 
symptoms 
and the 
urodynami
c 
diagnosis 
of DO in 
men than 
in women, 
more so in 
OAB wet 
than in 
OAB dry. 
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DOI:10.5213/
inj.2011.15.1.
48 
Retrospective 
Study 
Evidence 
Level: IIIb 
Quality: Good 
the presence or 
absence of DO. 
DO was 
calculated for 
symptoms alone 
or in 
combinations. 
vesical, 
bladder outlet 
and pelvic 
floor diseases 
or surgery. 
 
 
 
incontinence 
symptom with 
26.4% having 
urodynamic stress 
incontinence. 
6% of men and 
6.5% of women 
with OAB 
symptoms had 
urodynamic 
diagnosis of 
voiding difficulties 
with post-void 
residual greater 
than 100ml. 
Combination of 
symptoms is more 
accurate in 
predicting DO in 
OAB patients. 
The multivariate 
disease model for 
males included urge 
urinary 
incontinence (UUI) 
There was not 
adequate 
information 
regarding 
whether or not 
urodynamic 
findings 
altered 
management 
for these 
patients. 
 
Combinati
on of 
symptoms 
of OAB 
syndrome 
seems to 
have a 
better 
correlation 
with 
objective 
parameter
s from the 
bladder 
diary, 
filling 
cystometr
y, and 
with the 
occurrenc
e of DO. 
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and urgency while 
for females it 
included UUI and 
nocturia. 
The results were 
statistically 
evaluated using 
Mann-Whitney and 
Fisher’s exact 
probability tests for 
comparison of the 
findings between 
DO and no DO 
patients, and for 
comparison 
between symptoms 
and urodynamic 
findings. 
22. Reynolds, 
W.S., 
McPheeters, 
M., Blume, J., 
Surawicz, T., 
Worley, 
K.,Wang, L., 
Multiple 
reviewers 
screened original 
research 
published in 
English on 
community 
Bias, as 98% 
of the studies 
reported 
funding by 
industry.  
 
5 Data sources: 
MEDLINE, 
EMBASE, 
Cumulative 
Index to 
Nursing and 
Allied Health 
Effects of 
medication and 
placebo was 
assessed and no 
individual agent 
demonstrated 
None noted Evidence 
from more 
than 
27000 
women 
participati
ng in 
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Hartmann, K. 
(2015). 
Comparative 
effectiveness 
of 
anticholinergi
c therapy for 
overactive 
bladder in 
women: A 
systematic 
review and 
meta-analysis. 
(Review). 
Obstetrics 
and 
Gynecology,1
25(6):1423-
1432 
Evidence 
Level IIIb 
Quality: Good 
dwelling women 
with non-
neurogenic OAB 
undergoing 
pharmacotherapy 
with medications 
available in the 
USA. 
Study design 
included 
randomized 
controlled trial for 
meta-analysis and 
cohorts, case-
control, and case 
series for harms 
data. 
Literature, and 
ClinicalTrials.
gov 
Exclusion 
criteria: studies 
in which 
women 
comprised less 
than 75% of 
population; 
small sample 
size less than 
50. 
superiority over 
another. 
randomize
d 
controlled 
clinical 
trials 
suggests 
improvem
ent in 
symptoms 
with 
anticholin
ergic 
manageme
nt of 
overactive 
bladder is 
modest 
and rarely 
fully 
resolves 
symptoms
. 
23. Yamaguchi, 
O., Marui, E., 
Kakizaki, H., 
Randomized, 
double-blind, 
placebo-
Bias as some 
of the 
researchers 
1139 patients 
in multiple 
Mirabegron was 
found to be 
significantly 
None noted in 
article. 
Mirabegro
n 50mg 
daily is an 
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Homma, Y., 
Igawa, 
Y.,Takeda, 
M., 
Nishizawa, 
O., Gotoh, 
M., Yoshida, 
M.,Yokoyama
, O., Seki, 
Na., Ikeda, 
Y., Ohkawa, 
S. (2014). 
Phase III, 
randomized, 
double-blind, 
placebo-
controlled 
study of the 
βᶾ-
adrenoceptor 
agonist 
mirabegron, 
50mg once 
daily, in 
Japanese 
patients with 
overactive 
controlled phase 
III study enrolled 
Japanese patients 
experiencing 
OAB symptoms 
for ≥ 24 weeks. 
Patients with ≥ 8 
micturitions/24 
hours and ≥ 1 
urgency 
episode/24 hours 
or ≥1 urgency 
incontinence 
episode/ 24 hours 
were randomized 
to once daily 
placebo, 
mirabegron 50mg 
or tolterodine 
4mg (as an active 
comparator, 
without testing 
for non-inferiority 
of efficacy and 
were 
consultants 
for industry. 
Generalizabil
ity of results 
to other 
countries 
with diverse 
populations 
centers in 
Japan. 
Receiving 
placebo, 
n=381. 
Receiving 
mirabegron 
50mg, n=380. 
Receiving 
tolterodine 
4mg, 
N=378. 
Demographic 
and baseline 
characteristics 
were similar 
among the 
treatment 
groups. 
 
superior to placebo 
in terms of mean 
(SD) change from 
baseline in number 
of micturitions/24 
hours (-1.67 [2.212] 
vs -0.86 [2.354]; 
P<0.001) and mean 
[SD] change from 
baseline in number 
of urgency 
episodes/24 hours 
(-1.85) [2.555] vs -
1.37 [3.191]; 
P=0.025), 
incontinence 
episodes/24 hours 
(-1.12[1.475] vs -
0.66 [1.861]; 
P=0.003), urgency 
incontinence 
episodes/ 24 hours 
(-1.01 [1.338] vs -
0.60 [1.745]; 
P=0.008), and 
volume 
voided/micturition 
effective 
treatment 
for OAB 
symptoms
, with a 
low 
occurrenc
e of side 
effects in 
a Japanese 
population
. 
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bladder. BJU 
International,
113:951-960 
Randomized 
clinic trial 
study 
Evidence 
Level: Ib 
Quality: Good 
 
safety) for 12 
weeks. 
Primary endpoint 
was change in 
mean number of 
micturations/ 24 
hours from 
baseline to final 
assessment. 
Secondary 
endpoints 
included 
micturition 
variables related 
to urgency and/or 
incontinence and 
QOL domain 
scores on the 
King’s Health 
Questionnaire. 
Safety assessment 
included adverse 
events (AEs), 
post-void residual 
urine volume, 
(24.300 [35.4767] 
vs 9.715 [29.0864] 
ml; P< 0.001). 
Adverse events 
(AE) incidence 
were similar in both 
mirabegron and 
placebo groups. 
Most AEs were 
mild and none were 
severe. 
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laboratory 
variables, vital 
signs and 12 lead 
electrocardiogram
. 
24. Cardozo, L., 
Hebdorfer, E., 
Milani, R., 
Arano, P., 
Dewilde, L., 
Slack, M., 
Drogendijk, 
T., Wright, 
M., 
Bolodeoku, J. 
(2008). 
Solifenacin in 
the treatment 
of urgency 
and other 
symptoms of 
overactive 
bladder: 
results from a 
randomized, 
double-blind, 
The study 
(SUNRISE, 
solifenacin in the 
treatment of 
urgency 
symptoms of 
OAB in a rising 
dose, randomized, 
placebo-
controlled, 
double-blind, 
efficacy trial) was 
randomized, 
double-blind, 16-
week, placebo-
controlled, 
multicenter study 
of solifenacin 
5/10 mg in 
patients with 
symptoms of 
Potential 
bias, as the 
study was 
supported by 
industry 
863 patients in 
105 centers in 
14 European 
countries 
Solifenacin 5/10 
mg was 
significantly more 
effective than 
placebo in reducing 
the mean number of 
episodes of severe 
urgency with or 
without 
incontinence per 24 
hours from baseline 
to endpoint (-2.6 vs 
-1.8, P<0.001). 
There were also 
statistically 
significant 
differences in favor 
of solifenacin 5/10 
mg over placebo for 
all secondary 
variables measured 
None noted. Solifenaci
n 
significant
ly reduced 
the 
number of 
urgency 
episodes 
and the 
extent of 
urgency 
bother, 
and was 
well 
tolerated; 
it was 
effective 
as early as 
day 3 of 
treatment. 
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placebo-
controlled, 
rising-dose 
trial. BJU 
International, 
102 (1120-
1127). 
DOI:10.1111/
j.1464-
410X.2008.07
939.x 
Randomized 
clinical trial 
study 
Evidence 
Level: Ib 
Quality: Good 
 
OAB for ≥ 
3months.  
The primary 
efficacy variable 
was the change 
from baseline to 
endpoint in the 
number of 
episodes of severe 
urgency with or 
without urgency 
incontinence per 
24 hours, as 
measured using 
the Patient 
Perception of 
Intensity of 
Urgency Scale, 
grade 3+4. 
Secondary 
efficacy variables 
included patient-
reported 
outcomes for 
bladder condition, 
at endpoint, 
including patient-
reported outcomes. 
There was a 
significant 
improvement in 
urgency as early as 
day 3 of treatment. 
Treatment-
emergent adverse 
events with 
solifenacin 5/10 mg 
were mainly mild 
or moderate in 
severity, and only 
led to 
discontinuation in 
3.6% of patients. 
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urgency bother 
and treatment 
satisfaction.  
A 3-day voiding 
diary was used to 
record micturition 
frequency and 
episodes of 
urgency and 
incontinence. A 
7-day diary was 
used to assess 
speed of onset of 
effect. 
25. Nguyen, K., 
Hunter, K.F., 
Wagg, A. 
(2013). 
Knowledge 
and 
understanding 
of urinary 
incontinence: 
Survey of 
family 
A cross-sectional 
survey, using 
randomly selected 
sample of family 
physicians in 
Alberta, Canada. 
Family physicians 
were selected 
from the publicly 
available 
directory 
The findings 
may not be 
generalizable 
due to a low 
response rate 
of 
practitioners. 
An 
honorarium 
of $50 was 
offered to 
Of 158 of 1488 
family 
practitioners 
contacted 
participated. 
All 
practitioners 
completed the 
questionnaire 
Survey response 
rate was 10.6% 
(158 of 1488); 
84.2% (133 of 158) 
of respondents 
practiced in urban 
settings, 44.9% (71 
of 158) had been in 
practice for fewer 
than 15 years, 
24.1% (38 of 158) 
Low response 
rate. 
Declining 
response rates 
to surveys 
owing to 
survey fatigue. 
There 
continues 
to be 
considerab
le 
variation 
in 
knowledg
e about 
urinary 
incontine-
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practitioners 
in northern 
Alberta. 
Canadian 
Family 
Physician 
59(7):e330-
e337 
Retrieved 
from 
www.cfp.ca.p
allas2.tcl.sc.e
du/content/59/
7/e330 
Descriptive 
survey 
 
Evidence 
Level: 
IIIb 
Quality: Good 
 
published by the 
College of 
Physicians and 
Surgeons of 
Alberta using 
computer-
generated random 
number list. 
Standardized 
validated survey 
used. 
complete the 
survey and 
may 
potentially 
create a bias  
via telephone, 
and fax 
reported having no 
training in urinary 
incontinence (UI) 
management since 
graduation, and 
53.8% (85 of 158) 
reported that they 
proactively 
discussed UI with 
their patients. 
 Overall, 70.0% of 
respondents felt 
fairly confident in 
managing UI. Most 
family physicians 
referred patients for 
specialist care, with 
few referrals to 
community 
services. 
 Respondents 
thought that 
continence services 
were scarce, with 
long waiting times, 
nce 
manage-
ment and 
a relative 
overrelia-
nce on 
specialist 
care, 
despite 
well 
recogniz-
ed 
difficulties 
in gaining 
access to 
services. 
Responde
nts 
believed 
that 
increased 
awareness 
among 
patients 
and health 
care 
providers 
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and that such 
services were 
generally 
overstretched; they 
believed that 
although high 
quality continence 
care was a personal 
priority, it was not a 
priority for their 
practice 
partnerships or 
networks.  
In terms of the 
highest ranked 
areas for 
improvement in UI 
management, 
increased 
awareness and 
understanding 
among physicians 
(ranked first by 
28.5% of 
respondents), 
followed by 
coupled 
with 
greater 
access to 
continence 
services 
were key 
factors in 
improving 
care 
delivery. 
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dedicated 
incontinence clinics 
or nurses for 
referral (17.7%) 
and improving 
patient awareness 
and understanding 
(12.0%). 
26. Teunissen, D. 
T. A. M., 
Stegeman, 
M.M., Bor, H. 
H., Lagro-
Janssen, 
A.L.M. 
(2015). 
Treatment by 
a nurse 
practitioner in 
primary care 
improves the 
severity and 
impact of 
urinary 
incontinence 
in women. An 
An observational 
study examining 
how nurse 
practitioners 
(NPs)treated 
female patients 
with UI. 
All patients were 
examined and 
referred by the 
General 
Practitioner (GP) 
the NP working 
in the same 
practice.  
 At baseline the 
severity of the UI 
The 
generalizabili
ty of the 
study cannot 
be but is 
assumed to 
have 
improved the 
women’s life 
after three 
months of 
therapy. 
16 nurse 
practitioners 
working with a 
GP’s office in 
the 
Netherlands, 
undertook a 
training 
program in 
which they 
learned how to 
manage female 
patients with 
UI. 
 
103 women were 
included, mean age 
55 years (SD 12.6). 
The Sandvik 
severity categories 
improved 
significantly 
(P<0.001), as did 
the impact on daily 
life (2.54 points, 
P=0.012). Among 
the IIQ score the 
impact on daily 
activities increased 
0.73 points 
(P=0.032), on 
social functioning 
0.60 points 
The dropout 
rate in this 
study was 32% 
which is 
considered 
high. 
No control 
group was 
involved as a 
RCT which 
received care 
by the GP. 
The training 
program for 
patients with 
UI is time 
consuming, 
Treatment 
by a 
trained NP 
seems to 
have a 
small 
positive 
affect the 
severity of 
the UI and 
the impact 
on the 
quality of 
life. NPs 
involved 
in the care 
of patients 
generally 
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observational 
study. 
BioMed 
Central,15:51. 
DOI:10.1186/
s12894-015-
0047-0 
Observational 
study 
 
Evidence 
Level: IIIb 
Quality: Good 
(Sandvik-score), 
the impact of the 
quality of life 
(IIQ) and the 
impressed 
severity (PGIS) 
was measured and 
repeated after 
three months. 
Differences were 
tested by the 
paired t and the 
NcNemar test. 
Reasons for not 
completing 
treatment were 
documented by 
the nurse 
practitioner and 
differences 
between the 
group that 
completed 
treatment and the 
(P=0.030) and on 
emotional well-
being 0.63 points 
(P=0.031). The 
PGIS -score 
improved in 41.3% 
of the patients. 
The most important 
reasons for not 
completing the 
treatment were lack 
of improvement of 
the UI and 
difficulties in 
performing the 
exercises. Women 
who withdraw from 
guidance by the 
nurse practitioner 
perceived more 
impact on daily life 
(P=0.036), in 
particular on the 
scores for social 
functioning 
(P=0.015) and 
and not always 
easy to sustain 
and difficult to 
implement in 
daily life. 
 
leads to an 
improvem
ent of 
health 
outcomes 
and 
patient 
satisfactio
n. 
Women 
who did 
not 
complete 
treatment 
suffer 
from more 
impact on 
quality of 
life, 
experience 
not 
enough 
improvem
ent and 
mention 
difficulties 
  
 
1
5
2
 
drop-out group 
were tested. 
 
emotional well-
being (P=0.015). 
in 
performin
g 
exercises. 
27. Albers-
Heitner, C.P., 
Lagro-
Janssen, 
A.L.M., 
Venema, P.L., 
Berghmans, 
L.C.M., de 
Jonge, A., 
Joore, M.A. 
(2010). 
Experiences 
and attitudes 
of nurse 
specialists in 
primary care 
regarding 
their role in 
care for 
patients with 
urinary 
incontinence. 
A focus group 
conducted with 
nurse specialists 
who were trained 
in caring for 
patients with UI 
in a randomized 
clinical trial. 
The aim was to 
explore 
experiences and 
attitudes of nurse 
specialists in 
primary care. 
The focus group 
interview was 
audio-taped and 
transcribed 
verbatim. 
There may 
have been 
some bias, as 
all were 
interested 
participants. 
Due to the 
small sample 
size the 
generalizabil
-ity of the 
study was 
limited. 
16 nurse 
specialists in 
four Dutch 
regions who 
provided care 
to patients with 
UI. 
The study was 
carried out 
from May 
2005 until 
Mache 2008. 
All 
consecutive 
patients 
consulting 
their GP for UI 
within 1 year 
and patients 
already 
diagnosed with 
Descriptive 
statistics was used. 
To increase 
dependability and 
confirmability, the 
interview was 
transcribed 
verbatim. 
To improve 
consistency and 
reliability analysis, 
the external 
moderator and the 
researcher analyzed 
the transcript 
independently of 
each other. 
To promote 
trustworthiness, the 
researchers 
A small size 
was used. 
Only one focus 
group was 
conducted. 
The 
participants 
may have 
made socially 
desirable 
comments 
because they 
knew 
interviewers 
may have an 
interest in the 
subject. 
The focus 
group 
trained 
nurse 
specialist 
appeared 
to feel 
competent 
and 
satisfied 
to support 
GPs in 
caring for 
patients 
with UI. 
They also 
felt highly 
appreciate
d by both 
patients 
and GPs. 
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Scandinavian 
Journal of 
Caring 
Science. 
25:303-310. 
DOI:10.1111/
j.1471-
6712.2010.00
827.x 
Focus group 
study 
Evidence 
Level:IVb 
Quality: Good 
 
A questionnaire 
was filled out 
prior to the focus 
group. 
The data was 
analyzed using 
qualitative 
content analysis 
to identify 
themes. 
To understand 
obstacles and 
incentives for 
change, the 
researchers relied 
on an existing 
‘implementation 
model.’ 
UI were 
eligible. 
Approval was 
sought from 
the Medical 
Ethical 
Committees of 
all the involved 
medical 
centers and 
hospitals. 
discussed data 
fragments in the 
light of ‘potential 
barriers and 
facilitators for 
quality of care and 
change’ related to 
the individual’s 
cognitive, 
educational and 
motivational 
attributes as well as 
to social, 
organizational and 
economic factors. 
Nurse specialists 
value continuous 
education and 
feedback in daily 
care of patients 
with UI. 
Nurse 
specialist 
sometimes 
noticed 
the GPs 
lack of 
interest in 
UI. 
Having 
personal 
contact 
with GPs, 
availabilit
y of 
enough 
time, 
adequate 
equipment 
and 
financial 
resources 
are 
important 
preconditi
ons for 
effective 
  
 
1
5
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nurse 
specialist 
care. 
28. Keilman, L.J., 
Dunn, S. K. 
(2010). 
Knowledge, 
attitudes, and 
perceptions of 
advanced 
practice 
nurses 
regarding 
urinary 
incontinence 
in older adult 
women. 
Research and 
Theory for 
Nursing 
Pratice: An 
International 
Journal, 24 
(4):260-279. 
Across-sectional, 
descriptive, 
correlational 
design was used 
to study 
purposive sample 
of APNs who 
were identified 
from personal and 
professional 
contacts and an 
APN organization 
membership list.  
Eligible 
participants had 
completed a 
master’s degree in 
nursing from an 
accredited 
university, had 
achieved national 
certification as a 
A small 
sample size 
may limit the 
generalizabili
ty of the 
findings. 
Self-reported 
data may 
create a bias 
 
72 APNS 
initially agreed 
to participate; 
however, only 
56 
questionnaires 
were returned. 
2 
questionnaires 
were not 
excluded for 
failing to 
complete the 
questionnaire. 
The study 
sample of 54 
participants or 
a 75% 
response rate, 
Majority of 
participants 
Data was analyzed 
using SPSS17.0 
computer software.  
Approximately 
57% (n=31) of the 
APNs reported 
diagnosing UI in 
their clinical 
practice. 
Of the APNS who 
diagnosed UI, 60% 
also treat, manage, 
educate, and 
counsel patients 
regarding their 
condition. 
Only 48.1% felt 
their education on 
the topic was 
adequate. This 
group of APNs 
Sample was 
not a true 
representation 
of the entire 
population of 
APNs. 
There were 
148 questions, 
which took 
approximately 
1-2 hours to 
complete. 
Continuou
s 
education 
is a crucial 
componen
t in the 
manageme
nt of UI.  
APNs can 
make a 
difference 
in the 
manageme
nt of UI in 
women if 
they are 
taught the 
essentials 
and UI 
practice 
guidelines 
within 
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DOI:10.1891/
1541-
6277.24.4.260 
Cross-
sectional, 
descriptive, 
and 
correlational 
design study 
Evidence 
Level IIIb 
Quality: Good 
 
nurse practitioner, 
clinical nurse 
specialist, or 
midwife, and 
worked with older 
adult women. 
IRB approval was 
sought prior to 
recruitment. 
Participants 
where initially 
consulted by 
telephone, email 
or in-person. 
The study 
purpose, process, 
estimated 
timeframe for the 
questionnaire 
completion, and 
consent were then 
explained to 
participants. 
 
were female 
(n=51, 94.4%), 
Caucasian 
(n=46, 85.2%), 
married (n=40, 
84.1%).  
Age of the 
participants 
ranged from 
31.7 to 72.8 
years with a 
mean of 53.0 
(SD=10.25) 
Upon data 
entry, 2 
participants 
failed to 
complete the 
questionnaire 
appropriately. 
reported learning 
more about UI 
through attending 
conferences where 
UI was offered as a 
topic (n=30, 
72.2%); consulting 
a UI specialist 
n=21, 38.9%); or 
acquiring specific 
information through 
reading 
professional 
journals (n=48, 
88.9%). 
UI guidelines were 
used regularly in 
practice by only 
24.1% (n=13)) of 
the APNs. 
Participants also 
reported the 
prevalent gender of 
older adult patients 
treated for UI was 
their 
graduate 
education. 
Researche
rs have 
found that 
enhancing 
UI content 
with 
graduate 
curriculu
m may be 
warranted. 
Perhaps 
the single 
most 
important 
action that 
APNs can 
take is to 
ask every 
older adult 
about UI 
and then 
follow 
  
 
1
5
6
 
female (n=39, 
72.2%) and more 
than 50% of those 
individuals were 66 
years of age and 
older. 
All participants did 
not necessarily feel 
confident in their 
assessment/diagno-
stic skills related to 
UI (M=3.50, 
SD=0.95) and in 
managing and/or 
treating UI 
independently. 
APNS who 
reported a higher 
level of education 
regarding UI had 
more accurate 
perceptions, more 
positive attitudes, 
and more 
knowledge 
with the 
basic 
approache
s to 
evaluation 
and 
managem-
ent. 
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regarding older 
adult women with 
UI than those who 
reported lesser 
levels of education. 
Reliability of the 
KAPUIOW scale 
was estimated by 
Cronbach’s alpha. 
Total scale estimate 
was α=0.86, with 
α=0.81 for the 
Attitudes/Perceptio
n subscale, and 
α=0.77 for the 
Knowledge 
subscale. 
29. Duralde, E.R., 
Walter, L.C., 
Van Den 
Eeden, S.K., 
Nakagawa, S., 
Subak, L.L., 
Brown, J.S., 
Thom, D.H., 
An observational 
cohort study from 
2003-2012.  
Women aged 40 
years and older 
enrolled in a 
Northern 
California 
The 
generalizabili
ty of the 
study may be 
limited as the 
women in 
this study 
had few 
969 women in 
a Northern 
California 
integrated 
health care 
delivery 
system. 
Mean age of the 
participants was 
59.9 years and 55% 
were racial/ethnic 
minorities (171 
black, 233 Latina, 
133 Asian or Native 
American). Fifty-
Researchers 
relied on 
participants 
report on 
incontinence 
status, 
comorbid 
conditions and 
Lower 
income 
women 
and 
diabetic 
women 
were less 
likely to 
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Huang, A.J. 
(2016). 
Bridging the 
gap: 
determinants 
of 
undiagnosed 
or untreated 
urinary 
incontinence 
in women. 
American 
Journal of 
Obstetrics & 
Gynecology,2
14:266.e1-9 
Retrieved 
from 
http://dx.doi.o
rg/10.1016/j.a
jog.2015.08.0
72 
Evidence 
Level IIIb 
integrated health 
care delivery 
system who 
reported at least 
weekly 
incontinence. 
Structured 
questionnaires 
were used to 
assess clinical 
severity, type, 
treatment, and 
discussion of 
incontinence. 
barriers to 
care, were 
insurance, 
with 
relatively 
easy access 
to affordable 
primary care 
specialists. 
 
 five percent 
reported discussing 
their incontinence 
with a health care 
provider, 36% 
within 1 year of 
symptom onset, and 
with only 3% 
indicating that their 
provider initiated 
the discussion. 
 More than half 
(52%) reported 
being at least 
moderately 
bothered by their 
incontinence. Of 
these women, 324 
(65%) discussed 
their incontinence 
with a clinician, 
with 200 (40%) 
doing so within 1 
year of symptom 
onset. In a 
multivariate 
provider 
interactions 
around 
incontinence. 
Researchers 
utilized 
interviews in 
data collection, 
which have 
been 
associated with 
poorer 
reporting of 
sensitive topics 
such as 
incontinence. 
Only women 
with a least 
weekly 
incontinence 
participated, 
and did not 
include women 
who had 
previously 
discuss 
incontinen
ce issues 
with their 
providers. 
The 
findings 
provide 
support 
for 
systematic 
screening 
of women 
by 
providers 
to 
overcome 
barriers to 
evaluation 
and 
treatment. 
  
 
1
5
9
 
Quality: Good analysis, women 
were less likely to 
have discussed their 
incontinence if they 
had a household 
income <$30,000 
vs ≥ 120,000/year 
(adjusted odds ratio 
[AOR], 0.49, 95% 
confidence interval 
(CI), 0.28-0.86) or 
were diabetic 
(AOR, 0.71, 95% 
CI, 0.51-0.99). 
They were more 
likely to have 
discussed 
incontinence if they 
had clinically 
severe incontinence 
(AOR, 3.09, 95% 
CI, 1.89-5.07), 
depression (AOR, 
1.71, 95% CI, 1.20-
2.44), pelvic organ 
prolapse (AOR, 
suffered from 
incontinence, 
underwent 
evaluation, and 
were 
successfully 
treated, or 
those with less 
frequent 
incontinence. 
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1.98, 95% CI,1.13-
3.46), or arthritis 
(AOR, 1.44, 95% 
CI, 1.06-1.95). 
Among the subset 
of women reporting 
at least moderate 
subjective bother 
from incontinence, 
black race (AOR, 
0.45 95%CI, 0.25-
0.82, vs white race) 
and income < 
$30000/ year 
(AOR, 0.37, 95% 
CI 0.17-0.81, vs ≥ 
$120000/year) were 
associated with a 
reduced likelihood 
of discussing 
incontinence. Those 
with clinically 
severe incontinence 
(AOR, 2.93, 95% 
CI, 1.53-5.61, vs 
low to moderate 
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incontinence by the 
Sandvik scale) were 
more likely to 
discuss it with a 
clinician. 
30. Carcio, H.A. 
(2014). 
Calming the 
overactive 
bladder: a 
nurse 
practitioner 
perspective. 
Women’s 
Healthcare: A 
clinical 
journal for 
NPs, 2(3):26-
27 & 49. 
Retrieved 
from 
www.NPWo
menshealthcar
e.com 
The article 
explores the 
assessment and 
management of 
OAB by NPs 
None noted The article 
discussed a 
survey done by 
the National 
Association of 
Nurse 
Practitioners in 
Women’s 
Health on 300 
NPs to 
ascertain their 
own level of 
recognition 
and treatment 
of OAB in 
their practice 
OAB is lifestyle 
threatening and 
patients need not 
suffer with it, if 
OAB symptoms are 
identified quickly, 
by a NP or patient. 
The assessment 
includes a health 
history, focused 
physical 
examination that 
includes a 
gynecological exam 
to assess the 
bladder and pelvic 
floor muscles. 
 
None noted NPs have 
an 
opportunit
y to 
emerge as 
front-line 
practitione
rs in 
educating 
patients 
about 
OAB. 
Continued 
emphasis 
on OAB 
in 
academic 
programs 
and 
national 
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Evidence 
Level: IVb 
Quality: Good 
conferenc
es will 
increase 
NP 
knowledg
e and 
confidenc
e in 
assisting 
patients 
with 
OAB. 
31. Filipetto, F. 
A., Holthusen, 
A. E., 
McKeithen, 
T. M., 
McFadden, P. 
(2014). The 
patient 
perspective on 
overactive 
bladder: a 
mixed-method 
needs 
assessment. 
Mixed methods 
qualitative/quantit
ative needs 
assessment of 
patients with 
OAB and/or 
urinary 
symptoms. 
Researchers 
conducted in-
depth qualitative 
interviews via 
telephone with 40 
patients. 
Internal 
validity of 
the study 
may be 
affected due 
to selection 
bias of 
participants  
194 
participants, 98 
were men and 
96 were 
female. 
200 surveys 
filled out, 6 
were invalid. 
Most 
participants 
had a primary 
care provider 
Statistical and 
qualitative analysis 
of results were 
conducted. 
Among survey 
respondents, an 
average of 3.5 years 
elapsed between 
symptom onset and 
seeking diagnosis 
by a physician. In 
the long term, most 
patients do not 
The survey 
was developed 
using 
responses from 
the qualitative 
interviews. The 
survey was not 
pilot tested and 
was not 
validated. 
Participants 
were recruited 
using a 
The 
significant 
time gap 
between 
symptom 
onset and 
diagnosis 
indicates 
ongoing 
need for 
screening 
and 
diagnosis 
of 
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BMC Family 
Practice, 
15:96 
Doi:10.1186/1
47-2296-15-
96 
Mixed 
methods 
qualitative/qu
antitative 
needs 
assessment 
 
Evidence 
Level:IIb 
Quality:Good 
Interview 
respondents who 
had previously 
identified 
themselves as 
having OAB or 
bladder problems.  
 
managing their 
symptoms. 
Several men 
were treated by 
urologist, and 
two women 
were cared for 
by 
urogynecologi-
sts.  
experience 
improvement in 
symptoms. 
Medication non-
adherence is 
common and is 
related to therapy 
effectiveness and 
adverse effects. 
Patients clearly 
indicated that 
communication and 
patient/provider 
relationships are 
important to them 
and they would 
prefer the clinician 
initiate the 
conversation on 
overactive bladder. 
Patient experiences, 
perspectives, and 
attitudes toward 
their bladder 
symptoms differ in 
many ways from 
company that 
compiles 
panels of 
participants. 
overactive 
bladder. 
Contrary 
to 
guideline 
recommen
dations, 
urinalysis 
and 
physical 
examinati
on are not 
widely 
used in 
clinical 
practice. 
Many 
patients 
experience 
no 
improvem
ent in 
symptoms 
over time. 
Patients 
indicate 
that 
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provider 
assumptions. 
clinician/p
atient 
relationshi
p and 
communic
ation 
regarding 
the 
condition 
are 
important. 
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APPENDIX C: ACTIONABLE BLADDER SYMPTOM SCREENER (ABSST) 
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APPENDIX D: OAB CLASS CLIMATE SURVEY 
ORGANIZATION: University of South Carolina 
AUTHOR: Helen, Ngigi 
College of Nursing 
SURVEY: OAB Survey 
Activate contrast mode Activate contrast mode 
   
1Knowledge of Overactive Bladder and Perception of the 
Screening Tool Effectiveness Demographic    
   
  
DO NOT ADD YOUR NAME anywhere on the Survey.  
1.1 Please provide your mother’s birthdate starting with month, and then followed by year below 
so that we can link the pre-and post-survey to same provider. 
 
1.2 What is your age range?    
25-35 years 36-45 years 46-55 years Greater than 56 years  
1.3 Number of years of practice in a primary care setting 
1-3 years 4-7 years Greater than 8 years  
1.4What is your gender? 
Male Question Female Not applicable  
1.5 What is your title? 
NP PA MD  
 Please mark the box for the response that best reflects your opinion of the following statement.  
   
Strongly Disagree  Disagree  Neither Disagree or Agree  Agree  Strongly Agree  
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1.6 OAB is a common condition affecting many women globally and in the US 
Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly 
Agree  
   
 
   
 
1.7 Women with urinary incontinence problems often seek treatment immediately  
Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly 
Agree  
   
 
   
 
1.8 The validated overactive bladder screening tool (ABSST) is effective in highlighting 
the presence of bladder symptoms consistent with OAB 
 
Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly 
Agree  
   
 
   
 
1.9 The ABSST is effective in facilitating critical communication between patient and provider    
 
Strongly Disagree   Disagree  Neither Disagree or Agree Agree Strongly 
Agree  
   
 
   
   
  
1.10 How strongly would you agree or disagree that the following are barriers to assessing your 
patients for OAB symptoms?  
   
   Strongly Disagree   Disagree   Neither Disagree or Agree   Agree  Strongly Agree   
 
1.11 Lack of provider information about OAB symptoms  
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Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly 
Agree  
   
 
   
1.11 Not enough time  
  
Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly 
Agree  
   
 
   
1.12 Patients are uncomfortable bringing up the topic of OAB 
 
 Strongly Disagree Disagree Neither Disagree or Agree Agree Strongly Agree  
   
 
   
Submit
 
 
 
Licensed to UNIV OF SOUTH CAROLINA - Class Climate V6.1 (2051) - Scantron Corporation, All rights  
reserved. Copyright © 2015 Electric Paper Evaluations system GmbH  
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APPENDIX E: COVER LETTER AND INFORMATION SHEET PRE-SURVEY 
 
Overactive Bladder Assessment Tool Project 
Cover Letter and Information Sheet 
Principle Investigator: Helen Ngigi 
 December 2nd, 2016 
Dear HCC Providers, 
As part of my Doctor of Nursing scholarly project, I will be conducting a quality 
improvement project on overactive bladder symptoms in women who present at the HCC. 
Your participation in this project will play an important role in its success. The benefit 
will be to identify women who may have overactive bladder in order to improve 
outcomes. I will be conducting a quality improvement project on the effectiveness of the 
Actionable Bladder Symptom Screener tool when used by providers in the HCC. This 
project will be strictly voluntary. Participation is anonymous, and no provider personal 
identifiers will be collected. You will not receive any financial benefit for participating.  
As part of the project, your mother’s birthdate, using month and year, as in 101940, for 
example, will used to link the pre- and post-survey. The pre- and post-survey will be 
merged by using your mother’s birthdate. Your implied consent to participate in this 
project begins with the completion of the pre-survey that will be sent to you via email 
from Class Climate. 
Please click on this link to complete the pre-survey: 
 
https://classclimate.uts.sc.edu/classclimate/online.php?p=OABSURVEYPRE 
 
If the link above does not work, please copy and paste it to your browser. 
Instructions 
The Actionable Bladder Screening Tool will be sent to you once you complete the OAB 
Grand Rounds recording.  This tool is a validated tool that has been used in many 
primary care settings. 
o The participant provider will screen any eligible female patients that comes into 
the clinic on any given day with or without complaints of urinary symptoms. 
o Inclusion criteria are females age 40 years or greater with urinary tract infection 
complaints. 
o If a patient is found to meet the criteria for assessment, the provider will further 
evaluate the patient using the ABSST. 
o This form should be completed by the provider, not the patient. Also, under no 
circumstances should the ABSST tool form be scanned into the patient chart. It is 
only for this quality improvement project only. 
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o The forms will be used in the clinics for a four- week duration. All participating 
providers will receive reminder emails weekly of when to start and stop using the 
ABSST tool. 
o There is a OAB grand rounds educational teaching module that the researcher 
conducted on October 27th 2016, and I encourage all participants to access the 
recording via Healthstreams Grand Rounds. This grand round on overactive 
bladder discussed strategies of assessing and managing symptoms.  
o Upon completion of the study, participants will receive a post survey via Class 
Climate, to assess the effectiveness of the tool. 
Thank you for your participation on this project. 
Sincerely, 
Helen Ngigi, MSN, FNP-C 
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APPENDIX F: OAB INSTRUCTION LETTER TO USE ABSST 
 
Dear Providers, 
Thank you for completing the pre-survey and OAB grand rounds. The next step in the 
study is to utilize The Actionable Bladder Screening Tool starting today. 
Attached are two documents:  
1. OAB instructions – this has the instruction of all screening questions and the 
criteria for further follow-up 
2.  OAB tool (ABSST) – this is the tool you will need to print and start using with 
your patients who meet the criteria. 
See instructions below: 
1. Any female patients age 40 years or greater that comes into the clinic on any 
given day with or without complaints of urinary symptoms is eligible for 
screening. 
2. The OAB tool (ABSST)will be used in the clinics for a four- week duration.  
3. This OAB tool (ABSST) should be completed by the provider only, not the patient.  
4. Under no circumstances should the OAB tool (ABSST) be scanned into the 
patient chart. 
5.  Upon completion of the study, you will receive a post survey via Class Climate, 
to assess the effectiveness of the tool. 
 
Please feel free to reach out to me if you have any questions. 
 
 
Helen Ngigi 
 
 
Helen Ngigi, MSN, FNP-C 
Clinic Manager for Healthcare Clinics in Austell and Smyrna 
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APPENDIX G: COVER LETTER AND INFORMATION SHEET POST-
SURVEY  
Overactive Bladder Assessment Tool Project 
Cover Letter and Information Sheet 
Principle Investigator: Helen Ngigi 
  
Dear HCC Providers, 
As part of my Doctor of Nursing scholarly project, I have conducted a quality 
improvement project on overactive bladder symptoms in women who present at the HCC. 
Your participation in this project has played an important role in its success. The benefit 
was to identify women who may have overactive bladder in order to improve outcomes. I 
have conducted a quality improvement project on the effectiveness of the Actionable 
Bladder Symptom Screener tool when used by providers in the HCC. This project was 
strictly voluntary. Participation was anonymous, and no provider personal identifiers 
were collected. You did not receive any financial benefit for participating.  As part of the 
project, your mother’s birthdate, using month and year, as in 101940, for example, will 
used to link the pre- and post-survey. The pre- and post-survey will be merged by using 
your mother’s birthdate. Your implied consent to participate in this project began with the 
completion of the pre-survey that was sent to you via email from Class Climate. The 
conclusion of your part in the study is completing the post-survey. 
Please click on this link to complete the post-survey: 
 
 https://classclimate.uts.sc.edu/classclimate/online.php?p=OABSURVEYPO 
 
If the link above does not work, please copy and paste it to your browser. 
 
Instructions 
The Actionable Bladder Screening Tool has already been sent to you and you completed 
the OAB Grand Rounds recording.  This tool is a validated tool that has been used in 
many primary care settings. 
o As the participant provider you have screened any eligible female patients that 
came into the clinic on any given day with or without complaints of urinary 
symptoms. 
o Inclusion criteria was females age 40 years or greater with urinary tract infection 
complaints. 
o If a patient was found to meet the criteria for assessment, you as the participant 
provider further evaluated the patient using the ABSST. 
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o This form should only have been completed by the provider, not the patient. Also, 
under no circumstances was the ABSST tool form to be scanned into the patient 
chart. It was only for this quality improvement project only. 
o The forms were to be used in the clinics for a four- week duration. All 
participating providers received reminder emails of when to start and stop using 
the ABSST tool. 
o There is a OAB grand rounds educational teaching module that the researcher 
conducted on October 27th, 2016, and encouraged all participants to access the 
recording via Healthstreams GrandRounds. This grand round on overactive 
bladder discussed strategies of assessing and managing symptoms.  
o Upon completion of the study, you are now receiving a post survey via Class 
Climate, to assess the effectiveness of the tool. 
Thank you for your participation on this project. 
Sincerely, 
 
 
Helen Ngigi, MSN, FNP-C 
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APPENDIX H: POWER POINT OAB EDUCATIONAL MODULE 
PRESENTATION  
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